Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
AU728843B2 - 7alpha-(epsilon-aminoalkyl)estratrienes, process for preparing the same, pharmaceutical preparations containing said 7alpha-(epsilo-aminoalkyl)estratrienes and their use for preparing medicaments - Google Patents
[go: Go Back, main page]

AU728843B2 - 7alpha-(epsilon-aminoalkyl)estratrienes, process for preparing the same, pharmaceutical preparations containing said 7alpha-(epsilo-aminoalkyl)estratrienes and their use for preparing medicaments - Google Patents

7alpha-(epsilon-aminoalkyl)estratrienes, process for preparing the same, pharmaceutical preparations containing said 7alpha-(epsilo-aminoalkyl)estratrienes and their use for preparing medicaments Download PDF

Info

Publication number
AU728843B2
AU728843B2 AU45520/97A AU4552097A AU728843B2 AU 728843 B2 AU728843 B2 AU 728843B2 AU 45520/97 A AU45520/97 A AU 45520/97A AU 4552097 A AU4552097 A AU 4552097A AU 728843 B2 AU728843 B2 AU 728843B2
Authority
AU
Australia
Prior art keywords
estra
methyl
pentyl
triene
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU45520/97A
Other versions
AU4552097A (en
Inventor
Dieter Bittler
Rolf Bohlmann
Christa Hegele-Hartung
Josef Heindi
Nikolaus Heinrich
Helmut Hofmeister
Hermann Kunzer
Rosemarie Lichtner
Yukishige Nishino
Karsten Parczyk
Gerhard Sauer
Martin Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU4552097A publication Critical patent/AU4552097A/en
Application granted granted Critical
Publication of AU728843B2 publication Critical patent/AU728843B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

7a-(-Aminoalkyl)-estratrienes, Process for their Production, Pharmaceutical Preparations That Contain These 7a-(E-Aminoalkyl)-estratrienes as well as Their Use for the Production of Pharmaceutical Agents This invention relates to substituted 7a-(E-aminoalkyl)estratrienes of general formula I R11 R0R1" (16S
R
R'
4 i RiSS
SK
in which side chain SK is a radical of partial formula
(CH
2 m-N-CHH-H- (CH 2 n-SOx-(CH2) 3-E A B D whereby m is 4, 5 or 6, n is 0, 1 or 2, x is 0, 1 or 2, A is a hydrogen atom or a C.-5 alkyl group, B and D each are a hydrogen atom, or A and B together are an alkylene group -(CH 2 with p 2, 3, 4 or 5, and D is a hydrogen atom or A and D together are an alkylene group (CH 2 q- with q 2, 3 or 4, and B is a hydrogen atom, and E is an unsubstituted ethyl radical or an ethyl radical that is fluorinated in one to five places, or terminal substituent -(CH 2 3 -E in the side chain is replaced by an optionally substituted aryl or heteroaryl radical, which is bonded directly or via a mono-, di- or trimethylene group to the sulfur atom,
R
3 is a hydrogen atom, a hydrocarbon radical with up to 8 carbon atoms or a radical of partial formula
R
3 in which R 3 is a hydrogen atom or a hydrocarbon radical with up to 8 carbon atoms or a phenyl radical,
R
11 is a hydrogen atom, a halogen atom or a nitrooxy group
-O-NO
2
R
14
R
15
R
15 B, R 16a and R 16 3 each are a hydrogen atom or
R
14 and R 15 2 are an additional bond or a methylene bridge, or
R
158 is a methyl group and R 15 a is a hydrogen atom, or
R
15a and R 158 in each case are a methyl group, or
R
158 and R 1 6 B together are a methylene bridge, or
R
16 a or R 16 B is a halogen atom or
R
16 a and R 1 68 together are a methylidene group and the remaining substituents R 14
R
15 a, R 156
R
1 6 a and R 168 are each a hydrogen atom,
R
17 in a- or B-position is a hydrogen atom, a C,15 alkyl, alkenyl or C 2 5 alkinyl group or a trifluoromethyl group and 3
R
1 7 is a hydrogen atom or a radical of partial formula
R
17 in which R 17 is a hydrogen atom or a hydrocarbon radical with up to 8 carbon atoms, or, if
R
17 is in a-position, R" 7 together with R 14 means an ethano bridge, provided that unless A and B together stand for -(CH2) or A and D together stand for -(CH 2 at least one of substituents R",
R
1 4
R
15
R
1 56
R
16 and R 16 s is not a hydrogen atom, as well as their physiologically compatible addition salts with organic and inorganic acids.
In addition, this invention relates to these compounds of general formula I as well as their physiologically compatible Saddition salts with pharmaceutical preparations that contain organic and inorganic acids as well as their use for the production of pharmaceutical agents.
The invention further relates to estratriene intermediate compounds of the formula: *1.
OR'
7
R'
i 's"R'a A R I "*'(CH2s-X in which X is halogen, -NHMe, OH or a protected hydroxy group, the A ring is 3a
R
3 is a hydrogen atom or -OR 3 is a protected hydroxy group,
R
1 4
R
1 5a
R
1 5a
R
16 a and R 6 0 each are a hydrogen atom or
R'
4 and R' 5 are an additional bond or a methylene bridge, or
R
15 3 is a methyl group and R 15 is a hydrogen atom, or
R'
5 a and R' 5 P in each case are a methyl group, or
R'S
5 and R 1 6 together are a methylene bridge, or R" 6 or R 1 6 3 is a halogen atom or
R'
6a and R 6P together are a methylidene group and the others of substituents R 14 Ra, RS 1 P, R 6a and
SR
16 0 are each a hydrogen atom, R 7 'in a- or P-position is a hydrogen atom,
R'
7 is a hydrogen atom or a radical of partial formula
R
17 in which R 17 is a hydrogen atom or a hydrocarbon radical with up to 8 carbon atoms, or
R
7 and OR' 17 together are =0, as well as their physiologically compatible addition salts with organic and inorganic acids.
The estratriene intermediates are useful in the synthesis of the compounds of formula I.
3b In the compounds of general formula I, the nitrogen atom in the side chain is preferably separated by 5 methylene groups from carbon atom 7 of the steroid skeleton.
If A stands for an alkyl group with up to 5 carbon atoms, this is a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, or neopentyl group; a methyl group is preferred as A.
Index n can assume the value 0, 1 or 2, whereby if A is a hydrogen atom or an alkyl group with up to 5 carbon atoms, value 1 is preferred for n, so that the nitrogen atom and the sulfur atom are separated by 3 methylene groups.
e a*
S*
The nitrogen atom can be a component of a 4- to 7-membered or 5- to 7-membered heterocycle, which is substituted in 2- or 3position with the radical of side chain -(CH2)n-SOx-(CH 2 3
-E.
Preferably, A and B together are a trimethylene group, i.e., together with the nitrogen atom and its adjacent carbon atom, they form a pyrrolidine ring that is substituted in 2-position.
In the latter case, value 0 is preferred for n and value 0 is preferred for x.
The sulfur atom in the side chain can be present as a simple sulfur bridge (sulfide), as sulfone or sulfoxide. The sulfides are preferred.
As radical E, an unsubstituted ethyl radical or an ethyl radical that is fluorinated in one to five places is suitable; the perfluorine radical is preferred for E.
If terminal substituent -(CH 2 3 -E in the side chain is replaced by an optionally substituted aryl or heteroaryl radical, which is bonded directly or via a mono-, di- or trimethylene group to the sulfur atom, the aryl radical is preferably a phenyl radical; in the case of a heteroaryl radical, this is preferably a 2-furyl or 2-thienyl radical. As a substituent to this aryl or heteroaryl radical, for example, this can be a pentafluoroethyl or trifluoromethyl group, preferably a trifluoromethyl group, and this in turn will preferably be in the 4-position of a phenyl radical. A 2-furyl or 2-thienyl radical is preferably separated from the sulfur atom by a methylene group.
Substituent R 3 at the 3-oxygen atom is primarily a hydrogen atom. The hydroxy group can also, however, be etherified with a straight-chain or branched-chain, saturated or unsaturated hydrocarbon radical with up to 8 carbon atoms, such as, a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl, heptyl, hexyl or octyl radical or esterified with an acyl radical in which R 3 is a hydrogen atom or a hydrocarbon radical with up to 8 carbon atoms or a phenyl radical.
Substituents R 11 can be a hydrogen atom, a halogen atom (F, Cl, Br, I) or a nitrooxy group; a fluorine atom is preferred.
If R 11 stands for a hydrogen atom or if A and B together do not stand for -(CH 2 or if A and D together do not stand for -(CH2)q-- the D-ring exhibits a substitution from the group 14,15-double bond, 14a,15a-methylene, 158-methyl, 15,15-dimethyl, 158,168-methylene, 16a- or 168-halogen and of these especially 16a-fluorine, 16-methylidene or 14a,17a-ethano. A 158-methyl group or 16a-fluorine atom preferably can be mentioned.
R
17 can be in a- or B-position.
In the case of a C1-5 alkyl group, this is a methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl or neopentyl group. As a C 2 5 alkenyl group, for example, the vinyl or allyl radical can be mentioned. Typical representatives of a C 2 .5 alkinyl group are the ethinyl and 1-propinyl radicals.
If R 17 is in a-position, especially a hydrogen atom, a methyl or trifluoromethyl group or an ethano bridge that is formed together with R 14 stands for this.
For R 1 7 in B-position, primarily a hydrogen atom and a methyl group can be mentioned.
Especially those compounds of general formula I are preferred in which side chain SK is either a radical of partial formula (CH 2 5 N (d1 3
(CH.
2 3
CH
2 3
C
2
F
5 with x 0, 1 or 2 or (CH2) 5 2 S--(CH 2 3
C
2
F
5 with A B (CH 2 3 In the latter case, the compounds preferably exhibit a 17a-hydrogen atom.
Inorganic and organic acids, as they are known to one skilled in the art for forming physiologically compatible salts, are suitable for forming acid addition salts. As addition salts with acids, especially hydrochlorides and methanesulfonates can be mentioned.
The compounds below are especially preferred according to the invention: 14, 17-Ethano-7a-{5- (N-methyl-N-3- (4,4,5,5,5pentafluoropentylthio) -propylamino]-pentyl}-estra-l, 3,5(10) triene-3, 17B-diol 14, 17-ethano-7a-{5- [N-methyl-N-3- (4,4,5,5,5pentafluoropentanesulfinyl) -propylamino] -pentyl}-estra-l, 3,5(10) triene-3, 17B-diol 3,17B-diacetoxy-14ca,17c-ethano-7a-{5-[N-methyl-N-3- 5-pentafluoropentylthio) -propylamino]-pentyl}-estra- 1,3,5(10) -triene 14, 17-ethano-7a-{ 5- [N-methyl-N-3 pentafluoropentanesulfonyl) -propylamino] -pentyl}-estra-l, 3,5(10) triene-3, 17B-diol 7 17a-trifluoromethyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamiiol-pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 16B-methano-17a-methyl-7x- [N-methyl-N-3- 5,5, pentafluoro-pentylthio) -propylamino] -pentyl}-estra-1, 3,5 (10) triene-3, 17B-diol 15B,16B-methano-17ca-methyl-7a-5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfinyl) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 15B,16B-methano-7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio) -propylamino] -pentyl}-estra-1, 3,5(10) -triene-3, 17Bdiol 16B-methano-7h- [N-methyl-N-3- 5,5, pentanesulfinyl) -propylamino] -pentyl}-estra-1, 3,5(10) -triene- 3, 17B-diol 15B-methy1-7oa-{5-[N-rethyl-N-3-(4,4,5,5,5-pentafluoropentylthio) -propylamino]-pentyl}-estra-1, 3,5(10) -triene-3, 17Bdiol 15B,17ca-dimethyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)-propylamino]-pentyl}-estra-1, 3,5(10)-triene-3,17Bdiol 11B-fluoro-7a-{5- (N-methyl-N-3- (4,4,5,5,5pentafluoropentylthio) -propylamino] -pentyl}-estra-1,3,5(10) triene-3, 17B-diol 11B-fluoro-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfinyl) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 8 11B-fluoro-7a-{5- [N-methyl-N-3- (4,4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl }-estra-1, 3, 5(10) triene-3, 17B-diol 16a-fluoro-17a-methyl-7a-{5- [N-methyl-N-3- (4,4,5,5,5pentafluoropentyithic) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 16a-fluoro-17B-methyl-7cr-{5-[N-mnethyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3, 17ca-dio1 16a-fluoro-17a-mnethyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfinyl) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 178-diol 16a-fluoro-17a-methy-7a-{5- [N-methyl-N-3- (4,4,5,5,5pentafluoropentanesulfonyl) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 16a-fluoro-7cx-{5- [N-nethyl-N-3- (4,4,5,5,5pentafluoropentylthio) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3 ,17B-diol 16a-fluoro-7a-{5- [N-methyl-N-3- (4,4,5,5,5pentafluoropentyithic) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3, 17a-diol 16a-fluoro-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfinyl) -propylainino] -pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 16a-fluoro-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)propylaniino]-pentyl}-estra-1, 3,5(10) ,14-tetraene-3, 17B-di'ol 7a-{5-(N-methyl-N-3- 5-pentafluoropentanesulfinyl) propylamino)-pentyl}-estra-1, 3,5(10) ,14-tetraene-3, 17B-diol 7a-{5-[N-methyl-N-3-(4,4,5,5, 5-pentafluoropentanesulfonyl) propylamirio]-pentyl}-estra-1, 3,5(10) ,14-tetraene-3, 17B-diol (2S)-2-(4,4,5,5,5-pentafluoropentylthiomethyl)pyrrolidin-1-yl] -pentyl}-estra-1, 3,5(10) -triene-3, 17B-diol (2 R) 2 4, 5, 5, 5-penta fl1uoropenty lth iomethyl1) pyrrolidin-1-yl] -pentyl}-estra-1, 3,5(10) -triene-3, 17B-diol 17a-methyl-7a-{5-[2- 5-pentafluoropentyithiomethyl) :pyrrolidin-1-ylj-pentyl}-estra-1,3 ,5(10) -triene-3, 17B-diol 11B-fluoro-7a-{5-[2-(4 14, 5,5,5-pentafluoropentylthiomethyl) pyrrolidin-1-yl]-pentyl}-estra-1, 3,5(10) -triene-3 ,178-diol 11B-fluoro-17a-methy-7a-{5-[ pentafluoropentyithiomethyl) -pyrrolidin-1-yl] -pentyl}-estra- :1,3,5(10)-triene-3,175-diol 11B-fluoro-7z-methyl-7x-{5-[ S pentafluoropentanesulfinylmethyl) -pyrrolidin-1-yl) -pentyl}-estra- 1,3,5(10)-triene-3,17B-diol pentafluoropentanesulfonylmethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5 (10) -triene-3, 17B-diol 7a-{5-[(2S)-2-(4,4,5,5,5-pentafluoropentanesulfinylme thyl)pyrrolidin-1-yl) -pentyl-estra-1, 3,5 (10) -triene-3, 17B-diol PVU S (2S)-2-(4,4,5,5,5-pentafluoropentanesulfonylmethyl)pyrrolidin-1-yl] -pentyl-estra-1, 3,5(10) -triene-3, 17B-diol 11B-fluoro-17a-methyl-7a-{5- [N-methyl-N-3- (4,4,5,5,5pentafluoropentyithio) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 11B-fluoro-17a-methyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfinyl) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 11B-fluoro-17a-methyl-7a-{5-[N-inethyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3, 17B-diol, l1B-fluoro-7a-{ 5- [N-methyl-N-2- (4,4,5,5,5pentafluoropentanesulfonyl) -ethylamino] -pentyl}-estra-1, 3,5(10) triene-3, 17 B-dial 11B-fluoro-7ca-{5-[N-methy1-N-3-(4,4,5,5,5pentafluoropentyithio) -propylamino] -pentyl}-3-hydroxy-estra- 1,3,5(10) -trien-17-one 11B-fluoro-7h-{ 6- [N-methyl-N-3- (4,4,5,5,5pentafluoropentylthio) -propylamino] -hexyl}-estra-1, 3,5(10) triene-3, 17B-diol 11B-fluoro-7a-{ 6- [N-methyl-N-3- (4,4,5,5,5pentafluoropentanesulfinyl) -propylamino] -hexyl}-estra-1, 3,5(10) triene-3, 17B-diol 11B-fluoro-7r- (furan-2-ylmethylthio) -propyl] -N methyl-aminol-pentyl) -estra-1, 3,5(10) -triene-3, 17B-diol 11B-fluoro-7a- (5-{N-methyl- (thiophen-2-ylmethylthio) propyl]-amino}-pentyl}-estra-1,3,5(10)-triene-3,17B-diol 1lB-fluoro-7a-{5-[ (2S)-2-(4-trifluoromethylphenylthiomethyl) -pyrrolidin-l-yl] -pentyl}-estra-l, 3,5(10) -triene- 3, 17B-diol pentafluoropentanesulfinylmethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol 11B-fluoro-17a-methyl-7a-{s-[ pentafluoropentylthiomethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol pentafluoropentylthiomethyl) -pyrrolidin-l-yl] -pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol pentafluoropentanesulfinylmethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol pentafluoropentanesulfonylmethyl) -pyrrolidin-l-yl] -pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol.
The compounds of general formula I represent compounds with very strong antiestrogenic action.
The compounds according to the invention are, on the one hand, pure antiestrogens, or, on the other hand, so-called partial antagonists, antiestrogens with partial estrogenic action such as tamoxifen or raloxifen. The agonistic, estrogenic action is clearly less pronounced than in tamoxifen, however, in the compounds according to the invention in each case. Unlike tamoxifen, in the case of the partial antagonists of general formula I, their agonistic, estrogenic action occurs in a tissueselective manner. The agonistic action especially occurs on bones, in the cardiovascular system and in the CNS (central nervous system). No agonistic action occurs especially on the uterus.
Compounds with antiestrogenic properties, substances with inhibiting actions relative to estrogens, have already been described extensively.
As the compounds that come closest structurally to the compounds in question here of general formula I, on the one hand, the steroid derivatives that are described in EP-A 0 138 504 can be considered, and of the latter especially 7a-[9-(4,4,5,5,5pentafluoropentylsulfinyl)-n-nonyl]-estra-l,3,5(10)-triene-3,17Bdiol (EP-A 0 138 504, page 58, penultimate compound). This compound is currently under clinical development for hormonedependent tumors (breast cancer) and represents the compound that is best known at this time, the one with the strongest antiestrogenic activity, of these steroid derivatives.
Pharmaceutical compositions that contain sex steroid inhibitors and exhibit a steroidal skeleton, which exhibits a 7aside chain with the simultaneous presence of at least one other substituent in 14-, 15- or 16-position, are the subject of EP-A 0 376 576 and are also to be considered as the closest prior art.
A considerable number of the most varied compounds i.a., those of steroidal origin and those with a 2-phenylindole skeleton which act as antiestrogens and/or suppress the estrogen biosynthesis, are disclosed in WO 93/10741.
Other steroidal antiestrogens are described in EP-AS 0 384 842 and 0 629 635, which have an 11B-phenyl radical.
In the compounds according to the invention, there are antiestrogens with stronger antiestrogenic action than the already mentioned 7a-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nnonyl]-estra-l,3,5(10)-triene-3,178-diol.
The compounds of general formula I according to this application are distinguished in comparison to the already known steroid derivatives according to EP-A 0 138 504 and EP-A 0 367 576 by novel side chains on carbon atom 7 of the steroid skeleton. This structural modification results in especially greatly antiestrogenically active compounds, as was demonstrated in a transactivation test.
In addition, relative to the compounds of EP-A 0 138 504, the compounds of general formula I are distinguished with respect to the substitution on carbon atom 11 and/or of the D-ring (except in the case that A and B together stand for -(CH 2 or A and D together stand for In comparison to the compounds of EP-A 0 367 576, the compounds of general formula I on carbon atom 11 and/or in the D ring can carry the same or other substituents.
By the disclaimer in the definition of general formula I, compounds that are described from their scope in non-prepublished DE P 196 22 457 are excluded.
The antiestrogenic action of the compounds according to the invention was determined in transactivation assays [Demirpence, Duchesne, Badia, Gagne, D. and Pons, MVLN Cells: A Bioluminescent MCF-7-Derived Cell Line to Study the Modulation of Estrogenic Activity; J. Steroid. Molec. Biol. Vol.
46, No. 3, 355-364 (1993) as well as Berry, Metzger, D.; Chambon, Role of the Two Activating Domains of the Estrogen Receptor in the Cell-Type and Promoter-Context Dependent Agonistic Activity of the Anti-estrogen 4-Hydroxytamoxifen; The EMBO Journal Vol. 9, 2811-2818 (1990)].
The HeLa cells are transiently transfixed with human estrogen receptor-expression vector (HEGO) and Vit-TK-CAT reporter genes, and the MVLN cells are transfixed in a stable manner with reporter gene Vit-TK-LUC. The estrogenic active strength was determined in the presence of 0.1 Nm of estradiol.
The IC 50 values for the new compounds lie in the nanomolar range. In the HeLa cell line as well as the MVLN cell line, the following IC50 values are produced for the compounds of Examples 12, 15, 18, 25, 29, 31 and 36 as well as for 7a-[9-(4,4,5,5,5pentafluoropentylsulfinyl)-n-nonyl]-estra-l,3,5(10)-triene-3,17Bdiol (execution of test according to the above-indicated bibliographic references): Compound
IC
50 [nM] HeLa cells MVLN cells Example 12 0.06 2.4 Example 15 0.06 1.4 Example 18 0.05 0.13 Example 25 0.06 0.15 Example 29 0.13 0.2 Example 31 0.1 0.2 Example 36 0.05 0.4 Reference: 7a-[9-(4,4,5,5,5-pentafluoro- 0.5 pentanesulfinyl)-nonyl]-estra- 1,3,5(10)-triene-3,17B-diol In-vivo tests also confirm the superiority of the compounds according to the invention over 7a-[9-(4,4,5,5,5pentafluoropentanesulfinyl)-nonyl]-estra-l,3,5(10)-triene-3,17Bdiol. The tests that are described below were performed: 1. Uterus growth test in infantile rats, p.o. (test for antiestrogenic action) 2. Tumor test: Antitumor action on the hormone-dependent breast cancer DMBA'-induced breast cancer in rats dimethylbenzanthracene 1. Uterus growth test in infantile rats (Antiestrogenic action) 16 Principle of the Method In rodents, the uterus reacts to the administration of estrogens with a weight increase (both proliferation and water retention). This growth can be inhibited, depending on the dose, by simultaneous administration of compounds that have an antiestrogenic action.
Execution of the Test Animals: Infantile, female rats that weigh 35-45 g at the beginning of the test, 5-6 animals per dose.
Formulation and Administration of the Substances: For p.o. administration, the substances are dissolved in 1 part ethanol and made up with 9 parts peanut oil (EO).
Test Preparation The young rats just dropped by the mothers are delivered for acclimation one day before the beginning of treatment and immediately supplied with food right in the cage. The treatment then is carried out once daily over 3 days in combination with 0.5 gg of estradiolbenzoate EB is always administered subcutaneously while the test substance is administered p.o. (perorally). Twenty-four hours after the last administration, the animals are weighed, sacrificed, and the uteri are removed. The moist weights (less contents) are determined from the prepared uteri.
-1 Controls Negative control: Positive control: vehicle 0.2 ml/animal/day 0.5 ig of EB/O.1 ml/animal/day Evaluation From the relative organ weights (mg/100 g of body weight), the average values with standard deviation (X SD), and the significance of the differences to control group (EB) in the Dunnett test (p 0.05) are determined for each group. The calculation of inhibition (in compared to the EB control is carried out with a program. The relative actions of the test substances are determined by co-variance and regression analysis.
Antiuterotrophic Action on Rats Compound of Example 0.1 mg/kg p.o. Inhibition 12 91 0.01 33 0.24 18 16 >0.30 29 80 0.01 31 71 0.04 36 62 0.03 Reference ZM 182 8 0.39 780 These results demonstrate the much higher antiestrogenic action of the compounds of general formula I compared to compound 7a-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-n-nonyl]-estra- 1,3,5(10)-triene-3,17B-diol in each case after oral administration.
The compounds according to the invention are distinguished by a better bio-availability after oral administration.
2. Tumor Test Influencing the Tumor Growth in the DMBA* Model in Rats (DMBA Tumor Model) 9,10-Dimethyl-1,2-benzanthracene Biological Basis The growth of the DMBA-induced breast neoplasm in rats is largely dependent on estrogens and prolactin. Active antiestrogens, antigestagens and aromatase inhibitors result in inhibiting tumor growth. Substances that have antigonadotrophic and androgenic properties also exert a tumor-inhibiting action.
Animal Subjects 45-47-day-old female rats (Sprague-Dawley, ZIH or M6llegard strains), 8-10 animals per group.
Test Preparation The animals receive 10 mg of DMBA orally on a one-time basis. Then, the animals are checked once a week by palpation for tumor development. Six to ten weeks after the DMBA treatment, about 1 to 10 tumors develop per animal. The tumor size is determined once weekly with the aid of a sliding gauge.
If at least one tumor has reached a defined size (150 mm 2 of tumor surface area), the ovariectomy of the animals is carried out or the treatment of the animals with the test substance begins. In most cases, the treatment is carried out daily over about 28 days (for details of the procedure, see Test Plan). In addition, the tumor size is determined once a week.
Evaluation The total tumor size per animal is determined before the beginning of the treatment (previous values). For each group, the mean of the percentage changes in tumor size, relative to the starting values, is then calculated. In addition, the percentage of animals per group is determined whose tumors in each case (1) have totally regressed (total regression), have partially regressed (partial regression), are unchanged (no change) or have further progressed (increase).
The values that are determined are tested for significance in the Dunnett Test and are depicted graphically.
Test Result At an oral dose of 3 mg/kg/day, ll1-fluoro-7a-{5-[2- (4,4,5,5,5-pentafluoropentylthiomethyl)-pyrrolidin-l-yl]-pentyl}estra-1,3,5(10)-triene-3,178-diol (compound of Example 29) inhibits the tumor growth more greatly than an oral dose of mg/kg/day of 7a-[9-(4,4,5,5,5-pentafluoropentanesulfinyl)-nonyl]estra-l,3,5(10)-triene-3,17B-diol, which at this dose exerts only a slight action in comparison to the intact control. An ovariectomy results in a total remission of tumors (Figure 1).
The compounds have an inhibiting action on the growth of hormone-dependent tumor cells; they especially inhibit the growth of estrogen-dependent human breast neoplasm cells (MCF-7).
The antiproliferative activity of the new compounds in breast neoplasm cell lines is greater than that of 7a-[9- 4,4,5,5,5-pentafluoropentylsulfinyl)-n-nonyl]-estra-1,3,5(10)triene-3,17B-diol.
As pure antiestrogens for the purposes of this invention, those compounds of general formula I can be considered that show no agonistic action or only a slight agonistic action in the invitro test on estrogenic action below (up to about 10% of the action of estradiol).
In this case, the partial estrogenic action was also determined by transactivation assays. HeLa cells were transfixed with human estrogen receptor-expression vector (HEGO) and a reporter gene rPR-TK-CAT. This reporter gene contains the "estrogen responsive element" of the rabbit progesterone receptor gene (+698/+729 region) before a TK-CAT gene (Savouret, J. F.; Bailly, Misrahi, Rauch, Redeuilh, Chauchereau, Milgrom, Characterization of the Hormone Responsive Element that is Involved in the Regulation of the Progesterone Receptor Gene. EMBO J. 10, 1875-1883 (1991).
The estrogenic active strength was determined at a concentration of 1 AM.
Compound of Example Activation of the rPR-TK Promoter Estradiol]* 12 -11 18 -24 -21 29 31 36 -6 Reference ZM 182780 A negative value means suppression of the reporter gene activity below the values of the controls.
The compounds according to the invention, especially if they are pure antiestrogens, are suitable for treatment of estrogendependent diseases, for example, breast cancer (second-line treatment of tamoxifen-resistant breast cancer; for adjuvant treatment of the breast cancer instead of tamoxifen), endometrial carcinoma, prostatic hyperplasia, anovulatory infertility and melanoma.
In addition, the pure antiestrogens of general formula I can be used as components in the products that are described in EP 346 014 B1 and that contain an estrogen and a pure antiestrogen, 22 namely for simultaneous, sequential or separate use for the selective estrogen therapy of peri- or postmenopausal women. The compounds of general formula I, especially if these are pure antiestrogens, can be used together with antigestagens (competitive progesterone antagonists) for the treatment of hormone-dependent tumors (EP 310 542 A).
Other indications, in which the compounds of the general formula can be used, are male hair loss, diffuse alopecia, alopecia that is caused by chemotherapy and hirsutism (Hye-Sun Oh and Robert C. Smart. Proc. Natl. Acad. Sci. USA, 93 (1996) 12525- 12530).
In addition, the compounds of general formula I can be used for the production of medications for the treatment of endometriosis and endometrial carcinomas.
The compounds of general formula I can also be used for the production of pharmaceutical compositions for male and female birth control (male birth control: DE-A 195 10 862.0).
The compounds of general formula I with tissue-selective partial estrogenic action primarily can be used for prophylaxis and treatment of osteoporosis and for the production of preparations for substitution therapy in pre-, peri- and postmenopause (HRT) (Black, L. Sato, Rowley, E. Magee, D.
Bekele, Williams, D. Cullinan, G. Bendele, R.; Kauffman, R. Bensch, W. Frolik, C. Termine, J. D. and Bryant, H. Raloxifene [LY 139481 HC1] Prevents Bone Loss and Reduces Serum Cholesterol without Causing Uterine Hypertrophy in Ovariectomized Rats; J. Clin. Invest. 93: 63-69, 1994). The partial estrogenic action occurs only on the desired target organ.
The invention also relates to pharmaceutical preparations that contain at least one compound of general formula I (or physiologically compatible addition salts with organic and inorganic acids of them), and the use of these compounds for the production of pharmaceutical agents, especially for treating estrogen-dependent diseases and tumors and pharmaceutical agents for hormone replacement treatment (HRT).
The compounds according to the invention and the acid addition salts are suitable for the production of pharmaceutical compositions and preparations. The pharmaceutical compositions or pharmaceutical agents contain as active ingredient one or more of the compounds according to the invention or their acid addition salts, optionally in a mixture with other pharmacologically or pharmaceutically active substances. The production of the pharmaceutical agents is carried out in a known way, whereby the known and commonly used pharmaceutical adjuvants as well as other commonly used vehicles and diluents can be used.
As such vehicles and adjuvants, for example, those are suitable which are recommended or indicated in the following bibliographic references as adjuvants for pharmaceutics, cosmetics and related fields: Ullmans Encyklopadie der technischen Chemie [Ullman's Encyclopedia of Technical Chemistry], Volume 4 (1953), pp. 1 to 39; Journal of Pharmaceutical Sciences, Volume 52 (1963), pp. 918 and ff.; H. v.
Czetsch-Lindenwald, Hilfsstoffe fUr Pharmazie und angrenzende Gebiete [Adjuvants for Pharmaceutics and Related Fields]; Pharm.
Ind. Number 2, 1961, pp. 72 and ff.; Dr. H. P. Fiedler, Lexikon der Hilfsstoffe fur Pharmazie, Kosmetik und angrenzende Gebiete [Encyclopedia of Adjuvants for Pharmaceutics, Cosmetics and Related Fields], Cantor KG. Aulendorf in WUrttemberg 1971.
The compounds can be administered orally or parenterally, for example, intraperitoneally, intramuscularly, subcutaneously or percutaneously. The compounds can also be implanted in tissue. The amount of the compounds to be administered varies within a wide range and can cover any effective amount.
Depending on the condition to be treated and the type of administration, the amount of administered compound is 0.1-25 mg/kg of body weight, preferably 0.5-5 mg/kg of body weight, per day. In humans, this corresponds to a daily dose of 5 to 1250 mg.
The preferred daily dosage in humans is 50 to 200 mg. This holds true especially for tumor therapy.
For oral administration, capsules, pills, tablets, coated tablets, etc., are suitable. In addition to the active ingredient, the dosage units can contain a pharmaceutically compatible vehicle, such as, for example, starch, sugar, sorbitol, gelatin, lubricant, silicic acid, talc, etc. The individual dosage units for oral administration can contain, for example, 5 to 500 mg of active ingredient.
To achieve a better bio-availability of the active ingredient, the compounds can also be formulated as cyclodextrin clathrates. In this connection, the compounds with B- or ycyclodextrin or their derivatives are reacted (PCT/EP95/02656).
For parenteral administration, the active ingredients can be dissolved or suspended in a physiologically compatible diluent.
As a diluent, very frequently oils with or without the addition of a solubilizer, a surfactant, a suspending agent or emulsifier are used. Examples of oils that are used are olive oil, peanut oil, cottonseed oil, soybean oil, castor oil and sesame oil.
The compounds can also be used in the form of a depot injection or an implant preparation, which can be formulated so that a delayed release of active ingredient is made possible.
Implants can contain, as inert materials, for example, biodegradable polymers or synthetic silicones, such as, for example, silicone rubber. In addition, the active ingredients can be added to, for example, a patch, for percutaneous administration.
The compounds according to the invention can be produced as described below. The following examples are used for a more detailed explanation of the invention. By an analogous approach using reagents like those in the data that are contained in the examples, all compounds of general formula I can be obtained.
The saponification of the ester groupings as well as esterification and etherification of free hydrogen groups is carried out in each case according to established processes of organic chemistry. By observing the differing reactivity of the esterified and free 3- and 17-hydroxy groups, the 3,17-diesters can be cleaved selectively in 3-position, and the 3-hydroxy-17acyloxy compound can then be additionally functionalized specifically in the 3-position; it is equally possible to esterify or to etherify the 3,17-dihydroxy compound selectively only in the 3-position and then to introduce specifically another radical into the 17-position as already in the 3-position.
The acid addition salts of the compounds of general formula I can also be produced according to standard processes from the compounds of general formula I.
OFF\
27 The examples below are used for a more detailed explanation of the invention: Example 1 14,17-Ethano-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio)-propylamino]-pentyl}-estra-1,3,5(10)triene-3,17B-diol a) 7a-(5-tert-Butyldimethylsilyloxypentyl)-estr-4-ene-3,17-dione In 70 ml of absolute tetrahydrofuran, 15.1 g of Mg chips with 175.6 g of [Tetrahedron Letters 23, 1982, 40, 4147-4150], dissolved in 600 ml of absolute tetrahydrofuran, are reacted to form the Grignard reagent. 59 g of copper(I) iodide is added to this solution, cooled to -20 0 C, under a nitrogen stream, and then 50 g of estra- 4,6-diene-3,17-dione [Steroids Vol. 1, 1963, 233-249], dissolved in 300 ml of absolute THF, is added in drops within one hour.
For working-up, 37.5 ml of acetic acid is added in drops, the reaction mixture is diluted with ethyl acetate, washed with saturated ammonium chloride solution, water and sodium bicarbonate solution and dried. The residue that is obtained after the concentration by evaporation is chromatographed on silica gel. 35.4 g of estr-4-ene-3,17-dione is obtained. [a]D 22 +52.80 (c 0.535% in chloroform) b) 7a-(5-Hydroxypentyl)-estr-4-ene-3,17-dione A solution of 125.4 g of butyldimethylsilyloxypentyl)-estr-4-ene-3,17-dione in 625 ml of methanol and 347 ml of water is stirred with 694 ml of glacial acetic acid for 2.5 hours at 50 0 C. After the concentration by evaporation at 60 0 C in a vacuum, 94.1 g of crude hydroxypentyl)-estr-4-ene-3,17-dione is obtained as an oil.
c) 7a-(5-Acetoxypentyl)-estr-4-ene-3,17-dione A solution of 94 g of crude 7a-(5-hydroxypentyl)-estr-4-ene- 3,17-dione in 620 ml of pyridine is slowly mixed with 310 ml of acetic anhydride and stirred for 2 hours at 25 0 C. Then, it is slowly mixed with 116 ml of water while being cooled with ice, diluted with 3 1 of diethyl ether, the organic phase is dried and concentrated by evaporation after washing with sodium bicarbonate solution. The residue is chromatographed on silica gel, and 84.4 g of 7a-(5-acetoxypentyl)-estr-4-ene-3,17-dione is obtained as an oil.
d) 7a-(5-Acetoxypentyl)-3-hydroxy-estra-1,3,5(10)-trien-17-one 17.8 g of lithium bromide and 92.83 g of copper(II) bromide are added to a solution of 82.3 g of 7a-(5-acetoxypentyl)-estr-4ene-3,17-dione in 936 ml of acetonitrile at a bath temperature of 0 C. After 10 minutes at a bath temperature of 80 0 C, the reaction solution is cooled, extracted three times with ethyl acetate, washed with water and sodium bicarbonate solution and ried. The residue that is obtained after the concentration by 29 evaporation is chromatographed on silica gel, and 60.4 g of 7a- (5-acetoxypentyl)-3-hydroxy-estra-l,3,5(10)-trien-17-one is obtained as an oil.
e) 3-Acetoxy-7a-(5-acetoxypentyl)-estra-1,3,5(10)-trien-10-one A solution of 60.4 g of 7a-(5-acetoxypentyl)-3-hydroxyestra-l,3,5(10)-trien-17-one in 300 ml of pyridine is stirred with 150 ml of acetic anhydride for 1 hour at room temperature.
Then, it is precipitated with a mixture of ice/water/common salt/hydrochloric acid, taken up-with ethyl acetate, washed neutral with sodium bicarbonate and common salt solution, and dried on sodium sulfate and concentrated by evaporation in a vacuum. 63.9 g of 3-acetoxy-7a-(5-acetoxypentyl)-estra- 1,3,5(10)-trien-17-one is obtained as an oil.
f) 3-Acetoxy-7a-(5-acetoxypentyl)-17,17-ethylenedioxy-estra- 1,3,5(10)-triene A solution of 63.9 g of 3-acetoxy-7a-(5-acetoxypentyl)estra-1,3,5(10)-trien-17-one in 460 ml of dichloromethane is stirred with 460 ml of ethylene glycol, 155 ml of trimethyl orthoformate and 1.2 g of para-toluenesulfonic acid for 3 hours at a bath temperature of 50 0 C. Then, it is diluted with dichloromethane, washed with sodium bicarbonate and common salt solution and dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with hexane/ethyl acetate. 63.2 g of 3-acetoxy-7a-(5-acetoxypentyl)-17,17ethylenedioxy-estra-l,3,5(10)-triene is obtained as an oil.
g) 3-Acetoxy-7a-(5-acetoxypentyl)-16a-bromo-17,17-ethylenedioxyestra-1,3,5(10)-triene A solution of 63.2 g of 3-acetoxy-7a-(5-acetoxypentyl)- 17,17-ethylenedioxy-estra-1,3,5(10)-triene in 630 ml of tetrahydrofuran is mixed in portions at 0 0 C with 61.7 g of pyridine hydrobromide perbromide, and it is stirred for 2 hours at OOC0. Then, a solution of 15 g of sodium sulfide in 70 ml of water is added, diluted with ethyl acetate, washed with sodium bicarbonate and common salt solution and dried on sodium sulfate and concentrated by evaporation in a vacuum. 74.1 g of 3acetoxy-7a-(5-acetoxypentyl)-16a-bromo-17,17-ethylenedioxy-estra- 1,3,5(10)-triene is obtained as an oil.
h) 17,17-Ethylenedioxy-7a-(-hydroxypentyl)-estra-1,3,5(10),15tetraen-3-ol A solution of 74.1 g of 3-acetoxy-7a-(5-acetoxypentyl)-16bromo-17,17-ethylenedioxy-estra-1,3,5(10)-triene in 740 ml of dimethyl sulfoxide and 74 ml of methanol is stirred with 74 g of potassium hydroxide for 7.5 hours at a bath temperature of 850C.
Then, it is precipitated with ice/water/common salt, taken up with ethyl acetate, washed neutral, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with hexane/ethyl acetate. 36.12 g of pure 17,17ethylenedioxy-7a-(5-hydroxypentyl)-estra-1,3,5(10),15-tetraen-3ol is obtained as a foam.
i) 3-Hydroxy-7a-(5-hydroxypentyl)-estra-1,3,5(10),15-tetraen-17one A solution of 36.12 g of 17,17-ethylenedioxy-7a-(5hydroxypentyl)-estra-1,3,5(10),15-tetraen-3-ol in 958 ml of acetone and 111 ml of water is stirred for 2 hours at room temperature with 2.76 g of para-toluenesulfonic acid. Then, it is concentrated by evaporation in a vacuum to 1/3 of the volume, taken up with ethyl acetate, washed neutral, dried on sodium sulfate and concentrated by evaporation in a vacuum. 31.7 g of 3-hydroxy-7a-(5-hydroxypentyl)-estra-l,3,5(10),15-tetraen-17-one is obtained as crystals with a melting point of 194-196 0
C.
j) 3,17-Diacetoxy-7a-(5-acetoxypentyl)-estra-1,3,5(10),14,16pentaene A solution of 15.7 g of 3-hydroxy-7a-(5-hydroxypentyl)estra-1,3,5(10),15-tetraen-17-one in 330 ml of acetic anhydride is stirred with 4.6 g of para-toluenesulfonic acid for 4 hours at room temperature. Then, it is precipitated with pyridine/water/common salt, taken up in ethyl acetate, washed with sodium bicarbonate and common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with hexane/ethyl acetate. 11.1 g of pure 3,17-diacetoxy-7a-(5-acetoxypentyl)-estra- 1,3,5(10),14,16-pentaene is obtained as an oil.
k) 3, 178-Diacetoxy-7a- (5-acetoxypentyl) -14a, 17ca-etheno-estra- 1,3,5(10) -triene 11.0 g of 3, 17-diacetoxy-7a- (5-acetoxypentyl) -estral,3,5(10),14,16-pentaene in 120 ml of benzene is treated at 300 bar and 175 0 C for 6.5 days with ethene. Then, it is taken up in ethyl acetate, washed with sodium bicarbonate and common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with hexane/ethyl acetate. 8.4 g of 3,17B-diacetoxy-7a-(5-acetoxypentyl)-14a,17ais obtained as a foam.
1) 3, 17B-Diacetoxy-7a-(5-acetoxypentyl) -14a, l7c-ethano-estra- 1,3,5 (10) -triene A solution of 8.4 g of 3,17B-diacetoxy-7ca-(5-acetoxypentyl)- 14a,17a-etheno-estra-1,3,5(lO)-triene in 200 ml of ethyl acetate is shaken with 1.5 g of palladium on carbon for one hour at room temperature with hydrogen. Then, it is suctioned off on Celite, rewashed with ethyl acetate, concentrated by evaporation in a vacuum and chromatographed on silica gel with hexane/ethyl acetate. 6.0 g of 3,17B-diacetoxy-7a-(5-acetoxypentyl)-l4a,17aethano-estra-l,3,5(10)-triene is obtained as a foam.
m) 14a,17ca-Ethano-7a-(5-hydroxypentyl)-estra-1,3,5(10)-triene- 3, 17B-diol A solution of 6.0 g of 3,173-diacetoxy-7c-(5-acetoxypentyl)- 14a,l7c-ethano-estra-1,3,5(lO)-triene in 100 ml of a 1-molar potassium hydroxide solution is allowed to stand for 7.5 hours at 33 room temperature. Then, it is added to 1-molar hydrochloric acid, extracted three times with ethyl acetate, washed with sodium bicarbonate and common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and recrystallized from acetone/hexane. 4.57 g of 14a,17a-ethano-7a- (5-hydroxypentyl)-estra-1,3,5(10)-triene-3,17B-diol is obtained as colorless crystals with a melting point of 63-65 0
C.
n) 3-Benzyloxy-14a,17a-ethano-7a-(5-hydroxypentyl)-estra- 1,3,5(10)-trien-17B-ol A solution of 4.5 g of 14a,17a-ethano-7a-(5-hydroxypentyl)estra-1,3,5(10)-triene-3,17B-diol in 90 ml of acetonitrile is stirred with 1.91 g of potassium carbonate and 1.53 ml of benzyl bromide for 6.5 hours at a bath temperature of 80 0 C. Then, it is concentrated by evaporation in a vacuum to 1/3 of the volume, added to water, extracted three times with ethyl acetate, washed neutral, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/acetone. 4.8 g of 3-benzyloxy-14a,17a-ethano-7a- (5-hydroxypentyl)-estra-l,3,5(10)-trien-17B-ol is obtained as a foam.
o) 3-Benzyloxy-14a,17a-ethano-7a-(5-tosyloxypentyl)-estra- 1,3,5(10)-trien-178-ol A solution of 4.8 g of 3-benzyloxy-14a,17a-ethano-7a-(5hydroxypentyl)-estra-l,3,5(10)-trien-17B-ol in 50 ml of pyridine is stirred at 0°C with 3.63 g of toluenesulfonic acid anhydride for 4 hours. Then, it is diluted with ethyl acetate, extracted with 2-molar hydrochloric acid, washed neutral, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with hexane/ethyl acetate. 4.75 g of 3-benzyloxy-4a, 17a-ethano-7a- (5-tosyloxypentyl) -estral,3,5(l0)-trien-17B-ol is obtained as a foam.
p) 3-Benzyloxy-14a,17a-ethano-7a-{5-[N-methy1-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino] -pentyl}-estra-1, 3,5(10) trien-17B-ol A solution of 4.7 g of 3-benzyloxy-14a,17oa-ethano-7a-(5tosyloxypentyl)-estra-l,3,5(l0)-trien-l7B-ol in 100 ml of dimethylformamide is stirred with 2.7 g of methyl-[3-(4,4,5,5,5pentafluoropentylthio)-propyl]-amine for 4 hours at a bath temperature of 80 0 C. Then, it is added to water, extracted three times with ethyl acetate, washed with common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichioromethane/methanol. 3.8 g of 3-benzyloxy-14ca,17a-ethano-7oa-{5-(N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino] -pentyl}-estra-l, 3,5(10) trien-17B-ol is obtained as an oil.
q) 14a,17cx-Etharo-7a-{-(N-methyl-N-3-(4,4,5,5,5pentafluoropentyithio) -propylamino]-pentyl}-estra-1,3,5 triene-3, 17B-diol A solution of 3.7 g of 3-benzyloxy-14a,l7ca-ethano-7a-{5-[Nmethyl-N-3- 5-pentafluoropentanesulfinyl) -propylamino] pentyl}-estra-1,3,5(10)-trien-17B-ol in 65 ml of dichloromethane is stirred at 0 C with 2.1 ml of N,N-dimethylaniline for minutes, mixed with 2.75 g of anhydrous aluminum chloride and stirred for 3.5 hours at 0°C. Then, it is mixed with saturated, aqueous potassium sodium tartrate solution, added to water, extracted three times with dichloromethane, washed neutral, dried on sodium sulfate and concentrated by evaporation in a vacuum.
6.3 g of crude product, which is chromatographed on silica gel with dichloromethane/methanol, is obtained. 2.85 g of pure 14a,17a-ethano-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio)-propylamino]-pentyl}-estra-l,3,5(10)triene-3,178-diol is obtained as crystals with a melting point of 63-67 0 C, [a]D 22 +19.40 (c 0.505% in chloroform).
Example 2 14,17-Ethano-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfinyl)-propylamino]-pentyl}-estra-1,3,5(10)triene-3,178-diol A solution of 1.0 g of 14a,17a-ethano-7a-{5-[N-methyl-N-3- (4,4,5,5,5-pentafluoropentylthio)-propylamino]-pentyl}-estra- 1,3,5(10)-triene-3,178-diol in 37.5 ml of methanol and 1.78 ml of water is stirred with 381 mg of sodium periodate for 5 hours at room temperature. Then, it is added to water, extracted three times with dichloromethane, washed neutral, dried on sodium sulfate and concentrated by evaporation in a vacuum. 985 mg of crude product, which is chromatographed on silica gel with dichloromethane/methanol, is obtained. 514.3 mg of pure 14,17ethano-7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentanesulfinyl) -propylamnino] -pentyl}-estra-l,3,5(l0) -triene-3, 17B-diol is obtained as crystals with a melting point of 84-86 0 C; C ID 22 +13.00 (c 0.5% in chloroform).
Example 3 3, 178-Diacetoxy-14a, 17a-ethano-7a-{5-[N-methy1-N-3- (4,4,5,5,5 -pentaf luoropentylthio) -propylamino]J-pentyl }-estra- 1, 3, 5(10) -triene A solution of 600 mg of 14ca,17a-ethano-7ca-{5-[N-methyl-N-3- 5-pentafluoropentylthio) -propylamino]-pentyl}-estral,3,5(l0)-triene-3,17B-diol in 2 ml of pyridine and 1 ml of acetic anhydride is stirred with 5 mg of dimethylaminopyridine for 4.5 hours at room temperature. Then, it is diluted with ethyl acetate, washed with water and common salt solution, dried on sodium sulfate and concentrated by evaporation in a vacuum.
680 mg of 3,17B-diacetoxy-14oa,17a-ethano-7ca-{5-[N-methyl-N-3- 5-pentafluoropentylthio) -propylamino] -pentyl}-estra- 1,3,5(10)-triene is obtained as an oil.
Example 4 14,17-Ethano-7ca-{5-[N-methy-N-3-(4 4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl}-estra- 1,3,5 (10) -triene-3, 1713-diol A solution of 650 mg of 3,17B-diacetoxy-14oa,17a-ethano-7a- [N-methyl-N-3- 5-pentafluoropentylthio) -propylamino] pentyl}-estra-l,3,5(10)-triene-in 15 ml of glacial acetic acid is stirred with 1.5 g of sodium perborate tetrahydrate for 3 hours at room temperature. Then, it is added to water, extracted three times with dichloromethane, washed neutral, dried on sodium sulfate, concentrated by evaporation in a vacuum, taken up in ml of 0.2-molar methanolic potassium hydroxide solution, stirred for 24 hours at room temperature, added to water, extracted three times with dichloromethane, washed neutral, dried on sodium sulfate, concentrated by evaporation in a vacuum, suspended in ml of ethyl acetate, mixed with 10 ml of tin(II) chloride solution, stirred for 4 hours at room temperature, diluted with ethyl acetate, washed with common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with hexane/ethyl acetate. 300 mg of pure 14,17-ethano-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl)-propylamino]-pentyl}-estra-l,3,5(10)triene-3,17B-diol is obtained as crystals with a melting point of 55-58 0 C; [a] 0 22 +19.40 (c 0.51% in chloroform).
Example 17a-Trifluoromethyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio)-propylamino]-pentyl}-estra-1,3,5(10)triene-3,17B-diol a) 17B-Acetoxy-7a-(5-tert-butyl-dimethylsilyloxypentyl)-estr-4en-3-one In 200 ml of absolute THF, 22.9 g of Mg chips with 261 g of [Tetrahedron Letters 23, 1982, 40, 4147-4150], dissolved in 250 ml of absolute THF is reacted to form the Grignard reagent. 92.9 g of copper(I) iodide is added to this solution, cooled to -20 0 C under a nitrogen stream, and then 73.5 g of 178-acetoxyestra-4,6-dien-3-one
[J.
Am. Chem. Soc. 80, 1958, 2596-2597], dissolved in 300 ml of absolute THF, is added in drops within one hour. For working-up, 61.2 ml of acetic acid is added in drops, the reaction mixture is diluted with ethyl acetate, washed with saturated ammonium chloride solution, water and sodium bicarbonate solution and dried. The residue that is obtained after the concentration by evaporation is chromatographed on silica gel. 48 g of 178acetoxy-7a-(5-tert-butyl-dimethylsilyloxypentyl)-estr-4-en-3-one is obtained.
b) 17B-Acetoxy-7a-(5-hydroxypentyl)-estr-4-en-3-one A solution of 48 g of 17B-acetoxy-7a-(5-tert-butyldimethylsilyloxypentyl)-estr-4-en-3-one in 350 ml of methanol is allowed to stand with 35 ml of 8 vol% sulfuric acid for minutes at room temperature. The solution is diluted with diethyl ether, washed neutral with water, and dried. After the concentration by evaporation, 37.7 g of 17B-acetoxy-7a-(5hydroxypentyl)-estr-4-en-3-one is obtained as an oil.
c) 17B-Acetoxy-7a-(5-acetoxypentyl)-estr-4-en-3-one A solution of 37.7 g of 17B-acetoxy-7a-(5-hydroxypentyl)estr-4-en-3-one in 160 ml of pyridine is slowly mixed with 80 ml of acetic anhydride and stirred for 16 hours at 25 0 C. Then, it is diluted with ethyl acetate, and the organic phase, after )4U, ^t washing with sodium bicarbonate solution, is dried and concentrated by evaporation. The residue is chromatographed on silica gel, and 26.6 g of 17B-acetoxy-7a-(5-acetoxypentyl)-estr- 4-en-3-one is obtained as an oil. [a] 22 +20.0 0 (c 0.51% in chloroform) d) 17B-Acetoxy-7a-(5-acetoxypentyl)-estra-1,3,5(10)-trien-3-ol A solution of 5.18 g of lithium bromide and 26.73 g of copper(II) bromide in 260 ml of acetonitrile is added in drops to a solution, heated to 80 0 C, of 26.6 g of 178-acetoxy-7a-(5acetoxypentyl)-estr-4-en-3-one in 260 ml of acetonitrile within minutes while being stirred. After the addition is completed, the reaction solution is cooled, diluted with diethyl ether, washed with water and sodium bicarbonate solution and dried. The residue that is obtained after the concentration by evaporation is chromatographed on silica gel, and 21.3 g of 17B-acetoxy-7a- (5-acetoxypentyl)-l,3,5(10)-estratrien-3-ol is obtained as an oil. 22 +28.90 (c 0.535% in chloroform) e) 17B-Acetoxy-7a-(5-acetoxypentyl)-3-(tetrahydropyran-2-yloxy)estra-1,3,5(10)-triene A solution of 21.3 g of 17B-acetoxy-7a-(5-acetoxypentyl)estra-1,3,5(10)-trien-3-ol in 213 ml of tetrahydrofuran is allowed to stand with 21.3 ml of 3,4-dihydro-2H-pyran and 1.065 g of p-toluenesulfonic acid for 8 hours at room temperature. The reaction solution is mixed with 3 ml of pyridine, then diluted with diethyl ether, washed with water and dried. The residue that is obtained after the concentration by evaporation is chromatographed on silica gel, and 24.3 g of 17B-acetoxy-7a-(5acetoxypentyl)-3-(tetrahydropyran-2-yloxy)-estra-1,3,5(10)-triene is obtained as an oil. D 22 +31.50 (c 0.535% in chloroform) f) 17B-Acetoxy-7a-(5-hydroxypentyl)-3-(tetrahydropyran-2-yloxy)estra-1,3,5(10)-triene A solution of 10.2 g of 17B-acetoxy-7a-(5-acetoxypentyl)-3- (tetrahydropyran-2-yloxy)-estra-1,3,5(10)-triene in 205 ml of methanol is stirred with 33.7 ml of sodium hydroxide solution for minutes at 15 0 C. Then, it is diluted with diethyl ether, washed with water, dried on sodium sulfate and concentrated by evaporation in a vacuum. 5.6 g of 178-acetoxy-7a-(5hydroxypentyl)-3-(tetrahydropyran-2-yloxy)-estra-1,3,5(10)-triene is obtained. D2 +32.20 (c 0.505% in chloroform) g) 17B-Acetoxy-3-(tetrahydropyran-2-yloxy)-7a-(5-ptoluenesulfonyloxypentyl)-estra-1,3,5(10)-triene A solution of 5.5 g of 17B-acetoxy-7a-(5-hydroxypentyl)-3- (tetrahydropyran-2-yloxy)-estra-1,3,5(10)-triene in 47 ml of pyridine is allowed to stand with 5.5 g of p-toluenesulfonic acid anhydride for 45 minutes at room temperature. Then, the reaction solution is cooled in an ice bath, mixed with 4 ml of water and stirred for 45 more minutes. It is then diluted with ethyl acetate, washed with water, dried and concentrated by evaporation. 8.2 g of 178-acetoxy-3-(tetrahydropyran-2-yloxy)- 7a-(5-p-toluenesulfonyloxypentyl)-estra-l,3,5(lO) -triene is obtained as an oil.
h) 17B-Acetoxy-7r- (5-methylaminopentyl) (tetrahydropyran-2yloxy) -estra-1, 3,5(10) -triene 6.3 g of methylamine is condensed in a pressure pipe while being cooled with ice in a solution of 8.2 g of 17B-acetoxy-3- (tetrahydropyran-2-yloxy) -7cr-(5-p-toluenesulfonyloxypentyl) estra-l,3,5(10)-triene in 80 ml of tetrahydrofuran. The closed pressure pipe is then heated for 6 hours to 60 0 C. After cooling, it is evaporated to the dry state in a vacuum, and the residue is chromatographed on silica gel. 5.1 g of 17B-acetoxy-7cr-(5methylaminopentyl) (tetrahydropyran-2-yloxy) -estra-l, 3,5(10) triene is obtained as an oil. la) 2 2 +29.70 (c 0.535% in chloroform) i) 17B-Acetoxy-7cr-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthia) -propylamino] -pentyl)-3- (tetrahydropyran-2-yloxy) -estra- 1,3,5 (10) -triene A solution of 1.64 g of 173-acetoxy-7a-(5methylaminopentyl) (tetrahydropyran-2-yloxy) -estra-l, 3,5(10) triene in 25 ml of absolute DMF is stirred with 159 mg of sodium hydride under nitrogen for 2 hours at room temperature.
1.43 g of 3-chloropropyl-4,4,5,5,5-pentafluoropentylsulfide in 7 ml of absolute DMF is then added in drops and then stirred for 22 more hours at 80 0 C. The reaction solution is then diluted with ethyl acetate, washed with water, dried, concentrated by
Z)
OF:
evaporation, and the residue is chromatographed on silica gel.
820 mg of l7B-acetoxy-7ca-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino] -pentyl}-3- (tetrahydropyran-2yloxy-estra-l,3,5(l0)-triene is obtained as an oil.
D
2 2 +21.50 (c 0.51% in chlorofor~) j) 7a-{5-[N-Methy1-N-3-(4,4,5,5,5-pentafluoro-pentylthio)propylamino] -pentyl}-3- (tetrahydropyran-2-yloxy) -estra-1, 3,5(10) trien-178-ol A solution of 790 mg of 17B-acetoxy-7a-{5-[N-methyl-N-3- (4,4,5,5,5-pentafluoro-pentylthio) -propylarnino]-pentyl}-3- (tetrahydropyran-2-yloxy)-estra-l, 3, 5(10)-triene in 8 ml of methanol and 3 ml of THF is stirred with 430 mg of potassium carbonate for 18 hours at room temperature. The reaction solution is diluted with diethyl ether, washed with water, dried and concentrated by evaporation. 750 mg of crude N-3-(4,4,5,5,5-pentafluoro-pentylthio)-propylamino]-pentyl}-3- (tetrahydropyran-2-yloxy)-estra-l,3, 5(l0)-trien-17B-ol is obtained.
k) 7c-{-[N-Methyl-N-3-(4,4,5,5,5-pentafluoro-pentylthio)propylamino]-pentyl}-estra-1,3,5(1O) -triene-3,17B-diol A solution of 750 mg of 7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoro-pentylthio) -propylamino] -pentyl}-3- (tetrahydropyran- 2-yloxy)-estra-l,3,5(10)-trien-17B-ol in 28 ml of methanol and 2.8 ml of water is stirred with 350 mg of oxalic acid for 17 hours at room temperature. It is then diluted with ethyl 1'T acetate, washed with sodium bicarbonate solution and water, dried and concentrated by evaporation. The residue is chromatographed on silica gel, and 640 mg of 7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoro-pentylthio) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3,17B-diol is obtained as an oil. la ID 22= +24.00 (c= 0.515% in chloroform) 1) 7a-{5-[N-Methyl-N-3-(4,4, 5,5,S-pentafluoro-pentylthio) propylaminoJ-pentyl}-3- (tetrahydropyran-2-yloxy) -estra-1,3,5 trien-17 -one A solution of 900 mg of 7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoro-pentylthio) -propylamino]-pentyl}-3-(tetrahydropyran- 2-yloxy)-estra-l,3,5(10)-trien-17B-ol is mixed in 30 ml of toluene and 9.6 ml of cyclohexanone with a solution of 900 mg of aluminum isopropylate in 16 ml of toluene and heated for minutes while being distilled off slowly. The reaction solution is then diluted with ethyl acetate, washed with 20% potassium sodium tartrate solution, dried and concentrated by evaporation.
The residue is chromatographed on silica gel with hexane/ethyl acetate. 715 mg of 7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio) -propylamino]-pentyl}-3-(tetrahydropyran-2-yloxy) estra-l,3,5(10)-trien-17-one is obtained as an oil.
mn) 17c-Trifluoromethyl-3- (tetrahydropyran-2-yloxy) methyl-N-3- 5-pentafluoropentylthio) -propylamino] pentyl}-estra-i, 3,5 (10)-trien-17B-ol A solution of 500 mg of 7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino]-pentyl}-3-(tetrahydropyran-2yloxy)-estra-l,3,5(10)-trien-17-one (see Ausw.-Pat Example 2a) in ml of absolute tetrahydrofuran is mixed at a bath temperature of 0 0 C with 0.27 ml of (trifluoromethyl)-trimethylsi lane. Then, 0.2 ml of a 1.1-molar tetrabutylammonium fluoride solution is slowly added in drops and stirred for 45 minutes, again 1 ml of 1.1-molar tetrabutylammonium fluoride solution is added, and it is stirred for another 30 minutes. Then, it is diluted with ethyl acetate, washed with water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 285 mg of 17atrifluoromethyl-3-(tetrahydropyran-2-yloxy) -7oa-{5-[N-methyl-N-3- (4,4,5,5,5-pentafluoropentylthio) -propylamino]-pentyl}-estral,3,5(10)-trien-178-ol is obtained as an oil.
n) 17a-Trifluoromethyl-7ca-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino] -pentyl} -estra-1, 3,5 (10) triene-3, 17B-diol A solution of 280,mg of 17a-trifluoromethyl-3- (tetrahydropyran-2-yloxy)-7h-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino]-pentyl}-estra-l, 3,5(10) trien-17B-ol in 5.6 ml of methanol and 0.56 ml of water is stirred with 140 mg of oxalic acid for 18 hours at room temperature. Then, it is diluted with ethyl acetate, washed with sodium bicarbonate and water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 215 mg of 17atrifluoromethyl-7cr-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino]I-pentyl }-estra-l, 3 ,5(10) triene-3,17B-diol is obtained as an oil.
Example 6 15B,16B-Methano-17a-methyl-7a-{5-[N-methyl-N-3-(4,4,s,5,5pentafluoro-pentylthio) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3, 17B-diol a) 3-Benzyloxy-17, 17-ethylenedioxy-7a-(5-hydroxypentyl) -estra- 1,3,5(10) A solution of 32.7 g of 17,17-ethylenedioxy-7cr-(5hydroxypentyl)-estra-l,3,5(l0) ,15-tetraen-3-ol (see Example lh) in 327 ml of dimethylformamide is mixed at room temperature with 5.73 g of lithium hydroxide and stirred with 15.1 ml of benzyl bromide for 2 hours at 60 0 C. Then, it is diluted with ethyl acetate, washed with water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 32.8 g of 3-benzyloxy-17,17ethylenedioxy-7cr-(5-hydroxypentyl)-estra-1,3,5(1o) ,15-tetraene is obtained.
b) 3-Benzyloxy-7a-(5-hydroxypentyl)-estra-1,3,5(10),15-tetraen- 17-one A solution of 32.8 g of 3-benzyloxy-17,17-ethylenedioxy-7a- (5-hydroxypentyl)-estra-1,3,5(10),15-tetraene in 328 ml of acetone and 32.8 ml of water is stirred at room temperature with 1.033 g of para-toluenesulfonic acid for 2 hours. Then, it is diluted with diethyl ether, washed with sodium bicarbonate and water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane acetone. 25.4 g of 3-benzyloxy-7a-(5-hydroxypentyl)-estra- 1,3,5(10),15-tetraen-17-one is obtained.
c) 3-Benzyloxy-7a-(5-hydroxypentyl)-15B,16B-methano-estra- 1,3,5(10),15-tetraen-17-one 2.861 g of trimethylsulfoxonium iodide with 345 mg of sodium hydride is reacted in 65 ml of dimethylsulfoxide over a period of 2 hours at room temperature. 4.44 g of 3-benzyloxy-7a- (5-hydroxypentyl)-estra-1,3,5(10),15-tetraen-17-one is added to this solution, and it is stirred for 45 minutes at room temperature. The settled precipitate is filtered off, and it is washed with water. This precipitate is taken up with ethyl acetate, washed with water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with hexane/acetone. 2.8 g of 3-benzyloxy-7a-(5-hydroxypentyl)- 15B,16B-methano-estra-l,3,5(10),15-tetraen-17-one is obtained.
[a]D 22 +13.10 (c 0.525% in chloroform).
1 d) 3-Berizyloxy-15B, 16B-methano-7ca-(5-tosyloxypenty1) -estra- 1,3,5(10) ,15-tetraen-17-one A solution of 2.5 g of 3-benzyloxy-7cr-(5-hydroxypentyl)- 15B,16B-methano-estra-l,3,5(l0) ,15-tetraen-l7-one in 25 ml of pyridine is mixed at room temperature with 2.5 g of paratoluenesulfonic acid anhydride and allowed to stand for minutes, mixed with 1 ml of water while being cooled with ice and allowed to stand for another 45 minutes. Then, it is diluted with diethyl ether, washed with water, dried on sodium sulfate and concentrated by evaporation in a vacuum. 3.4 g of crude 3- 16B-methano-7a- (5-tosyloxypentyl) -estra- 1,3,5(10) ,15-tetraen-17-one is obtained.
e) 3-Benzyloxy-15B,16B-methano-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoro-pentylthio)-propylamino]-pentyl}-estra-1,3,5(10) tetraen-17-one A solution of 2.1 g of methyl-[3-(4,4,5,5,5pentafluoropentylthio)-propyl]-amine in 1 ml of dimethylformamide is added to a solution of 3.4 g of crude 3-benzyloxy-15B,16Bmethano-7a- (5-tosyloxypentyl) -estra-l, 3,5(10) ,15-tetraen-17-one in 34 ml of dimethylformamide, and it is stirred for 3.5 hours at 100 0 C. Then, it is diluted with ethyl acetate, washed with water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 2.6 g of 3-benzyloxy-15B,16B-methano- 7ca-5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-pentylthio)propylamino]-pentyl}-estra-1,3,5(l0) ,15-tetraen-17-one is obtained as an oil.
f) 15B,16B-Methano-7a-{5-[N-methy1-N-3-(4,4,5,5,5-pentafluoropentylthio) -propylaminoJ-pentyl}-3-hydroxy-estra-1, 3,5(10),15tetraen-17 -one A solution of 2.3 g of 3-benzyloxy-l5,l68-methano-7ca-{5-[Nmethyl-N-3- 5-pentaf luoro-pentylthio) -propylamino] ,15-tetraen-17-one in 53 ml of dichioromethane is stirred at a bath temperature of 0 0 C with 1. 12 ml of N,N-dimethylaniline and 1.64 g of aluminum chloride (anhydrous) for 4.5 hours. Then, it is diluted with ethyl acetate, washed with 30% potassium-sodium tartrate solution and water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/ methanol. 1.52 g of 15B,161-methano-7a-{5-[N-methyl-N-3- (4,4,5,5,5-pentafluoro-pentylthio)-propylamino]-pentyl}-3hydroxy-estra-l,3,5(l0),15-tetraen-17-one is obtained as an oil.
I tI 2= -2.50 (c 0.505% in chloroform) g) 15B,16B-Methano-17a-methyl-7ca-{5-[N-methy1-N-3-(4,4,5,5,5pentafluoro-pentylthio) -propylanino] -pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 1.8 ml of a 3-molar methylmagnesium bromide solution is added in drops to a solution of 515 mg of 158,16B-methano-7a-{5- [N-methyl-N-3- 5-pentafluoro-pentylthio) -propylamino] .,pentyll-3-hydroxy-estra-1,3,5(10) ,15-tetraen-17-one in 10 ml of tetrahydrofuran at a bath temperature of 0 0 C, and it is stirred for 2 hours at room temperature. Then, it is diluted with ethyl acetate, washed with saturated ammonium chloride solution and water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 395 mg of 15B,168-methano-l7cr-methyl- [N-methyl-N-3- 5-pentafluoro-pentylthio) propylamino]-pentyl}-estra-l,3,5(lo)-triene-3,l7B-diol is obtained as an oil. a I 2 5.10 (c 0.52% in chloroform) Example 7 158,16B-Methano-17ca-methyl-7ca-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoro-pentanesulfinyl) -propylamino) -pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol A solution of 115 mg of 15B,16B-methano-17a-methyl-7a-{5-[Nmethyl-N-3- 5-pentafluoro-pentylthio) -propylamino] pentyl}-estra-l,3,5(lQ)-triene-3,17B-diol (see Example 6) in 5 ml of methanol is stirred with 80 mg of sodium periodate for 3 hours at room temperature. Then, it is diluted with ethyl acetate, washed with water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 65 mg of 15f3,161-methano-17ca-methy1- [N-methyl-N-3- 5,5, 5-pentafluoro-pentanesulfinyl) propylamino]-pentyl}-estra-l,3,5(1o)-triene-3,l7B-diol is obtained as an oil. I CCI D 22 -l13.30 (c 0.27% in chloroform) Example 8 15B,16B-Methano-7cr-{S-[N-me thyl-N-3-(4,4,5,5,5-pentafluoropentylthio) -propylamino]-pentyl}-estra-1,3,5 (10) -triene-3,178diol A solution of 500 mg of 15B,16B-methano-7a-{5-[N-methyl-N-3- 5, 5,5-pentafluoro-pentylthio) -propylamino] -pentyl hydroxy-estra-l,3,5(l0),15-tetraen-17-one (see Example 6f) in ml of methanol and 1 ml of water is stirred with 100 mg of sodium borohydride for 3 hours at room temperature. Then, it is diluted with ethyl acetate, washed with water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 340 mg of 15B,16Bmethano-7ca-{5-[N-methyl-N-3- 5-pentafluoro-pentylthio) propylamino]-pentyl}-estra-l,3,5(l0)-triene-3,17B-diol is obtained as an oil. [alo 22 +11.90 (c 0.52% in chloroform) Example 9 15B,168-Methano-7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentanesulfinyl) -propylamino]-pentyl}-estra-1,3, 5(10) -triene- 3, 17B-diol A solution of 100 mg of 15B,16B-methano-7a-{5-[N-methyl-N-3- 5-pentafluoro-pentylthio) -propylamino]-pentyl}-estral,3,5(10)-triene-3,17B-diol (see Example 8) in 5 ml of methanol is stirred with 80 mg of sodium periodate for 3 hours at room temperature. Then, it is diluted with ethyl acetate, washed with water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/ 51 methanol. 70 mg of 15B,16B-methano-7a-{5-[N-methyl-N-3- (4 5, 5,5-pentafluoro-pentanesulfinyl) -propylamino]I-pentyl estra-l,3,5(l0)-triene-3,17B-diol is obtained as an oil. [CrID 22 +12.20 (c 0.515%) in chloroform).
Example 15B-Methyl-7cz-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio) -propylamino]-pentyl}-estra-1,3,5 (10) -triene-3, 17Bdiol a) 3-Benzyloxy-7a-(5-hydroxypentyl) -15B-methyl-estra-1,3,5 trien-17-one 5.35 g of copper(I) iodide is added to an ice-cooled solution of 11.9 ml of a 3-molar methylmagnesium bromide solution in 68 ml of tetrahydrofuran under a nitrogen stream. Then, a solution of 4.26 g of 3-benzyloxy-7ca-(5-hydroxypentyl)-estral,3,5(l0),15-tetraen-17-one (see Example 6b) in 50 ml of tetrahydrofuran is added in drops and stirred for 30 minutes at a bath temperature of 0 0 C. Then, the excess reagent is decomposed with saturated ammonium chloride solution, diluted with ethyl acetate, washed with ammonium chloride solution and water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with hexane/acetone. 3.6 g of 3benzyloxy-7a- (5-hydroxypentyl) -15B-methyl-estra-l, 3, 5(10) -trien- 17-one is obtained as an oil. [a ID 22 +66.40 (c =0.515% in chloroform) b) 3-Benzyloxy-158-methyl-7a-(5-tosyloxypentyl)-estra-1,3,5(10)trien-17-one A solution of 3.6 g of 3-benzyloxy-7a-(5-hydroxypentyl)-15Bmethyl-estr a-1,3,5(l0)-trien-17-one is tosylated as described in Example 6d. 4.9 g of crude 3-benzyloxy-15B-methyl-7a-(5tosyloxypentyl) -estra-l, 3,5(10) -trien-17-one is obtained.
c) 3-Benzyloxy-15B-methy1-7a- (5-N-methylaminopentyl) -estra- 1,3,5(10) -trien-17-one 3.8 g of methylamine is condensed in a solution of 4.9 g of 3-benzyloxy-15B-methy-7a- (5-tosyloxypentyl) -estra-l, 3,5 (10) trien-17-one in 30 ml of tetrahydrofuran in a pressurized reactor while being cooled, the closed reactor is heated for 5.5 hours to cooled and opened. Then, it is diluted with ethyl acetate, washed with water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol/1% triethylamine. 3.15 g of 3benzyloxy-15B-methyl-7a- (5-N-methylaminopentyl) -estra-l, 3,5(10) trien-17-one is obtained as an oil.
d) 3-Benzyloxy-15B-methyl-7a-{5-[N-methy1-N-3-(4,4,5,5,5pentafluoro-pentylthio) -propylamino] -pentyl}-estra-1, 3,5(10) trien-17-one A solution of 3.15 g of 3-benzyloxy-1513-methyl-7a-(5-Nmethylaminopentyl)-estra-l,3,5(lo)-trien-l7-one in 31.5 ml of absolute dimethylformamide'is mixed with 228 mg of 80% sodium hydride and stirred for 5 hours at room temperature, mixed with 2.6 g of 3-chloropropyl-4,4,5,5,5-pentafluoropentylsulfide in 2 ml of absolute dimethylformamide and stirred for 24 hours at 8000. Then, it is diluted with ethyl acetate, washed with sodium bicarbonate and wat er, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 3.1 g of 3-benzyloxy-158-methyl-7a-{5- [N-methyl-N-3- 5-pentafluoro-pentylthio) -propylamino] pentyl}-estra-1,3,5(lQ) ,15-trien-17-one is obtained as an oil.
e) 3-Hydroxy-158-methy1-7a-{5-[N-methy1-N-3-(4,4,5,5,5pentafluoro-pentylthio) -propylamino] -pentyl}-estra-1, 3,5(10)trien-17-one A solution of 3.1 g of 3-benzyloxy-15B-methyl-7ca-{5-[Nmethyl-N-3- 5-pentafluoro-pentylthio) -propylamino] pentyl}-estra-l,3,5(l0)-trien-17-one is debenzylated as described in Example 6f. 830 mg of 3-hydroxy-15B-methyl-7cx-{5-[N-methyl-N- 3- 5,5, 5-pentafluoro-pentylthio) -propylamino] -pentyl} -estral-,3,5(l0)-trien-17-one is obtained as an oil.
f) 15B-Methyl-7cr-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)-propylamino]-pentyl}-estra-1,3,5(1o)-triene-3,17Bidiol A solution of 460 mg of 3-hydroxy-15B-methyl-7oa-{5-[Nmethyl-N-3- 5-pentafluoro-pentylthio) -propylamino] pentyl}-estra-l,3,5(lO)-trien-l7-one is reduced as described in Example 8. 200 mg of 158-methyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoro-pentylthio) -propylamino] -pentyl}-estra-l, 3,5 (10) triene-3,17B-diol is obtained as an oil. [aID 22 +4.5 (c 0.51% in chloroform) Example 11 15B,17a-Dimethyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)-propylamino]-pentyl}-estra-1,3,5(10)-triene-3,17Bdiol 1.44 g of dried cerium(III) chloride is stirred for 2 hours at room temperature in 15 ml of tetrahydrofuran, mixed with 3.75 ml of a 3-molar methylmagnesium bromide solution while being cooled with ice, stirred for 15 minutes while being cooled and for 30 minutes at room temperature, a solution of 650 mg of 3hydroxy-15B-methyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)-propylamino]-pentyl}-estra-l,3,5(10)-trien-17-one (see Example 10e) in 7 ml of tetrahydrofuran is added in drops, stirred for 2 hours at room temperature, and excess reagent is decomposed with saturated ammonium chloride solution. Then, it is diluted with ethyl acetate, washed with saturated ammonium chloride solution and water, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 145 mg of 15B,17adimethyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-pentylthio)propylamino]-pentyl}-estra-l,3,5(10)-triene-3,17B-diol is obtained as an oil. 22 -7.30 (c 0.505% in chloroform).
Example 12 11B-Fluoro-7Cx-{5-[N-methyl-N-3- 4,5, 5,5-pentafluoropentylthio) propylamino]-pentyl}-estra-1,3, 5(10) -triene-3, 17B-diol a) 11B-Fluoro-estr-4-ene-3, 17-dione 4.6 ml of perfluorobutane-l-sulfonic acid fluoride is added in drops to 5.0 g of lla-hydroxy-estr-4-ene-3,17-dione in 100 ml of toluene and 7.3 ml of l,8-diazabicyclo[5,4,0]undec-7-ene at 0 0 C. After 30 minutes, the solution is diluted with ethyl acetate, washed with saturated sodium chloride solution, dried and concentrated by evaporation in a vacuum. After the crude product is chromatographed on silica gel with a hexane-ethyl acetate gradient, 3.8 g of llB-fluoro-estr-4-ene-3,17-dione with a melting point of 173-174 0 C is obtained.
b) 113-Fluoro-3-methoxy-estra-3, 5-dien-17-one 7.8 g of llB-fluoro-estr-4--ene-3,17-dione is stirred in ml of 2,2-dimethoxypropane with 780 mg of pyridinium-toluene-4sulfonate for 5 hours at 80 0 C. Then, 1.5 ml of triethylamine is added, it is diluted with ethyl acetate and washed with saturated sodium chloride solution. After crystallization from methanol, 5.3 g of llB-fluoro-3-methoxy-estra-3,5-dien-17-one with a melting point of 173 0 C is obtained.
c) 11B-Fluoro-estra-4, 6-diene-3, 17-dione ml of a 10% sodium acetate solution and, in portions, g of l,3-dibromo-5,5-dimethylhydantoin are added in succession to g of llB-fluoro-3-methoxy-estra-3,5-dien-17-one in 50 ml of DMF at 0 C. After 30 minutes, 2.3 g of sodium sulfite is added and then 2.5 g of lithium bromide and 2.0 g of lithium carbonate, and it is stirred for 2 hours at 100 0 C. The reaction mixture is stirred into ice water. The precipitated product is suctioned off, dissolved in ethyl acetate, washed with water, dried and concentrated by evaporation in a vacuum. After recrystallization from ethyl acetate, 3.6 g of 118-fluoro-estra-4,6-diene-3,17dione with a melting point of 198 0 C is obtained.
d) 11B-Fluoro-7a-(5-tert-butyl-dimethylsilyloxypentyl)-estr-4ene-3,17-dione 7.9 g of magnesium in 40 ml of THF is reacted to form the Grignard reagent under nitrogen with a solution of 95.3 g of 1- [Tetrahedron Letters 1982, 4147-4150] in 260 ml of THF. At -30 0 C, 32 g of copper(I) iodide is added, and then 29 g of 118-fluoro-estra-4,6-diene- 3,17-dione in 290 ml of THF is added in drops. After the reaction is completed, it is mixed with 20.4 ml of glacial acetic acid, and the reaction mixture is stirred into ice water. The precipitated product is suctioned off, dissolved in ethyl acetate, washed neutral with water and dried. After the crude product is chromatographed on silica gel with a hexane-ethyl acetate gradient, 23.9 g of 118-fluoro-7a-(5-tert-butyldimethylsilyloxypentyl)-estr-4-ene-3,17-dione is obtained as a foam.
e) 11B-Fluoro-7a-(5-hydroxypentyl)-estr-4-ene-3,17-dione A solution of 23.1 g of 118-fluoro-7a-(5-tert-butyldimethylsilyloxypentyl)-estr-4-ene-3,17-dione in 115 ml of THF and 64 ml of water are stirred with 128 ml of glacial acetic acid for 2.5 hours at 50 0 C. The reaction mixture is concentrated by evaporation in a vacuum, taken up in ethyl acetate, washed with water and dried. 20.4 g of 118-fluoro-7a-(5-hydroxypentyl)-estr- 4-ene-3,17-dione is obtained as a foam.
f) 7a-(5-Acetoxypentyl)-11B-fluoro-estr-4-ene-3,17-dione g of 11B-fluoro-7a-(5-hydroxypentyl)-estr-4-ene-3,17dione in 100 ml of pyridine can be reacted over a period of 2 hours with 50 ml of acetic anhydride at 25 0 C. Then, 5 ml of water is added at 0 0 C, and it is stirred for 45 minutes. It is extracted with diethyl ether, washed with 2N sulfuric acid, pyridine-free, and the solution is neutralized in succession with saturated sodium bicarbonate solution and water. After drying and concentration by evaporation in a vacuum, the crude product is chromatographed on silica gel with a hexane-ethyl acetate gradient. 17 g of 7a-(5-acetoxypentyl)-118-fluoro-estr-4-ene- 3,17-dione with a melting point of 78.4 0 C is obtained.
g) 7a-(5-Acetoxypentyl)-11B-fluoro-3-hydroxy-estra-1,3,5(10)trien-17-one 18.6 of copper(II) bromide and 3.6 g of lithium bromide are added to 16.5 g of 7a-(5-acetoxypentyl)-118-fluoro-estr-4-ene- 3,17-dione in 190 ml of acetonitrile at 80 0 C. After 15 minutes, RjZ, iffl-ta the reaction mixture is stirred into sodium bicarbonatecontaining ice water. The precipitated product is suctioned off, dissolved in ethyl acetate, washed with water, dried and concentrated by evaporation in a vacuum. After the crude product is chromatographed on silica gel with a hexane-ethyl acetate gradient, 8.5 g of 7a-(5-acetoxypentyl)-118-fluoro-3-hydroxyestra-1,3,5(10)-trien-17-one is obtained as a foam.
h) 7a-(5-Acetoxypentyl)-11B-fluoro-3-(tetrahydropyran-2-yloxy)estra-1,3,5(10)-trien-17-one 8.2 g of 7a-(5-acetoxypentyl)-118-fluoro-3-hydroxy-estra- 1,3,5(10)-trien-17-one in 86 ml of THF is stirred with 8.6 ml of 3,4-dihydro-2H-pyran and 820 mg of p-toluenesulfonic acid hydrate for 2.5 hours at room temperature. Then, 0.5 ml of triethylamine is added, it is diluted with ethyl acetate, washed with saturated sodium chloride solution, dried and concentrated by evaporation in a vacuum. After the crude product is chromatographed on silica gel with a hexane-ethyl acetate gradient, 7.8 g of acetoxypentyl)-118-fluoro-3-(tetrahydropyran-2-yloxy)-estra- 1,3,5(10)-trien-17-one is obtained as a foam.
i) 11B-Fluoro-7a-(5-hydroxypentyl)-3-(tetrahydropyran-2-yloxy)estra-1,3,5(10)-trien-17-one 7.4 g of 7a-(5-acetoxypentyl)-118-fluoro-3-(tetrahydropyran- 2-yloxy)-estra-1,3,5(0)-trien-17-one in 370 ml of methanol and 37 ml of water is stirred at room temperature with 1.8 g of potassium carbonate. After 3 hours, the reaction mixture is added to ice water. The precipitated product is suctioned of f, dissolved in ethyl acetate, washed neutral with water, dried and concentrated by evaporation in a vacuum. 7.0 g of llB-fluoro-7a- (tetrahydropyran-2-yloxy) -estra-l, 3,5(10) trien-17-one is obtained as a foam.
j) 11B-Fluoro-3-(tetrahydropyran-2-yloxy) -7a- toluenesulfonyloxypentyl) -estra-1,3, 5(10) -trien-17-one 6.7 g of llB-fluoro-7a- (5-hydroxypentyl) (tetrahydropyran- 2-yloxy)-estra-1,3,5(10)-trien-17-one in 70 ml of pyridine is stirred at room temperature with 6.0 g of p-toluenesulfoiic acid anhydride for 3 hours. The solution is diluted with ethyl acetate, washed with saturated sodium chloride solution, dried and concentrated by evaporation in a vacuum. The crude product is chromatographed on silica gel with a hexane-ethyl acetate gradient. 5.7 g of llt8-fluoro-3-(tetrahydropyran-2-yloxy)-7a-(5p-toluenesulfonyloxy-pentyl) -estra-1, 3,5(10) -trien-17-one is obtained as a foam.
kc) 111-Fluoro-7c-{-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino] -pentyl}-3- (tetrahydrapyran-2yloxy) -estra-1, 3,5 (10) -trien-17-one g of llB-fluoro-3-(tetrahydropyran-2-yloxy)-7z-(5-ptoluenesulfonyloxypentyl)-estra-l,3,5(lo)-trien-l7-one in 44 ml of DMF is stirred at 80 0 C with 1.2 g of methyl-(3-(4,4,5,5,5pentafluoropentyl-thio) -propyl]-amine. After 6.5 hours, the reaction mixture is mixed with water. It is extracted with ethyl acetate, washed with saturated sodium chloride solution and concentrated by evaporation in a vacuum. After the crude product is chromatographed on silica gel with a methylene chloridemethanol gradient, 1.3 g of 111-fluoro-7a-{5-fN-methyl-N-3- 5-pentafluoropentylthio) -propylamino] -pentyl}-3- (tetrahydrapyran-2-yloxy)-estra-1,3,5(10)-trien-17-one is obtained as an oil.
1) 118-Fluoro-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino] -perityl}-3- (tetrahydrapyran-2yloxy)-estra-1,3,5 (1O)-trien-17B-ol 350 mg of sodium borohydride is added in portions to 2.0 g of 11B-fluoro-7cz-{5-(N-methyl-N-3-(4,4,5,5,5-pentafluoropenthylthio) -propylaminolpentyl}-3- (tetrahydrapyran-2-yloxy) estra-l,3,5(l0)-.trien-17-one in 17 ml of THF, 10 ml of ethanol* and 4.2 ml of water at 0 0 C. After 30.minutes,.the reaction mixture is stirred into ice water, extracted with ethyl acetate, washed with saturated sodium chloride solution and concentrated by evaporation in a vacuum. 1.7 g of crude methyl-N-3- (4 5-pentafluoropentylthio) -propylamino] pentyl}-3-(tetrahydrapyran-2-yloxy) -estra-l, 3,5(10)-trien-17B-ol is obtained as a foam.
m) 11B-Fluoro-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 17B-diol A solution of 1.6 g of llB-fluoro-7ca-{5--[N-methyl-N-3- (4,4,5,5,5-pentafluoropentylthio) -propylalnino]-pentyl}-3- (tetrahydrapyran-2-yloxy)-estra-l,3,5 (10) -trien-17B-ol in 20 ml of methanol and 2 ml of water is stirred with 1.0 g of oxalic acid. After 3 hours, the reaction mixture is added to ice water.
It is extracted with methylene chloride, washed with saturated sodium chloride solution, dried and concentrated by evaporation in a vacuum. After the crude product is chromatographed on silica gel with a methylene chloride-methanol gradient, 1.1 g of 18-fluoro-7a-{5-[N-methyl-N-3-(4,4,5,5, propylamino]-pentyl}-estra-l,3,5(l0)-triene-3,17B-diol with a melting point of 95 0 C is obtained.
Example 13 11B-Fluoro-7ca-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfinyl) -propylamino] -pentyl}-estra- 1,3,5 (10)-triene-3,178-diol 580 mg of llB-fluoro-7a-{5-(N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino]-pentyl}-estra-l, 3,5(10) triene-3,17B-diol in 24 ml of methanol and 1.1 ml of water are stirred at room temperature with 350 mg of sodium periodate.
After 1.5 hours, it is diluted with methylene chloride, washed with saturated sodium chloride solution, dried and concentrated by evaporation in a vacuum. The crude product is chromatographed on silica gel with a methylene chloride-methanol gradient. 287 mg of 11B-fluoro-7ca-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfinyl) -propylamino] -pentyl}-estra-l, 3,5(10) triene-3, 17B-diol with a melting point of 87'C is obtained.
Example 14 118-Fluoro-7a-{5-[N-methyl-N-3- (4,4,5,5,5pentafluoropentanesulfonyl) -propylamino) -pentyl}-estra- 1,3,5(10) -triene-3, 178-diol a) 118-Fluoro-7ca-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl}-3- (tetrahydrapyran-2-yloxy) -estra-1,3, 5(10) -trien-17-one 2. 0 g of llB-fluoro-3- (tetrahydropyran-2-yloxy-7a- toluenesulfonyloxypentyl)-estra-1,3, 5(lQ)-trien-17-one in 40 ml of DMF is stirred with 2.1 g of methyl-[3-(4,4,5,5,5-pentafluoropentanesulfonyl)-propyl]-amine at 80'C. After 7 hours, the reaction mixture is added to ice water, extracted with ethyl acetate, washed with saturated sodium chloride solution, dried and concentrated by evaporation in a vacuum. After the crude product is chromatographed on silica gel with a methylene chloride-methanol gradient, 1.1 g of 1113-fluoro-7a-{5-jjN-methyl- N-3- 5-pentaf luoropentanesulfonyl) -propylamino] -pentyl}- 3-(tetrahydrapyran-2-yloxy)-estra-1, 3,5(lO)-trien-17-one is obtained as an oil.
b) 18-Fluoro-7ca-{5-[N-methy1-N-3-(4,4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl}-3- (tetrahydrapyran-2-yloxy) -estra-1, 3,5(10) -trien-178-ol g of llB-fluoro-7a-{5-(N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl}-3- (tetrahydrapyran-2-yloxy) -estra-1, 3,5(10) -trien-17-one is mixed at 0 0 C in a mixture of 13 ml of THF, 7.5 ml of ethanol and 3.2 ml of water in portions with 270 mg of sodium borohydride. After minutes, water is added, it is extracted with ethyl acetate, washed with saturated sodium chloride solution, dried and concentrated by evaporation in a vacuum. 1.5 g of llB-fluoro-7a- [N-methyl-N-3- 5-pentaf luoropentanesulfonyl) propylamino] -pentyl}-3-(tetrahydrapyran-2-yloxy) -estra-l, 3,5(10) trien-17B-ol is obtained as a crude product.
c) 11B-Fluoro-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl) -propylamino]-pentyl}-estra-1,3,5 triene-3, 17B-diol 1.4 g of 18-fluoro-7a-{5-(N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl}-3- (tetrahydrapyran-2-yloxy) -estra-l,3,5(l0) -trien-17B-ol is stirred in 18 ml of methanol and 1.8 ml of water at room temperature with 900 mg of oxalic acid. After 4 hours, the reaction mixture is stirred into ice water. The precipitated product is taken up in methylene chloride, washed with water, dried and concentrated by evaporation in a vacuum. After the crude product is chromatographed on silica gel with a methylene chloride-methanol gradient, 325 mg of 118-fluoro-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl)-propylamino]-pentyl}-estra-1,3,5(10)triene-3,17B-diol with a melting point of 70 0 C is obtained.
Example 16a-Fluoro-17a-methyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio)-propylamino]-pentyl}-estra-1,3,5(10)triene-3,17B-diol a) 7a-(5-Chloropentyl)-estr-4-ene-3,17-dione 11.6 g of magnesium chips is suspended in 150 ml of anhydrous tetrahydrofuran, and the Grignard reagent is prepared with 58.8 ml of l-bromo-5-chloro-pentane in 40 ml of anhydrous tetrahydrofuran. It is stirred for 30 minutes at room temperature, diluted with another 100 ml of anhydrous tetrahydrofuran and cooled to -70 0 C. Then, the solution of 3.04 g of copper(I)-bromide-dimethylsulfide complex in 72 ml of 1,3dimethyltetrahydro-2(1H)-pyrimidinone (DMPU) and 150 ml of tetrahydrofuran are added in drops at an internal temperature of to -70 0 C. Ultimately, the solution of 50 g of estra-4,6diene-3,17-dione (Steroids Vol. 1, 1963, 223) and 75 ml of trimethylchlorosilane in 700 ml of anhydrous tetrahydrofuran is added within 2.5 hours. The mixture can be heated slowly to room temperature in a cooling bath while being stirred, acidified the next morning with 48 ml of acetic acid while being cooled with ice and mixed with ethyl acetate after being stirred for minutes. The organic phase is extracted three times with saturated ammonium chloride solution, the aqueous phase is extracted with ethyl acetate, then the combined organic phases are washed with sodium bicarbonate solution, dried with magnesium sulfate and concentrated by evaporation in a vacuum. The residue of 53 g is chromatographed on silica gel with hexane/ dichloromethane and ethyl acetate, yield 35 g of chloropentyl)-estr-4-ene-3,17-dione The same product is obtained from 8.05 g of hydroxypentyl)-estr-4-ene-3,17-dione (Example Ib) by a reaction with 8.66 g of triphenylphosphine in 85 ml of carbon tetrachloride and 30 ml of acetonitrile at room temperature. The reaction mixture is diluted with dichloromethane, shaken out with saturated bicarbonate solution and with saturated common salt solution, dried with sodium sulfate and concentrated by evaporation in a vacuum. The residue is chromatographed on silica gel with dichloromethane and ethyl acetate, whereby 4.08 g of 7a-(5-chloropentyl)-estr-4-ene-3,17-dione is obtained, [a]D 22 +680 (c 0.5% in chloroform) b) 7a-(5-Chloropentyl)-3-hydroxy-estra-1,3,5(10)-trien-17-one 18.96 g of 7a-(5-chloropentyl)-estr-4-ene-3,17-dione is dissolved in 350 ml of anhydrous acetonitrile and mixed under inert gas at 80 0 C with a solution of 4.36 g of lithium bromide and 22.5 g of copper(II) bromide in 390 ml of anhydrous acetonitrile. It is stirred for 5 more minutes, the mixture is cooled in an ice bath and mixed with water and ethyl acetate.
The organic phase is shaken out with saturated sodium bicarbonate solution, the aqueous phase with ethyl acetate, the combined organic phases with saturated common salt solution, dried with sodium sulfate and concentrated by evaporation in a vacuum. The raw yield of 19.1 g is chromatographed on silica gel in hexane and ethyl acetate, whereby 10.0 g of oily 7a-(5-chloropentyl)-3hydroxy-estra-1,3,5(10)-trien-17-one is obtained, which can be crystallized from hexane/dichloromethane.
Melting point 143.5 0 C, [a]D 22 +1120 (c 0.5% in chloroform) c) Bis-3,17-trimethylsilyloxy-7a-(5-chloropentyl)-estra- 1,3,5(10),16-tetraene 5.65 g of 7a-(5-chloropentyl)-estra-1,3,5(10)-trien-3-ol-17one, 9 ml of triethylamine and 9 ml of trifluoromethanesulfonic acid trimethylsilyl ester are dissolved in 75 ml of benzene, and it is refluxed for 2 hours. After cooling, it is diluted with hexane, the upper phase is shaken out with saturated sodium bicarbonate solution and with saturated common salt solution, dried with sodium sulfate, and concentrated by evaporation in a vacuum, and it yields bis-3,17-trimethylsilyloxy-7a-(5chloropentyl)-estra-1,3,5(10),16-tetraene as an oil.
d) 7a-(5-Chloropentyl)-16a-fluoro-estra-1,3,5(10)-trien-3-ol-17one The product of the test above is dissolved in 150 ml of anhydrous dichloromethane and mixed with 14.2 g of Nfluorobenzenesulfonimide. After 2 hours of stirring at room temperature, 50 ml of 8% sulfuric acid is added, it is stirred intensively for another 3 hours, and then the phases are separated. The water phase is shaken out twice with dichloromethane, the organic phase is shaken out in succession with saturated sodium bicarbonate and sodium chloride solution, dried with sodium sulfate and concentrated by evaporation in a vacuum. The crude product of 15.3 g is chromatographed on silica gel with dichloromethane/diisopropyl ether, whereby 2.92 g of 7a- (5-chloropentyl)-16a-fluoro-estra-l,3,5(10)-trien-3-ol-17-one is obtained as an oil. The substance can be crystallized from diisopropyl ether, melting point 176°C, [a]D 22 +1140 (c 0.5% in chloroform).
e) 7a-(5-Chloropentyl)-16a-fluoro-17a-methyl-estra-1,3,5(10)triene-3,17B-diol g of 7a-(5-chloropentyl)-16a-fluoro-estra-l,3,5(10)trien-3-ol-17-one is dissolved in 300 ml of anhydrous toluene under inert gas and mixed with 3 portions of 20 ml each of a molar solution of methyllithium and lithium bromide in ether at room temperature at an interval of 15 minutes. After another minutes, the reaction mixture is stirred into a semi-saturated ammonium chloride solution while being cooled with ice, acidified with 8% sulfuric acid and extracted with ethyl acetate. The combined organic phases are shaken out with sodium chloride solution, dried with sodium sulfate and concentrated by evaporation in a vacuum. The crude product of 3.2 g is chromatographed on silica gel with hexane and methyl-tert-butyl ether. The polar fraction of 1.21 g is 7a-(5-chloropentyl)-16afuluoro-17a-methyl-estra-l,3,5(10)-triene-3,178-diol, which crystallizes from diisopropyl ether/hexane, melting point 700C, (I tID 22- +70 (c 0. 5% in chloroform) f) 16a-Fluoro-17a-methyl-7a-s-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino]-pentyl}-estra-i, 3,5(10)triene-3, 178-diol 40.8 mg of 7a-(5-chloropentyl)-l6a-fluoro-17a-methyl-estral,3,5(l0)-triene-3,17B-diol is dissolved in 0.5 ml of dimethylformamide, and the solution of 58 mg of 3-(Nmethylamino)-propyl-4,4,5,5,5-pentafluoropentyl-sulfide and 13 mg of lithium iodide is added and heated for 17 hours to 10000 under inert gas. After cooling, the mixture is mixed with ethyl acetate, shaken out in succession with saturated sodium bicarbonate and common salt solution, dried with sodium sulfate, and the solvent is evaporated in a vacuum. The residue is chromatographed on silica gel with ethyl acetate/methanol, yield mg of 16a-fluoro-17a-methyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino] -pentyl}-estra-l, 3,5(10) triene-3,17B-diol as an oil.
Example 16 16c-Fluoro-17B-methyl-7a-{s-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino]-pentyl}-estra-i, 3,5(10)trierie-3, 17a-diol As a nonpolar product of the chromatography in Example 7a- (5-chloropentyl) -16a-fluoro-17B-methyl-estra-l, 3,5(10) -triene- 1QN\3,17a-diol accumulates in an amount of 0.48 g. By 1. 11 crystallization from diisopropyl ether/hexane, crystals with a melting point of 65 0 C and (a]I D' 2- +50 (c 0.5% in chloroform) are obtained.
41 mg of the crystals are reacted as described in Example whereby 23 mg of 16a-fluoro-17B-methyl-7a-{5-(N-methyl-N-3- 5-pentafluoropentylthio) -propylamino]-pentyl}-estral,3,5(l0)-triene-3,17a-diol is obtained.
Example 17 16a-Fluoro-17a-methy1-7a-{5- [N-methyl-N-3- 5,5,5-pentafluoropentanesulfinyl) -propylaiuinoj-pentyl}estra-1,3,5 (1O)-triene-3, 178-diol By oxidation with sodium periodate, as described in Example 2, 38 mg of l6a-fluoro-17a-methyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfinyl)-propylamino]-pentyl}-estra-1,3,5(lo)triene-3,17B-diol is obtained from 72 mg of 16a-fluoro-17amethyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)propylamino] -pentyl}-estra-l, 3,5 (10) -triene-3, 17B-diol.
Example 18 16a-Fluoro-17a-methyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3, 17B-diol As described in Example 15f) 40.8 mg of chloropentyl)-16a-fluoro-17a-methyl-estra-1,3,5(1o)-triene-3,17Bdiol in dimethylformamide is reacted with 70 mg of 3-(N- ,Fethylamino)-propy1-4,4,5,5,5-pentafluoropentylsulfone. After working-up, 21 mg of 16a-fluoro-17a-methyl-7ca-{5-[N-methyl-N-3- (4,4,5,5,5-pentafluoropentanesulfonyl)-propylamino]-pentyl}estra-l,3,5(lO)-triene-3,17B-diol is obtained as an oil.
Example 19 16ca-Fluoro-7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)propylaminoJ-pentyl}-estra-1,3,5(1O)-triene-3,17B-diol a) 7a-(5-Chloropentyl)-16Q-fluoro-estra-1,3,5(10)-triene-3,17Bdiol and 7a-(5-chloropentyl)-16ca-fluoro-estra-1,3,5(lo)-triene- 3, 17a-diol 392 mg of 7ca-(5-chloropentyl)-l6a-fluoro-estra-l,3,5(10)trien-3-ol-17-one, Example 15d), in 2 ml of anhydrous tetrahydrofuran is dissolved, and 1.1 ml of a 1-molar solution of lithium tri-tert-butoxyaluminum hydride in tetrahydrofuran is added while being cooled in an ice bath. It is allowed to stir for 30 minutes at O 0 C, then mixed with water and 8% sulfuric acid until a weakly acidic reaction is achieved, and it is extracted three times with ethyl acetate. The organic phase is washed with saturated sodium chloride solution, dried with sodium sulfate and evaporated to the dry state in a vacuum. The crude product is chromatographed on silica gel with hexane/ethyl acetate, whereby 118 mg of 7a-(5-chloropentyl) -16a-fluoro-estra-l,3,5(lO)-triene- 3,17B-diol and 138 mg of 7a-(5-chloropentyl)-l6cr-fluoro-estra- 1,3,5(l0)-triene-3,l7r-diol is obtained, both as solid foam.
b) 16c-Fluoro-7a-{5-[N-methyl-N-3-(4,4,S,5,5pentafluoropentylthio) -propylamino]-pentyl}-estra-1,3,s triene-3, 17B-diol By reaction of 100 mg of 7cx-(5-chloropentyl)-l6ca-fluoroestra-1,3,5(l0)-triene-3,17B-diol with 3-(N-methylamino)-propyl- 4,4,5,5,5-pentafluoropentyl sulfide, as described in Example 83 mg of l6a-fluoro-7ca-{5-[N-methy1-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino]-pentyl}-estra-l, 3,5(10) triene-3,17B-diol is obtained as solid foam.
Example 16a-Fluoro-7a-{5-[N-methy1-N-3-(4,4,5,5,5-pentafluoropentylthio)propylamino] -pentyl}-estra-1, 3,5(10) -triene-3, 17a-diol Analogously, 75 mg of 16ca-fluoro--T-{5-[N-methyl-N-3- 5-pentafluoropentylthio) -propyl-amino] -pentyl}-estra- 1,3,5(10)-triene-3,l7x-diol is obtained as a foam in the same way from 100 mg of 7a-(5-chloropentyl)-16a-fluoro-estra-l,3,5(1o)triene-3, 17a-diol.
Example 21 16a-Fluoro-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfinyl) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3 ,17B-diol By oxidation of 85 mg of l6c-fluoro-7c-5-N-methyl-N-3- 5-pentafluoropentylthio) -propylamino] -pentyl}-estral,3,5(l0)-triene-3,17B-diol with sodium periodate, as described in Example 17, 47 mg of 16ca-fluoro-7ca-f5-[N-methyl-N-3-
A
'j O0 (4,4,5,5,5-pentafluoropentyl-sulfinyl)--propylamino]-pentyl}estra-1,3,5(l0)-triene-3,17B-diol is obtained as a foam.
Example 22 16c-Fluoro-7c-{-[-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol As described in Example 15f), 65 mg of 16a-fluoro-estra-1,3,5(lO)-triene-3,17B-diol is reacted with mg of 3-(N-methylamino)-prpyl-4,4,5, sulfone, and 53 mg of 16a-fluoro-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl}-estra-l, 3,5(10) triene-3,17B-diol is obtained as an oil.
Example 23 7c-5-[N-Methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)propylamino]-pentyl}-estra-1,3,5 (10) ,14-tetraene-3,17B-diol a) 7r- (5-tert-Butyl-dimethylsilyloxypentyl) -estr-4-ene-3, 17dione In 34 ml of absolute tetrahydrofuran, 8.9 g of magnesium chips with 103 g of dissolved in 110 ml of tetrahydrofuran, are reacted to form the Grignard reagent. 2.5 g of copper(I) bromide-dimethyl sulfide complex and a mixture of 60 ml of l,3-dimethyl-3,4,5,6tetrahydro-2(lH)-pyrimidinone and 70 ml of tetrahydrofuran are added to this solution at -70 0 C to -65 0 C, and the resulting suspension is stirred for 30 more minutes at -70 0 C under argon atmosphere.
Then, at -70 0 C to -65 0 C, a solution of 50 g of estra-4,6diene-3,17-dione [Steroids Vol. 1, 1963, 233-249] in 730 ml of absolute tetrahydrofuran and 62.7 ml of chlorotrimethylsilane is added in drops, and the mixture is stirred overnight at -70 0
C.
For working-up, the reaction mixture is mixed with 48 ml of glacial acetic acid at -15 0 C, and, after 15 minutes of stirring, it is poured at this temperature into a mixture of saturated ammonium chloride solution and ethyl acetate. The organic phase is separated, and washed neutral in succession with saturated ammonium chloride solution, saturated sodium bicarbonate solution and ultimately with saturated common salt solution, dried on sodium sulfate and concentrated by evaporation.
The residue is chromatographed on silica gel with dichloromethane/acetone. 47 g of dimethylsilyloxypentyl)-estr-4-ene-3,17-dione is obtained as a yellow oil. []D 22 +62.20 (c 0.545 in chloroform).
b) 3-Hydroxy-7a-(5-hydroxypentyl)-estra-1,3,5(10),15-tetraen-17one According to the procedure indicated in Example lb-li, 62.7 g of 7a-(5-tert-butyl-dimethylsilyloxypentyl)-estr-4-ene-3,17dione is reacted to form 15.8 g of 3-hydroxy-7a-(5hydroxypentyl)-estra-1,3,5(10),15-tetraen-17-one.
c) 3-Benzyloxy-7a-(5-hydroxypentyl)-estra-,3,5(10),15-tetraen- 17-one A solution of 2.85 g of 3-hydroxy-7a-(5-hydroxypentyl)estra-1,3,5(10),15-tetraen-17-one in 57 ml of acetone is mixed with 3.25 g of cesium carbonate and 1.14 ml of benzyl bromide, and the mixture is refluxed for 1 hour. The reaction mixture is concentrated by evaporation, the residue is mixed with water, shaken out with ethyl acetate, the organic phase is dried on sodium sulfate and concentrated by evaporation. The residue is chromatographed on silica gel with hexane/ethyl acetate. 3.12 g of 3-benzyloxy-7a-(5-hydroxypentyl)-estra-1,3,5(10),15-tetraen- 17-one is obtained as a foam.
d) 17-Acetoxy-7a-(5-acetoxypentyl)-3-benzyloxy-estra- 1,3,5(10),14,16-pentaene A solution of 6.12 g of 3-benzyloxy-7a-(5-hydroxypentyl)estra-1,3,5(10),15-tetraen-17-one in 717 ml of acetic anhydride is stirred with 920 mg of p-toluenesulfonic acid for 1 hour at room temperature. The reaction mixture is worked up according to the procedure that is indicated in Example 1j, and the crude product is chromatographed on silica gel with hexane/ethyl acetate. 4.6 g of 17-acetoxy-7a-(5-acetoxypentyl)-3-benzyloxyestra-1,3,5(10),14,16-pentaene is obtained as an oil.
T
PA
e) 7a-(5-Acetoxypentyl)-3-benzyloxy-estra-1,3,5(10),14-tetraen- 178-ol A solution of 1.25 g of sodium borohydride in 90 ml of ethanol and 18 ml of water is added in drops to a solution of 4.58 g of 17-acetoxy-7a-(5-acetoxypentyl)-3-benzyloxy-estra- 1,3,5(10),14,16-pentaene in 26.8 ml of tetrahydrofuran and 161 ml of ethanol at room temperature, and the mixture is stirred for 1 hour. The reaction mixture is mixed with 4 ml of glacial acetic acid, concentrated by evaporation, and the residue is taken up in ethyl acetate. The organic phase is washed with sodium bicarbonate, dried on sodium sulfate and concentrated by evaporation. The residue is chromatographed on silica gel with hexane/ethyl acetate. 2.16 g of 7a-(5-acetoxypentyl)-3benzyloxy-estra-1,3,5(10),14-tetraen-17B-ol is obtained as a foam.
f) 3-Benzyloxy-7a-(5-hydroxypentyl)-estra-1,3,5(10),14-tetraen- 178-ol 2.16 g of 7a-(5-acetoxypentyl)-3-benzyloxy-estra- 1,3,5(10),14-tetraen-178-ol is saponified with 38 ml of 1N methanolic potassium hydroxide solution overnight at room temperature. The reaction mixture is poured into ice-cold saturated common salt solution, the precipitate is suctioned off, taken up in dichloromethane, washed with saturated common salt solution, dried on sodium sulfate and concentrated by evaporation. 1.86 g of 3-benzyloxy-7a-(5-hydroxypentyl)-estra- 1,3,5(10),14-tetraen-17B-ol is obtained as a foam.
g) 3-Benzyloxy-7ct-(5-tosyloxypentyl)-estra-1,3,5(1O) ,14-tetraen- 1713-ol Under the conditions of Example 1o, 3.03 g of 3-benzyloxy- 7a-(5-hydroxypentyl)-estra-l,3,5(10) ,14-tetraen-17B-ol with 2.31 g of p-toluenesulfonic acid anhydride in 58 ml of pyridine is reacted, worked up and chromatographed on silica gel. 3 g of 3- -estra-l,3,5(l0) ,14-tetraen-17Bol is obtained as a foam.
h) 3-Benzyloxy-7a-{5-[N-methyl-N-3-(4,4,5,5,5perltafluoropentylthio) -propylamino]-pentyl}-estra-1,3,5 (1O),14tetraen-17B-ol A solution of 2 g of 3-benzyloxy-7cz-(5-tosyloxypentyl)estra-l,3,5(l0),14-tetraen-178-ol in 28 ml of ethyl methyl ketone is stirred with 1.77 g of N-methyl-3-(4,4,5,5,5pentafluoropentylthio)-propylamine in the presence of 950 mg of potassium carbonate and 230 mg of potassium iodide for 5 hours at a bath temperature of 80 0 C. The reaction mixture is poured into common salt solution, extracted with ethyl acetate, washed with common salt solution, dried on sodium sulfate and concentrated by evaporation. The residue is chromatographed on silica gel with hexane/ethyl acetate. 1.93 g of 3-benzyloxy-7a-{5-[N-methyl-N-3- (4,4,5,5,5-pentafluoropentylthio)-propylamino]-pentyl}-estral,3,5(l0),14-tetraen-17B-ol is obtained as a resin. [a D 2 2 +47.30 (c =0.505 in chloroform) 77 i) 7ae-{5-[N-Methyl-N-3-(4,4,s,s,s-pentafluoropentylthio)propylaminoJ-pentyl}-estra-1,3,5(lo) ,14-tetraene-3,17B-diol 10.2 ml of a 1.2-molar solution of diisobutylaluminum hydride in toluene is added in drops to a solution of 850 mg of 3-benzyloxy-7a-{5-[N-methyl-N-3- (4,4,5,5,5pentafluoropentylthio)-propylamino]-pentyl-estra-135(lo) ,14tetraen-17B-ol in 10.2 ml of toluene at room temperature, and the mixture is heated for 5 hours at a bath temperature of 120 0
C.
while being stirred and under argon atmosphere, the reaction mixture is added in drops to a mixture of saturated common salt solution and 2N sulfuric acid, extracted three times with ethyl acetate, the organic phase is washed twice with 2N sulfuric acid and three times with saturated common salt solution, dried on sodium sulfate and concentrated by evaporation. The residue is chromatographed on silica gel with hexane/ethyl acetate/0-30% methanol. 670 mg of 7a-{5-(N-methyl-N-3-(4,4,5,5,5- ,14tetraene-3,17B-diol is obtained as a foam. [c]D 22 +430 (c 0.520 in chloroform/methanol).
Example 24 7a-{5-[N-Methyl-N-3- 5-pentaf luoropentanesulfinyl) propylamino]-pentyl}-estra-1,3,5 (10) ,14-tetraene-3,17B-diol Under the conditions of Example 2, 400 mg of methyl-N-3- 5-pentafluoropentylthio) -propylamino] ,14-tetraene-3,17B-diol with 177 mg of sodium periodate is reacted, worked up, and the crude product is chromatographed on silica gel with ethyl acetate/methanol. 287 mg of the title compound is obtained as a foam. [C'ID 22 =+30.70 (c =0.530 in chloroform/methanol).
Example (N-Methyl-N-3- 5-pentafluoropentanesulfonyl) propylamino]-pentyl}-estra-1,3,5(10) ,14-tetraene-3,17B-diol a) 3-Benzyloxy-7-cx{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl} -estra- 1,3,5(10) ,14-tetraen-17B-ol Under the conditions of Example 23h, 1 g of 3-benzyloxy-7a- (5-tosyloxypentyl)-estra-l,3,5(l0) ,14-tetraen-17B-ol is reacted with 990 mg of N-methyl-3-(4,4,5,5,5-pentafluoropentanesulfonyl)propyl-amine, worked up, and the crude product is chromatographed on silica gel with ethyl acetate/methanol. 960 mg of 3benzyloxy-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl) -propylamino] -pentyl}-estral,3,5(l0),14-tetraen-17B-ol is obtained as an oil. [I D 22 +48.50 (c 0.535 in chloroform) b) 7c-5-[N-Methyl-N-3-(4,4,5,5,5-pentafJluoropentanesulfony.)propylamino]-pentyl}-estra-1,3,5(10) ,14-tetraene-3,17B-diol A solution of 100 mg of 3-benzyloxy-7oa-{5-[N-methyl-N-3- 5-pentafluoropentanesulfonyl) -propylamino] -pentyl}estra-l,3,5(l0),14-tetraen-17B-ol in 1 ml of dichloromethane is mixed with 0.2 ml of dimethylaniline and 73 mg of aluminum chloride while being cooled in an ice bath, and it is stirred for 1 hour at this temperature. The reaction mixture is poured onto 1N hydrochloric acid, shaken out with ethyl acetate, washed with sodium bicarbonate solution and saturated common salt solution, dried on sodium sulfate and concentrated by evaporation. The crude product is chromatographed on silica gel with dichloromethane/0-10% of methanol. 74 mg of the title compound is obtained as a foam. 22 +360 (c 0.525 chloroform/methanol).
Example 26 2
S)-
2 -(4,4,5,5,5-Pentafluoropentylthiomethyl)-pyrrolidin- 1-yl]-pentyl}-estra-l,3,5(10)-triene-3,17B-diol a) 7a-(5-Acetoxypentyl)-3-benzyloxy-estra-1,3,5(10)-trien-17-one A solution of 6.5 g of 7 a-(5-acetoxypentyl)-3-hydroxy-estra- 1,3,5(10)-trien-17-one (Example Id) in 65 ml of dimethylformamide is mixed with 3.3 ml of benzyl chloride, 8.7 g of cesium carbonate and 400 mg of sodium iodide, and it is stirred overnight at room temperature. The reaction mixture is poured into water, shaken out with ethyl acetate, the organic phase is washed with saturated common salt solution, dried on sodium sulfate and concentrated by evaporation. The residue is chromatographed on silica gel with hexane/ethyl acetate. 7.26 g of 7 a-(5-acetoxypentyl)-3-benzyloxy-estra-l,3,5(10)-trien-17-one is obtained as an oil.
b) 3-Benzyloxy-7a-(5-hydroxypentyl)-estra-1,3,5(10)-trien-17-one A solution of 7.26 g of c-(5-acetoxypentyl)-3-benzyloxyestra-l,3,5(l0)-trien-17-one in 80 ml of methanol and 3 ml of tetrahydrofuran is saponified with 22.2 ml of 2N sodium hydroxide solution overnight at room temperature. The reaction solution is poured into 2N hydrochloric acid, shaken out with ethyl acetate, the organic phase is washed with saturated common salt solution, dried on sodium sulfate and concentrated by evaporation. 6.7 g of 3-benzyloxy-7ca-(5-hydroxypentyl)-estra-l,3,5(1Q)-trien-17-one is obtained as a foam.
c) 3-Benzyloxy-7a- (5-tosyloxypentyl) -estra-1, 3,5(10) -trien-17one Under the conditions of Example 1o, 6.5 g of 3-benzyloxy-7a- (5-hydroxypentyl)-estra-l,3,5(l0) -triene is reacted with 7.14 g of p-toluenesulfonic acid anhydride, worked up and chromatographed on silica gel with hexane/ethyl'acetate. 7.45 g of 3-benzyloxy-7oa-(5-tosyloxypentyl) -estra-l, 3,5(lQ)-trien-17-one is obtained as a foam. fa ID 22= +80.60 (c 0.620 in chloroform).
d) 3-Benzyloxy-7ca-{5-[(2S)-2-(4,4,5,5,5pentafluoropentylthiomethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5(10) -trien-17-one Under the conditions of Example 23h, 4.58 g of 3-benzyloxy- 7a-(5-tosyloxypentyl)-estra-l,3,5(lo)-trien-l7-one is reacted _-with 3.17 g of (2S)-2-(4,4,5,5,5-pentafluoropentylthiomethyl)- Spy.rrolidine, worked up, and the crude product is chromatographed 3, .44 on silica gel with hexane/ethyl acetate. 3.9 g of 3-benzyloxy- 7a-{5-[(2S)-2-(4,4,5,5,5-pentafluoropentyl-thiomethyl)pyrrolidin-l-yl]-pentyl}-estra-1,3,5 (l0)-trien-17-one is obtained as an oil. C' 0
D
22 +32.50 (c 0.117 in chloroform).
e) 3-Hydroxy-7a-{5-[(2S)-2-(4,4,5,5,5pentafluoropentylthiomethyl) -pyrrolidin-l-yl] -pentyl}-estra- 1,3,5(10) -trien-17-oie Under the conditions of Example 6f, 2.05 g of 3-benzyloxy- (2S)-2-(4,4,5,5,5-pentafluoropentylthiomethyl)-pyrrolidin- 1-yl]-pentyl}-estra-l,3,5(lo)-trien-l7-one is debenzylated. 1.25 g of 3-hydroxy-7a-{5-[(2S)-2-(4,4,5,5,5pentafluoropentylthiomethyl) -pyrrolidin-l-yl]-pentyl}-estra- 1,3,5(l0)-trien-17-one is obtained as an oil. Ia] -tD2 +22.70 (c -0.475 in chloroform).
f) 7a-{5-[(2S)-2-(4,4,5,5,5-Pentafluoropentylthiomethy1)pyrrolidin-1-ylJ-pentyl}-estra-1,3,s (10)-triene-3,178-diol Under the conditions of Example 8, 500 mg of 3-hydroxy-7a- (2S)-2-(4,4,5,5,5-pentafluoropentylthiomethyl)-pyrrolidin-lyl]-pentyl}-estra--l,3,5(l0)-trien-l7-one is reduced with 100 mg of sodium borohydride. 325 mg of the title compound is obtained as an oil. a]ID 22 70 (c 0. 510 in methanol) Example 27 (2R)-2-(4,4,5,5,5-Pentafluoropentylthiomethyl)pyrrolidin-1-ylJ -pentyl}-estra-1, 3,5(10) -triene-3, 17B-diol Similar to what is described in Example 26d-f, 612 mg of the title compound is obtained as an oil from 2.3 g of 3-benzyloxy- 7a-(5-tosyloxypentyl)-estra-1,3,5(10)-trien-17-one (Example 26c) and 1 .6 g of (2R)-2-(4,4,5,5,5-pentafluoro-pentylthiomethyl)pyrrolidine.
Example 28 17a-Methyl-7cx-{5-[ (28) -2-(4,4,5,5,5-pentafluoropentylthiomethyl)pyrrolidin-l-ylJ-pentyl}-estra-1,3,5(1o)-triene-3,17B-diol a) 7c-(5-Chloropentyl)-17ca-methyl-estra-1,3,5(10)-triene-3,17Bdiol A suspension of 5.21 g of anhydrous cerium(III) chloride in 53.2 ml of tetrahydrofuran is stirred for 2 hours at room temperature, 7 ml of a methylmagnesium bromide solution (3M in diethyl ether) is added in drops at 0 0 C, and the mixture is stirred for 30 minutes at 0 0 C and for 15 minutes at room temperature. Then, a solution of 1 g of 7c-(5-chloropentyl)-3hydroxy-estra-l,3,5(l0)-trien-l7-one (Example 15b) in 24 ml of tetrahydrofuran is added, and it is stirred for another minutes at room temperature. The reaction mixture is poured onto ice-cold, saturated ammonium chloride solution, shaken out with ethyl acetate, the organic phase is dried on sodium sulfate and concentrated by evaporation. The residue is chromatographed on silica gel with hexane/ethyl acetate. 753 mg of chloropentyl)-7a-methyl-estra-1,3,s (10)-triene-3,l7B-diol is obtained as a foam. I[C' D 22 +2 7. 30 (c 0. 515 in chloroform) b) 7ca-(5-Iodopenty1)-17a-methyl-estra-1,3,5(10)-triene-3,173diol A solution of 735 mg of 7a-(5-chloropentyl)-17a-methylestra-l,3,5(l0)-triene-3,l7B-diol in 4 ml of ethyl methyl ketone is mixed with 5.6 g of sodium iodide and heated for 17 hours at a bath temperature of 80'C. The reaction mixture is poured into water, shaken out with ethyl acetate, the organic phase is washed with saturated common salt solution, dried on sodium sulfate and concentrated by evaporation. 834 mg of 7c-(5-iodopentyl)-l7crmethyl-estra-l,3,5(l0)-triene-3,17B-diol is obtained as a foam.
[I C1D2= 20.20 (c 0.500 in chloroform).
c) 17a-Hethyl-7a-{5-[(2S)-2-(4,4,5,5,5pentafluoropentylthiomethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol A solution of 453 mg of 7ou-(5-iodopentyl)-17a-methy1-estral,3,5(l0)-triene-3,17B-diol and 390 mg of pentafluoropentylthiomethyl)-pyrrolidine in 8 ml of N-methyl-2pyrrolidinone is heated for 4 hours to a bath temperature of 0 C. The cooled reaction mixture is poured into saturated sodium bicarbonate solution, shaken out with ethyl acetate, the organic phase is washed with saturated common salt solution, dried on sodium sulfate and concentrated by evaporation. The ,,esidue is chromatographed on silica gel with n II o dichloromethane/ethyl acetate. 413 mg of the title compound is obtained as a foam. [a]D 22 -25.80 (c 0.500 in chloroform).
Example 29 11B-Fluoro-7a-{5-[2-(4,4,5,5,5-pentafluoropentylthiomethyl)pyrrolidin-1-yl]-pentyl}-estra-1,3,5(10)-triene-3,17B-diol a) 7a-(5-Chloropentyl)-1lB-fluoro-estr-4-ene-3,17-dione A solution of 78.7 g of 11l-fluoro-7a-(5-hydroxypentyl)estr-4-ene-3,17-dione (Example 12e) in 1.4 1 of carbon tetrachloride and 475 ml of acetonitrile is stirred with 71 g of triphenylphosphine for 8.5 hours at room temperature. Then, it is extracted with water, aqueous sodium bicarbonate and common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with hexane/ethyl acetate. 48.0 g of estr-4-ene-3,17-dione is obtained as crystals with a melting point of 51-53 0 C. [a]D 22 +78.50 (c 0.5% in chloroform).
b) 7a-(5-Chloropentyl)-118-fluoro-3-hydroxy-estra-l,3,5(10)trien-17-one A solution of 10.34 g of lithium bromide and 53.2 g of copper(II) bromide in 280 ml of acetonitrile is added in drops to a solution of 47 g of 7a-(5-chloropentyl)-118-fluoro-estr-4-ene- 3,17-dione in 470 ml of acetonitrile at a bath temperature of 0 C. After 20 ml is added, the bleaching of the solution is awaited, and the remainder of the solution is added in 12 minutes and then stirred for 5 more minutes at a bath temperature of 0 C. Then, it is cooled to 0 0 C, mixed with sodium bicarbonate solution, added to water, extracted 4 times with ethyl acetate, washed neutral, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with hexane/ethyl acetate. 25.3 g of 3-hydroxy-estra-l,3,5(lo)-trien-l7-one is obtained. a 2 +115.40 (c 0.5%s in chloroform).
c) 118-Fluoro-3-hydroxy-7a-{5-[2-(4,4,5,5,5pentafluoropentylthiomethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5(10) -trien-17-one SA solution of 785.9 mg of 7a-(5-chloropentyl)-llB-fluoro-3hydroxy-estra-l,3,5(lo)-trien-l7-one in 7 ml of N-methyl-2pyrrolidinone is mixed with 535.5 mg of lithium iodide and 520 mg of 2 S)-2-(4,4,5,5,5-pentafluoropentylthiomethyl)-pyrrolidine, and it is stirred for 2.5 hours at a bath temperature of 100 0
C.
Then, it is poured onto water, extracted 3 times with diethyl ether, washed neutral, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 525 mg of pure llB-fluoro-3-hydroxy- 7 2 -(4,4,5,5,5-pentafluoropentylthiomethyl)-pyrrolidin-lyl]-pentyl}-estra-l,3,5(lo)-trien-l7-one is obtained. I[Ca] D 22 +29.30 (c in chloroform).
d) 11B-FlUoro-7c-{5-[2-(4,4,5,5,5-pentafluoro-pentylthiomethyl)pyrrolidin-1-yl]-pentyl}-estra-1,3,5 (10)-triene-3,17-diol 500 mg of llB-fluoro-3-hydroxy-7a-{5-(2-(4,4,5,5,5pentafluoropentyithiomethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5(l0)-trien-17-one in 5 ml of tetrahydrofuran, 2.75 ml of ethanol and 1.1 ml of water, and 100 mg of sodium borohydride is added at a bath temperature of 0 0 C, and it is stirred for hour at room temperature. Then, it is added to water, extracted 3 times with ethyl acetate, washed neutral with saturated common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 441.3 mg of 1lB-fluoro-7a-{5-[2- (4,4,5,5,5-pentafluoropentylthiomethyl)-pyrrolidin-1-yl]-pentyl}estra-l,3,5(l0)-triene-3,17B-diol is obtained as crystals with a melting point of 174-176 0 C. Ea]D 2 2 90 (c 0 in pyridine).
Example 11B-Nitrooxy-7a- 4,5,5, nonyl) -estra-1, 3,5(10) -triene-3, 17B-diol a) 3,17B-Diacetyloxy-7cx-(9-[4,4,5,5,5pentafluoropentanesulfonyl]-nonyl)-estra-l,3,s (10) -triene 6.28 g of 7a-(9-[4,4,5,5,5-pentafluoropentanesulfinyl]nonyl)-estra-l,3,5(l0)-triene-3,17B-diol is dissolved in 30 ml of pyridine, mixed with 15 ml of acetic anhydride while being cooled with water and then allowed to stir for 5 hours at room temperature.
For working-up, the reaction solution is poured onto ice water, the diacetate is extracted with ethyl acetate, the organic phase is washed with dilute sulfuric acid, water, saturated common salt solution and dried on sodium sulfate. As a crude product, an oil, which is taken up in 100 ml of acetic acid, is obtained, and it is mixed with 15 g of sodium perborate. After five hours of stirring at room temperature, the reaction is complete.
The reaction mixture is poured onto ice water and then extracted with ethyl acetate. The organic phase is freed from acid residues with aqueous bicarbonate solution. After drying on sodium sulfate, it is filtered, concentrated by evaporation and chromatographed on silica gel (hexane/ethyl acetate, 6.83 g of product is obtained as a foam.
b) 3,17B-Diacetyloxy-llB-nitrooxy-7a-(9-[4,4,5,5,5pentafluoropentanesulfonyl]-nonyl)-estra-1,3,5(10)-trien-9-ol 18.6 g of cerium ammonium nitrate is added to a solution of g of 3,178-diacetyloxy-7a-(9-[4,4,5,5,5pentafluoropentanesulfonyl]-nonyl)-estra-l,3,5(10)-triene-in ml of aqueous acetic acid and it is stirred for 4 hours at room temperature.
For working-up, the reaction solution is poured onto ice water, extracted with ethyl acetate, and the organic phase is washed neutral with aqueous bicarbonate solution. Then, it is washed with saturated common salt solution and dried on sodium sulfate.
The crude product is chromatographed on silica gel (hexane/ ethyl acetate, 2.0 g of product is obtained as a yellowcolored foam.
c) 3,17B-Diacetyloxy-11B-nitrooxy-7a-(9-[4,4,5,5,5pentafluoropentanesulfonyl]-nonyl)-estra-1,3,5(10)-triene For reductive removal of the 9a-hydroxy group in 3,17Bdiacetyloxy-11B-nitrooxy-7a-(9-[4,4,,5,55pentafluoropentanesulfonyl]-nonyl)-estra-1,3,5(10)-trien-9-ol, g of starting material is dissolved in 25 ml of dichloromethane, cooled to -15 0 C and mixed successively with ml of triethylsilane and 2.2 ml of boron trifluoride ethorate.
After one hour of stirring at -15 0 C, the cold bath is removed and allowed to thaw to room temperature.
For working-up, it is poured onto ice water, extracted with dichloromethane, the organic phase is washed with aqueous bicarbonate solution, saturated common salt solution and dried on sodium sulfate.
The crude product is chromatographed on silica gel (hexane/ ethyl acetate, yield 1.3 g of foam.
d) 11B-Nitrooxy-7a-(9-[4,4,5,5,5-pentafluoropentanesulfonyl]nonyl)-estra-1,3,5(10)-triene-3,17B-diol For saponification, 1.0 g of 3,17B-diacetyloxy-llB-nitrooxy- 7a-(9-[4,4,5,5,5-pentafluoropentane-sulfonyl]-nonyl)-estra- 1,3,5(10)-triene is dissolved in 50 ml of methanol, mixed with ml of 3% methanolic potassium hydroxide solution and allowed to stand for 4 hours at room temperature.
The reaction mixture is poured into citric acid ice water and then extracted with ethyl acetate. After the organic phase is washed with water and saturated common salt solution, it is dried on sodium sulfate.
The crude product is chromatographed on silica gel (hexane/ ethyl acetate, gradient to yield 0.53 g as an oil.
Example 31 11B-Fluoro-17a-methyl-7a-{5-[(2S)-2-(4,4,5,5,5pentafluoropentylthiouethyl) -pyrrolidin-1-yl]-pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol a) 7ca-(5-Chloropentyl)-11B-fluoro-17az-methy1-estra-1,3,5(10)triene-3, 178-diol Under the conditions of Example 28a, 750 mg of chloropentyl) -llB-fluoro-3-hydroxy-estra-l,3,5(l0) -trien-17-one (Example 29b) is reacted with 4.9 ml of methylmagnesium bromide solution (3 M in diethyl ether), worked up and chromatographed.
561 mg of 7ca-(5-chloropentyl) -llB-fluoro-17a-methyl-estral,3,5(l0)-triene-3,17B-diol is obtained as a foam. D 2 2 +51.60 (c 0.515 in chloroform) pentafluoropentyithiomethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5 (10) -triene-3, 176-diol Under the conditions of Example 15f, 408 mg of chioropentyl) -118-f luoro-17a-methyl-estra-1, 3, 5(10) -triene-3, 178diol in 5 ml of N-methyl-2-pyrrolidinone is reacted in the presence of 130 mg of lithium iodide with 606 mg of (2S)-2- 5-pentafluoropentyithiomethyl) -pyrrolidine, worked up and chromatographed. 326 mg of the title compound is obtained as crystals with a melting point of 120-121 0
C.
[a]D 22 5.80 (c 0.535% in chloroform).
Example 32 11B-Fluoro-l7cx-methyl-7a-{5-[ pentafluoropentanesulfinylmethyl) -pyrrolidin-1-yl]-pentyl}-estra- 1,3,5 (10) -triene-3, 17B-diol Under the conditions of Example 13, 260 mg of liB-fluoro- 17a-methyl-7a-{5-[ (2S)-2-(4,4,5,5,5-pentafluoropentylthiomethyl)pyrrolidin-l-yl] -pentyl}-estra-l,3,5(l0) -triene-3, 178-diol (Example 31b) is reacted with 151 mg of sodium periodate, worked up and chromatographed. 129 mg of the title compound is obtained as an oil.
Example 33 3,178-Diacetoxy-11B-fuoro-17r-methyl-7a-{5-[ (2S)-2- 5-pentafluoropentanesulfonylmethyl) -pyrrolidin- 1-yl]-pentyl}-estra-l, 3,5(10) -triene Under the conditions of Example 3, 65 mg of 1lB-fluoro-17a- (2S)-2-(4,4,5,5,5-pentafluoropentylthiomethyl)- (10) -triene-3,17B-diol (Example 31b) is acetylated with acetic anhydride, and the crude product is oxidized with sodium perborate tetrahydrate, as described in Example 4, worked up and chromatographed. 27 mg of the title compound is obtained as an oil.
Example 34 (2S)-2-(4,4,5,5,5-Pentafluoropentanesulfinylmethyl)pyrrolidin-1-yl]-pentyl}-estra-l,3,5 (10)-triene-3,17B-diol By oxidation with sodium periodate, 66 mg of the title compound, as described in Example 2, is obtained as an oil from 152 mg of 7ca-{5-[ (2S)-2-(4,4,5,5,5-pentafluoropentylthiomethyl)pyrrolidin-l-yl]-pentyl}-estra-l,3, 5(10) -triene-.3, 17B-diol (Example 26f). 22 +11.80 (c =0.53% in methanol).
Example (2S)-2-(4,4,5,5,5-Pentafluoropentanesulfonylmethyl)pyrrolidin-1-yl]-pentyl}-estra-1,3,5(10)-triene-3,17B-diol Under the conditions of Example 3, 76 mg of 7cr-{5-II(2S)-2- (4,4,5,5,5-pentafluoropentylthiomethyl) -pyrrolidin-l-yl]-pentyl}estra-l,3,5(10)-triene-3,173-diol (Example 26f) is acetylated
V-R
with acetic anhydride, and the-*crude product is oxidized, as described in Example 4, with sodium perborate tetrahydrate, worked up and chromatographed. 31 mg of the title compound is obtained as an oil. a 2= 3 0.60 (c 0. 515% in methanol).
Example 36 11B-Fluoro-17cz-methyl-7cx-{5-[N-methyl-N-3- (4,4,5,5,5perltafluoropentylthio) -propylamino]-pentyl}-estra-1,3,5 triene-3, 17B-diol a) 118-Fluoro-3-hydroxy-17a-methy1-7ca-{5-[N-methyl-N-3- (4,4,5,5,5-pentafluoropentylthio) -propylamino] -pentyl}-estra- 1,3,5 (1O)-trien-17-one A solution of 2.0 g of llB-fluoro-7a-{5-(N-methyl-N-3- 5-pentaf luoro-pentylthio) -propylamino] pentyl}-3- (tetrahydrapyran-2-yloxy) -estra-l,3, 5(lO)-trien-17-one in 20 ml of methanol and 2 ml of water is stirred at room temperature with 1.2 g of oxalic acid. After 2.5 hours, it is added to ice water, extracted with dichloromethane, washed with saturated common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 1.2 g of 118-fluoro-3-hydroxy-17amethyl-7a-{5-[N-methyl-N-3- 5-pentafluoropentylthio) propylamino]-pentyl}-estra-l,3,5(10) -trien-17-one is obtained as a foam. I[a ID 2 2 +690 (c 0. 5% in chloroform) b) 11B-Fluoro-17a-methy1-7ca-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino] -pentyl}-estra-1, 3,5(10)triene-3, 178-diol 33 ml of a 1.6-molar ethereal lithium methylate solution is added in drops to 5 g of llB-fluoro-3-hydroxy-17a-methyl-7m-{s- [N-methyl-N-3- 5-pentafluoropentylthio) -propylamino]pentyl}-estra-l,3,5(10)-trien-17-one in 150 ml of tetrahydrofuran at room temperature. After 2.5 hours, saturated ammonium chloride solution is added while being cooled with ice, extracted with ethyl acetate, washed with saturated common salt solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. After chromatography on silica gel, which contains 2% triethylamine, with dichloromethane/methanol, 2.0 g of liBfluoro-17a-methyl-7cx-{5- [N-methyl-N-3- (4 pentafluoropentylthio) -propylamino] -pentyl}-estra-l, 3,5(10) triene-3,17B-diol is obtained as crystals with a melting point of 83 0
C.
Example 37 11B-Fluoro-17a-methyl-7a-{5- [N-methyl-N-3- 5, pentafluoropentanesulfinyl) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3, 17B-diol A solution of 500 mg of 1lB-fluoro-17ca-methyl-7a-{5-[Nmethyl-N-3-(4,4,5,5,5-pentafluoropentylthio) -propylamino]pentyl}-estra-l,3,5(lQ)-triene-3,l7B-diol in 20 ml of methanol and 0.9 ml of water is stirred at room temperature with 355 mg of sodium periodate for 3 hours. Then, it is poured onto ice water, .1 .1 extracted with dichioromethane, washed with saturated common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichioromethane/methanol. 216 mg of llB-fluoro-l7a-methyl-7a-{5- [H-methyl-N-3- 5-pentafluoropentanesulfinyl) propylamino]-pentyl}-estra-l,3,5(10)-triene-3,l7B-diol is obtained as crystals with a melting point of 83.4 0
C.
Example 38 11B-Fluoro-17ca-methyl-7c-{5-[N-methyl-N-3-(4,4,5,5,spentafluoropentanesulfonyl) -propylamino]-pentyl}-estra-1,3,5 triene-3, 17B-diol a) 111-Fluoro-3-hydroxy-17c*-methyl-7ca-{5-[N-methyl-N-3- (4,4,5,5,5-pentafluoropentanesulfonyl) -propylamino]-pentyl}estra-1,3,5 (1O)-trien-17-one A solution of 3 g of 7a-(5-chloropentyl)-llB-fluoro-3hydroxy-estra-l,3,5(l0)-trien-l7-one in 50 ml of dimethylformamide is stirred with 1.6 g of lithium iodide and 6.2 g of methyl-[3-(4,4,5,5,5-pentafluoropentanesulfonyl) -propyl]amine for 22 hours at 100 0 C. Then, it is extracted with ethyl acetate, washed with saturated common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. g of 1lB-fluoro-3-hydroxy-l7a-methyl-7a-{s-[N-methyl-N-3- 4,5,5, 5-pentafluoropentanesulfonyl) -propylamino] -pentyl}estra-1,3,5(l0)-trien-17-one is obtained as a foam.
b) 11B-Fluoro-17a-methyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl)-propylamino]-pentyl}-estra-1,3,5(10)triene-3,17B-diol A suspension of 11.4 g of anhydrous cerium(III) chloride in 120 ml of tetrahydrofuran is stirred for 2 hours at room temperature under nitrogen, mixed at 0 C drop by drop with 17.5 ml of a 3-molar, ethereal methylmagnesium bromide solution, stirred for 30 minutes, a solution of 3.5 g of 118-fluoro-3hydroxy-17a-methyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl)-propylamino]-pentyl}-estra-l,3,5(10)trien-17-one in 24 ml of tetrahydrofuran is added, and it is stirred for another 30 minutes. Then, saturated ammonium chloride solution is added, diluted with ethyl acetate, washed with saturated common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 2.2 g of 118-fluoro- 17a-methyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfonyl)-propylamino]-pentyl}-estra-l,3,5(10)triene-3,178-diol is obtained as crystals with a melting point of 82.5 0
C.
Example 39 11B-Fluoro-7a-{5-[N-methyl-N-2-(4,4,5,5,5pentafluoropentanesulfonyl)-ethylamino]-pentyl}-estra-l,3,5(10)triene-3,17B-diol a) 7a-(5-Bromopentyl)-11B-fluoro-estr-4-ene-3,17-dione A solution of 33 g of 4-ene-3,17-dione in 330 ml of dichloromethane is mixed at -5 0
C
with 28.9 g of triphenylphosphine and 36.7 g of carbon tetrabromide, and it is stirred for 0.5 hour. Then, dichloromethane is added, and it is washed with water, saturated sodium bicarbonate and common salt solution. The organic phase is dried on sodium sulfate and concentrated by evaporation in a vacuum. Then, the crude product is chromatographed on silica gel with a hexane-ethyl acetate gradient. 28.5 g of bromopentyl)-11l-fluoro-estr-4-ene-3,17-dione with a melting point of 75-76 0 C is obtained.
b) 7a-(5-Bromopentyl)-llB-fluoro-3-hydroxy-estra-1,3,5(10)trien-17-one 17.0 g of copper(II) bromide is added to 27.8 g of bromopentyl)-118-fluoro-estr-4-ene-3,17-dione in 190 ml of acetonitrile at 80 0 C. After 8 hours, the reaction mixture is stirred into water, extracted three times with ethyl acetate, washed twice with ammonium chloride, with sodium bicarbonate and common salt, dried and concentrated by evaporation in a vacuum.
After the crude product is chromatographed on silica gel with a hexane-ethyl acetate gradient, 20.4 g of fluoro-3-hydroxy-estra-1,3,5(10)-trien-17-one is obtained as colorless crystals with a melting point of 178 0
C.
c) 7a-(5-Bromopentyl)-11B-fluoro-estra-1,3,5(10)-triene-3,17Bdiol A solution of 16.2 g of 7a-(5-bromopentyl)-118-fluoro-3hydroxy-estra-1,3,5(0)-trien-17-one in 162 ml of tetrahydrofuran as well as 90 ml of ethanol and 36 ml of water are mixed in portions at OOC with 4.7 g of sodium borohydride and stirred for 2 hours at OOC. Then, it is added to water, extracted four times with ethyl acetate, washed with water and common salt solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. 17.1 g of crude product is obtained. After chromatography on silica gel with hexane/ethyl acetate, 15.6 g of pure 7a-(5-bromopentyl)-118-fluoro-estra-1,3,5(10)-triene-3,178diol is obtained.
d) 11B-Fluoro-7a-[5-(methylamino)-pentyl]-estra-1,3,5(10)triene-3,17B-diol A solution of 2 g of 7a-(5-bromopentyl)-118-fluoro-estra- 1,3,5(10)-triene-3,178-diol in 20 ml of dimethylformamide is stirred with 8 ml of a 40% aqueous methylamine solution for hours at 80 0 C. Then, it is added to water, extracted three times with ethyl acetate, washed with water and common salt solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. 1.77 g of 118-fluoro-7a-[5-(methylamino)-pentyl]-estra- 1,3,5(10)-triene-3,178-diol is obtained.
e) llB-Fluoro-7ct-{5-[N-methyl-N-2-(4,4,5,5,5pentafluoropentanesulfonyl)-ethylamino]-pentyl}-estra-l,3,5(l0)triene-3, 178-diol A solution of 440 mg of llB3-fluoro-7ca-(5-(methylamino)pentyl]-estra-l,3,5(lO)-triene-3,1713-diol in 15 ml of methanol is stirred with 500 mg of 4,4,5,5,5-pentafluoropentylvinylsulfone for 1 hour at 90 0 C. Then, it is added to water, extracted three times with ethyl acetate, washed with water and common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/ methanol. 488 mg of 11B-fluoro-7ca-{5-(N-methyl-N-2-(4,4,5,5,5pentafluoropentanesulfonyl) -ethylamino] -pentyl}-estra-l, 3,5(10) triene-3,17B-diol is obtained as crystals with a melting point of 74-76 0
C.
The reacted intermediate stage 12k) has a strong antiestrogenic action: Example llB-Fluoro-7a-{5-[N-methyl-N-3- 5-pentafluoropentylthio) propylamino] -pentyl}-3-hydroxy-estra-1, 3,5(10) -trien-17-one A solution of 1.6 g of llB-fluoro-7a-{5-[N-methyl-N-3- (4,4 5, 5-pentafluoropentylthio) -propylamino] -pentyl (tetrahydropyran-2-yloxy)-estra-1, 3,5(10)-trien-17-one in 20 ml of methanol and 2 ml of water is stirred with 1.0 g of oxalic acid. After 3 hours, the reaction mixture is added to ice water.
It is extracted with methylene chloride, washed with saturated sodium chloride solution, dried and concentrated by evaporation in a vacuum. After the crude product is chromatographed on silica gel with a methylene chloride-methanol gradient, 1.1 g of 118-fluoro-7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)propylamino]-pentyl}-3-hydroxy-estra-1,3,5(10)-trien-17-one is obtained. 2 2 +690 (c 0.5% in chloroform) Example 41 118-Fluoro-7a-{6-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)propylamino]-hexyl}-estra-1,3,5(10)-triene-3,17B-diol a) 7a-(6-Chlorohexyl)-11B-fluoro-estr-4-ene-3,17-dione First, 30 ml of a solution that consists of 41 ml of 1bromo-6-chlorohexane in 270 ml of THF is added to a suspension of 6.8 g of magnesium chips in 100 ml of THF. After the reaction starts, the remaining solution is added in drops in such a way that the internal temperature does not exceed 35 0 C. In a second flask, 48.1 g of lithium bromide is added to a suspension of 26.4 g of copper(I) iodide in 120 ml of THF at OOC, whereby the internal temperature climbs to 40 0 C. Without cooling, 46.4 ml of 1,3-dimethyl-3,4,5,6-tetrahydro-(lH)-pyrimidin-2-one is now added and stirred for 30 minutes at 40 0 C. A clear solution is obtained, which is added in drops to the Grignard solution that is cooled to -40 0 C. Then, it is stirred for 30 more minutes at 0 C and mixed drop by drop at -50 0 C with a solution of 23.5 g of 118-fluoro-estra-4,6-diene-3,17-dione in 230 ml of THF, 24.6 ml of 1,3-dimethyl-3,4,5,6-tetrahydro-(lH)-pyrimidin-2-one and 55 ml of trimethylchlorosilane in such a way that the internal temperature does not exceed -40 0 C. It is stirred for 1 hour 100 cold, then 32 ml of glacial acetic acid is added in drops, the cooling bath is removed and stirred for 1 more hour at room temperature. For working-up, the reaction mixture is added to 1 of water, diluted with the same amount of ethyl acetate, the precipitate is separated on Celite, rewashed with ethyl acetate, the aqueous phase is extracted 3 times with ethyl acetate, washed with sodium bicarbonate and common salt solution, dried on magnesium sulfate and concentrated by evaporation in a vacuum. After the crude product is chromatographed on silica gel with a hexane-ethyl acetate gradient, 25.2 g of 7a-(6chlorohexyl)-118-fluoro-estr-4-ene-3,17-dione is obtained.
b) 7a-(6-Chlorohexyl)-ll-fluoro-3-hydroxy-estra-1,3,5(10)trien-17-one 28.1 g of copper(II) bromide and 5.4 g of lithium bromide in 105 ml of anhydrous acetonitrile are added to 25.2 g of 7a-(6chlorohexyl)-118-fluoro-estr-4-ene-3,17-dione in 175 ml of anhydrous acetonitrile at 80 0 C. After 15 minutes, the reaction mixture is cooled to 0 C, and 250 ml of saturated sodium bicarbonate solution is added in drops. Then, the solution is stirred into 1 liter of water, brought to pH 6 with 2N hydrochloric acid, extracted 3 times with ethyl acetate, washed with common salt solution, dried on magnesium sulfate and concentrated by evaporation in a vacuum. Chromatography of the crude product on silica gel with a hexane-ethyl acetate gradient yields 5.7 g of 7a-(6-chlorohexyl)-118-fluoro-3-hydroxy-estra- 1,3,5(10)-trien-17-one as a foam.
c) 118-Fluoro-3-hydroxy-7a-(6-iodohexyl)-estra-1,3,5(10)-trien- 17-one 2.7 g of 7a-(6-chlorohexyl)-l1B-fluoro-3-hydroxy-estra- 1,3,5(10)-trien-17-one is dissolved in 40 ml of ethyl methyl ketone, mixed with 3.0 g of sodium iodide and stirred overnight at a bath temperature of 90 0 C. For working-up, the reaction mixture is cooled to room temperature, stirred into water, extracted 3 times with ethyl acetate, washed with common salt solution, dried on magnesium sulfate and concentrated by evaporation in a vacuum. 3.4 g of 118-fluoro-3-hydroxy-7a-(6iodohexyl)-estra-1,3,5(10)-trien-17-one is obtained as a crude product, which is used without further purification in the next stage.
d) 118-Fluoro-3-hydroxy-7a-{6-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio)-propylamino]-hexyl}-estra-1,3,5(10)-trien- 17-one g of 11B-fluoro-3-hydroxy-7a-(6-iodohexyl)-estra- 1,3,5(10)-trien-17-one in 20 ml of anhydrous DMF is stirred at a bath temperature of 100 0 C with 2.0 g of methyl-[3-(4,4,5,5,5pentafluoropentylthio)-propyl]-amine. After 2 hours, the reaction solution is poured into semi-saturated sodium bicarbonate solution, extracted 3 times with methylene chloride, dried on magnesium sulfate and concentrated by evaporation in a vacuum. The residue is chromatographed on silica gel with a methylene chloride-methanol gradient. 3.15 g of 118-fluoro-3hydroxy-7a-{6-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)o 102 propylamino]-hexyl}-estra-1,3,5(lQ) -trien-l7-one is obtained as a foam.
e) 118-Fluoro-7a-{6-[N-methyl-N-3-(4,4,5,5,5pentafluoropentylthio) -propylamino] -hexyl}-estra-1, 3,5(10) triene-3, 17-diol 250 mg of llB-fluoro-3-hydroxy-7cr-{6-[N-methyl-N-3- 5-pentafluoropentylthio) -propyl-amino] -hexyl}-estral,3,5(l0)-trien-l7-one is dissolved in 4.5 ml of methanol and mixed at O 0 C in portions with 60 mg of sodium borohydride. After 3 hours of stirring at room temperature, the solvent is drawn off in a vacuum, the residue is mixed with saturated common salt solution, extracted 3 times with methylene chloride, dried on magnesium sulfate and concentrated by evaporation in a vacuum.
After chromatography on silica gel with a methylene chloridemethanol gradient, 165 mg of llB-fluoro-7ca-{6-[N-methyl-N-3- 5-pentafluoropentylthio) -propylamino] -hexyl}-estral,3,5(l0)-triene-3,17-diol is obtained as a foam, lcQ]D +370 (c 1.01 in chloroform).
103 Example 42 118-Fluoro-7a-{6-[N-methy1-N-3- (4,4,5,5,5pentafluoropentanesulfinyl) -propylamino]-hexyl}-estra-1,3, 5(10) triene-3, 17-diol a) 11B-Fluoro-3-hydroxy-7a-{6-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfinyl) -propylamino]-hexyl}-estra-1,3, 5(10) trien-17-one 500 mg of 1lB-fluoro-3-hydroxy-7a-{6-[N-methyl-N-3- (4,4,5,5,5-pentafluoropentylthio) -propyl-amino]-hexyl}-estral,3,5(l0)-trien-17-one is dissolved in 17 ml of methanol and 3.3 ml of water, mixed with 262 mg of sodium periodate and stirred for 2 hours at room temperature. For working-up, the reaction mixture is mixed with semi-saturated common salt solution, extracted 3 times with methylene chloride, dried on magnesium sulfate and concentrated by evaporation in a vacuum. The residue is purified on silica gel with a methylene chloride-methanol gradient. 149 mg of llB-fluoro-3-hydroxy-7a-{6-(N-methyl-N-3- 5-pentafluoropentanesulfinyl) -propylamino] -hexyl}-estral,3,5(l0)-trien-17-one is isolated as a foam, D +450 (c= 1.015 in chloroform).
b) 11B-Fluoro-7ca-{6-[N-methyl-N-3-(4,4,5,5,5pentafluoropentanesulfinyl)-propylamino]-hexyl}-estra-1,3,5(10)triene-3, 17-diol 149 mg of llB-fluoro-3-hydroxy-7a-{6-[N-methyl-N-3- 5-pentafluoropentanesulfinyl) -propyl-amino] -hexyl}estra-1,3,5(1Q)-trien-l7-one is dissolved in 3 ml of methanol and S 104 mixed in portions with 35 mg of sodium borohydride. After minutes of stirring at room temperature, the solvent is drawn off in a vacuum, the residue is mixed with water, extracted 3 times with methylene chloride, dried on magnesium sulfate and concentrated by evaporation in a vacuum. Preparative thin-layer chromatography with methylene chloride/methanol 9/1 as a solvent provides 109 mg of llB-fluoro-7a-{6-[N-methyl-N-3- (4,4,5,5,5-pentafluoropentanesulfinyl)-propylamino]-hexyl}-estra- 1,3,5(10)-triene-3,17-diol as a foam, [a]D +240 (c 0.51 in chloroform).
Example 43 11B-Fluoro-7a-(5-{[N-3-(furan-2-ylmethylthio)-propyl]-N-methylamino}-pentyl)-estra-l,3,5(10)-triene-3,17B-diol a) 7a-(5-Chloropentyl)-11B-fluoro-estr-4-ene-3,17-dione First, 20% of a solution of 39 ml of in 300 ml of THF is added to a suspension of 7.2 g of magnesium chips in 100 ml of THF under nitrogen. After the reaction starts, which can be achieved by adding iodine and dibromomethane, the remaining solution is added in drops in such a way that the internal temperature does not exceed 35 0 C. In a second flask, 51.2 g of lithium bromide is added to a suspension of 28.1 g of copper(I) iodide in 130 ml of THF at 0°C, whereby the internal temperature climbs to 40 0 C. Without cooling, 49.4 ml of 1,3-dimethyl-3,4,5,6-tetrahydro-(1H)-pyrimidin-2-one is now added and stirred for 15 minutes at 40 0 C. A clear solution is obtained, which is added in drops to the Grignard solution that is cooled to -50 0 C. Then, it is stirred for 15 more minutes at 0 C and mixed at -70 0 C drop by drop with a solution of 25 g of 11B-fluoro-estra-4,6-diene-3,17-dione in 260 ml of THF, 26 ml of 1,3-dimethyl-3,4,5,6-tetrahydro-(lH)-pyrimidin-2-one and 59 ml of trimethylchlorosilane in such a way that the internal temperature does not exceed -65 0 C. It is stirred for 30 minutes cold, then 34.7 ml of glacial acetic acid is added in drops, the cooling bath is removed, and it is stirred for 1 more hour at room temperature. For working-up, the reaction mixture is added to 1 of water, diluted with the same amount of ethyl acetate, the precipitate is separated on Celite, rewashed with ethyl acetate, the aqueous phase is extracted 3 times with ethyl acetate, washed with sodium bicarbonate and common salt solution, dried on magnesium sulfate and concentrated by evaporation in a vacuum. After the crude product is chromatographed on silica gel with a hexane-ethyl acetate gradient, 22.1 g of chloropentyl)-11B-fluoro-estr-4-ene-3,17-dione is obtained.
b) 7a-(5-Chloropentyl)-11-fluoro-3-hydroxy-estra-1,3,5(10)trien-17-one 25.4 g of copper(II) bromide and 4.9 g of lithium bromide in ml of anhydrous acetonitrile are added to 22.1 g of chloropentyl)-118-fluoro-estr-4-ene-3,17-dione in 160 ml of anhydrous acetonitrile at 80 0 C. After 20 minutes, the reaction mixture is cooled to 0C, and 200 ml of saturated sodium bicarbonate solution is added in drops. Then, the solution is
Y^
1 Z.i 106 stirred into 750 ml of water, brought to pH 6 with 2N hydrochloric acid, extracted 3 times with ethyl acetate, washed with common salt solution, dried on magnesium sulfate and concentrated by evaporation in a vacuum. Chromatography of the crude product on silica gel with a hexane-ethyl acetate gradient yields 14.7 g of 7a-(5-chloropentyl)-11-fluoro-3-hydroxy-estra- 1,3,5(10)-trien-17-one.
c) 11B-Fluoro-3-hydroxy-7a-(5-iodopentyl)-estra-1,3,5(10)-trien- 17-one g of 7c-(5-chloropentyl)-llB-fluoro-3-hydroxy-estra- 1,3,5(10)-trien-17-one is dissolved in 80 ml of ethyl methyl ketone, mixed with 5.7 g of sodium iodide and stirred overnight at a bath temperature of 90 0 C. For working-up, the reaction mixture is cooled to room temperature, stirred into water, extracted 3 times with ethyl acetate, washed with common salt solution, dried on magnesium sulfate and concentrated by evaporation in a vacuum. 6.8 g of 11B-fluoro-3-hydroxy-7a-(5iodopentyl)-estra-l,3,5(10)-trien-17-one is obtained as a crude product, which is used without further purification in the next stage.
d) 11B-Fluoro-3-hydroxy-7a-[5-(methylamino)-pentyl]-estra- 1,3,5(10)-trien-17-one 5.1 g of methylamine is condensed in a solution of 6.8 g of 118-fluoro-3-hydroxy-7a-(5-iodopentyl)-estra-l,3,5(10)-trien-17one in 35 ml of anhydrous tetrahydrofuran at -78 0 C, and it is stirred overnight at room temperature in a pressurized reactor.
After the pressurized reactor was opened at -20 0 C, it was allowed to come to room temperature to be able to evaporate excess methylamine. Then, the reaction solution is added to saturated sodium bicarbonate solution, extracted 3 times with ethyl acetate, dried on magnesium sulfate and concentrated by evaporation in a vacuum. 6.7 g of 118-fluoro-3-hydroxy-7a-[5- (methylamino)-pentyl]-estra-1,3,5(10)-trien-17-one is obtained as a crude product.
e) 11-Fluoro-7a-(5-{[N-3-(furan-2-ylmethylthio)-propyl]-Nmethyl-amino}-pentyl)-3-hydroxy-estra-1,3,5(10)-trien-17-one 526 mg of 118-fluoro-3-hydroxy-7a-[5-(methylamino)-pentyl]estra-1,3,5(10)-trien-17-one and 95 mg of 2-(3-chloropropylthiomethyl)-furan are dissolved in 5 ml of ethyl methyl ketone, mixed with 112 mg of sodium iodide and 104 mg of potassium carbonate and stirred for 3 hours at a bath temperature of 90 0 C. For working-up, the reaction mixture is added to semisaturated sodium bicarbonate solution, extracted 3 times with methylene chloride, washed with common salt solution, dried on magnesium sulfate and concentrated by evaporation in a vacuum.
Chromatography of the crude product on silica gel with a methylene chloride-methanol gradient yields 229 mg of 118-fluoro- 7a-{5-{[N-3-(furan-2-ylmethylthio)-propyl]-N-methyl-amino}pentyl)-3-hydroxy-estra-l,3,5(10)-trien-17-one as a foam.
108 f) 11B-Fluoro-7a-(5-{[N-3-(furan-2-ylmethylthio)-propyl]-Nmethyl-amino}-pentyl) -estra-1, 3,5(10) -triene-3, 17B-diol 217 mg of 1lB-fluoro-7a-(5-{[N-3-(furan-2-ylmethylthio)propyl]-N-methyl-amino}-pentyl) -3-hydroxy-estra-l, 3,5(10) -trien- 17-one is dissolved in 6 ml of methanol and mixed in portions with 44 mg of sodium borohydride. After 1 hour of stirring at room temperature, the solvent is drawn off in a vacuum, the residue is mixed with common salt solution, extracted 3 times with methylene chloride, dried on magnesium sulfate and concentrated by evaporation in a vacuum. Preparative column chromatography with a methylene chloride/methanol gradient provides 146 mg of 18-fluoro-7r-(5-{ (N-3-(furan-2-ylmethylthio)propyl]-N-methyl-amino}-pentyl) -estra-1, 3,5(10) -triene-3, 17B-diol as a foam.
Example 44 11B-Fluoro-7x- (5-{N-methyl-[N-3- (thiophen-2-ylmethylthio) propyl]-amino}-pentyl)-estra-1,3,5(lo)-triene-3,17B-diol a) 11B-Fluoro-3-hydroxy-7a- (5-{N-methyl-[N-3- (thiophen-2ylmethylthio) -propyl]-amino}-pentyl) -estra-1, 3,5(10) -trien-17-one 526 mg of 1lB-fluoro-3-hydroxy-7cr-(5-(methylamino)-pentyl]estra-l,3,5(10)-trien-17-one and 103 mg of 2-(3chloropropylthiomethyl)-thiophene are dissolved in 5 ml of ethyl methyl ketone, mixed with 112 mg of sodium iodide and 104 mg of potassium carbonate and stirred for 4.5 hours at a bath temperature of 90 0 C. For working-up, the reaction mixture is added to semi-saturated sodium bicarbonate solution, extracted 3 N 4 109 times with methylene chloride, washed with common salt solution, dried on magnesium sulfate and concentrated by evaporation in a vacuum. Chromatography of the crude product on silica gel with a methylene chloride-methanol gradient yields 191 mg of llB-fluoro- 3-hydroxy-7x- N-methyl- (thiophen-2-ylmethylthio) -propyl] amino}-pentyl)-estra-1,3,5(10)-trien-l7-one as a foam.
b) 11B-Fluoro-7a- (5-{N-methyl-[N-3- (thiophen-2-ylmethylthio)propyl]-amino}-pentyl) -estra-1, 3,5(10) -triene-3, 17B-diol 185 mg of 11B-fluoro-3-hydroxy-7ca-(5-{N-methyl-[N-3- (thiophen-2-ylmethylthio)-propyl]-amino}-pentyl)-estra-1,3,5(1o)trien-17-one is dissolved in 5 ml of methanol and mixed in portions with 28 mg of sodium borohydride. After 45 minutes of stirring at room temperature, the solvent is drawn off for the most part in a vacuum, the residue is added to common salt solution, extracted 3 times with methylene chloride, dried on magnesium sulfate and concentrated by evaporation in a vacuum.
Preparative column chromatography with a methylene chloride/methanol gradient provides 93 mg of 111-fluoro-7a-(5-{Nmethyl-(N-3-(thiophen-2-ylmethylth-io)-propyl]-amino}-pentyl)estra-1,3,5(10)-triene-3,17B-dio1 as a foam.
110 Example 11B-Fluoro-7a-{5-[ (2S)-2-(4-trifluoromethylphenylthiomethyl)pyrrolidin-1-yl]-pentyl}-estra-1,3,5(10)-triene-3,17B-diol a) 118-Fluoro-3-hydroxy-7z-{s-[ trifluoromethyiphenyithiomethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5 (10) -trien-17-one A solution of 0.5 g of 7a-(5-chloropentyl)-llf3-fluoro-3hydroxy-estra-l,3,5(lO)-trien-17-one in 4 ml of dimethylformamide is stirred with 0.55 g of trifluoromethylphenylthiomethyl)-pyrrolidine and 0.32 g of lithium iodide for 2 hours at a bath temperature of 100 0 C. Then, it is added to sodium bicarbonate solution, extracted three times with ethyl acetate, washed with common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/acetone. 0.45 g of llB-fluoro-3-hydroxy-7a-{5-[ trifluoromethylphenylthiomethyl) -pyrrolidin-l-yl] -pentyl}-estral,3,5(l0)-trien-17-one with I a ID 22 +32.70 (c 0.51% in chloroform) is obtained.
b) 11B-Fluoro-7ca-{5-( (2S)-2-(4-trifluoromethylphenylthiomethyl)pyrrolidin-1-ylJ-pentyl}-estra-1,3,5(10)-triene-3,17B-diol A solution of 0.43 g of llB-fluoro-3-hydroxy-7a-{5-[(2S)-2- (4-trifluoromethylphenylthiomethyl) -pyrrolidin---yl] -pentyl}estra-l,3,5(l0)-trien-17-one in 4 ml of tetrahydrofuran, 2.3 ml of ethanol and 1 ml. of water is mixed in portions at 0 0 C with 111 ,-ig of sodium borohydride, and it is stirred for 2 hours. Then, 111 it is added to ice water, extracted three times with ethyl acetate, washed with common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/acetone. 0.32 g of 1lB-fluoro-7a-{5-[(2S)-2-(4trifluoromethylphenylthiomethyl) -pyrrolidin-l-yl]-pentyl}-estral,3,5(l0)-triene-3,17B-diol with D 22- +16.20 (c 0.51% in methanol) is obtained.
Example 46 11B-Fluoro-17x-methy1-7ca-{5-[ pentafluoropentanesulfinylmetiyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5 (1O)-trierle-3,17B-diol A solution of 0.2 g of llB-fluoro-17a-methyl-7a-{5-[(2S)-2- 5-pentafluoropentylthiomethyl) -pyrrolidin-l-yl]-pentyl}estra-1,3,5(l0)-triene-3,17B-diol in 5.8 ml of methanol and 2.9 ml of water is stirred with 82 mg of sodium periodate for 5 hours at room temperature. Then, it is added to water, extracted three times with dichloromethane, washed neutral, dried on sodium sulfate and concentrated by evaporation in a vacuum. 210 mg of crude product, which is chromatographed on silica gel with dichloromethane/methanol, is obtained. 105 mg of pure 14,17ethano-7cx-{5-[N-methyl-N-3- (4,4,5,5,5pentafluoropentanesulfinyl) -propylamino] -pentyl}-estra-1,3,5(l0) triene-3,17B-diol IR 1610 and 1190 [cm-1] is obtained.
-T
AF~
112 Example 47 11B-Fluoro-17a-methyl-7r-{5-[ pentafluoropentylthiomethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5 (10)-triene-3, 17B-diol Analogously to Example 29, 11B-fluoro-17a-methyl-7ca-{5- ((2R)-2-(4,4,5,5,5-pentafluoropentylthiomethyl)-pyrrolidin-l-yl]pentyl}-estra-l,3,5(l0)-triene-3,73-diol with [caeI D 22- +68.70 (c 0.74% in chloroform) is obtained.
Example 48 IIB-Fluoro-17cz-methyl-7ca-{5-[(2S)-2-(4,4,5,5,5pentafluoropentanesulfonylmethyl) -pyrrolidin-1-ylJ -pentyl}-estra- 1,3,5(10) -triene-3,1713-diol A solution of 100 mg of 3,17B-diacetoxy-11B-fluoro.-17apentafluoropentanesulfonylmethyl) -pyrrolidin-1-yl]-pentyl}-estra- 1,3,5(10)-triene in 1.3 ml of 0.2 M methanolic potassium hydroxide solution is stirred for 2 hours at room temperature.
Then, it is added to water, extracted three times with dichloromethane, washed with common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichioromethane/acetone. 63 mg of llB-fluoro-17ai-methyl-7a-{5-[ pentafluoropentanesulfonylmethyl) -pyrrolidin-l-yl] -pentyl}-estral,3,5(l0)-triene-3,17B-diol is obtained.
IR: 1710, 1660, 1610 113 Example 49 111-Fluoro-7c-{-[(2S)-2-(4,4,5,5,5pentaf luoropentanesulfinylmethyl) -pyrrolidin-1-yl] -pentyl}I-estra- 1,3,5(10) -triene-3, 17B-diol A solution of 300 mg of 118-f luoro-7oa-{5- (4,4,5,5,5pentafluoropentyithiomethyl) -pyrrolidin-l-yl]-pentyl}-estral,3,5(10)-triene-3,17B-diol in 4.3 ml of methanol and 2.1 ml of water is stirred with 131 mg of sodium periodate for 4 hours at room temperature. Then, it is added to water, extracted three times with ethyl acetate, washed with common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with, dichloromethane/ ethyl acetate.
203 mg of 11B-fluoro-7cr-{5-[(2S)-2-(4,4,5,5,5pentafluoropentanesulfinylmethyl) -pyrrolidin-l-yl]-pentyl}-estra- 1,3,5(l0)-triene-3,17B-diol is obtained. [a1]22 +11.80 (c= 0.53% in methanol).
Example 11I3-Fluoro-7ca-{5-[ (2S)-2-(4,4,5,5,5-pentafluoropentanesulfonylmethyl)-pyrrolidin-1-ylJ-pentyl}-estra-1,3,5(10)-triene-3,17Bdiol Analogously to what is described in Example 48, liB-fluoro- (2S)-2-(4,4,5,5,5-pentatluoropentanesulfonylmethyl)pyrrolidin-l-yl]-pentyl}-estra-l,3,5(10)-triene-3,17B-diol is obtained. la]D 2 2 +30.60 (c 0. 515% in methanol) Production of the Starting Compounds: N-Methyl-[3-(4,4,5,5,5-pentafluoropentylthio)-propyl]-amine a) 3-Iodopropyl-4,4,5,5,5-pentafluoropentylsulfide A solution of 22.8 g of 3-chloropropyl-4,4,5,5,5pentafluoropentylsulfide in 500 ml of ethyl methyl ketone is stirred with 40 g of sodium iodide for 5 hours at a bath temperature of 100 0 C under nitrogen. Then, it is evaporated to the dry state in a vacuum, added to water, extracted three times with ethyl acetate, washed neutral, and dried on sodium sulfate and concentrated by evaporation in a vacuum. 30.6 g of 3iodopropyl-4,4,5,5,5-pentafluoropentylsulfide is obtained.
b) N-Methyl-[3-(4,4,5,5,5-pentafluoropentylthio)-propyl]-amine In a solution of 30.6 g of 3-iodopropyl-4,4,5,5,5pentafluoropentylsulfide in 200 ml of absolute tetrahydrofuran, g of methylamine is condensed at a bath temperature of -78 0
C,
and it is stirred for 1.5 hours at room temperature and for 4 hours at 60 0 C in the pressurized reactor. To open the reactor, it is allowed to cool overnight to room temperature and then to -78 0 C. Then, it is allowed to come to room temperature, excess methylamine is evaporated, diluted with ethyl acetate, washed neutral, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 15.7 g of N-methyl-[3-(4,4,5,5,5pentafluoropentylthio)-propyl]-amine is obtained as an oil.
115 N-Methyl-[3-(4,4,5,5,5-pentafluoropentanesulfonyl)-propyl]-amine a) 3-Chloropropyl-4,4,5,5,5-pentafluoropentanesulfone A solution of 23 g of 3-chloropropyl-4,4,5,5,5pentafluoropentylsulfide in 230 ml of chloroform is mixed in portions at 0°C with 41.8 g of 70% m-chloroperbenzoic acid, and it is stirred for 1.5 hours at room temperature. Then, it is diluted with dichloromethane, washed with sodium hydrogen sulfite solution, sodium bicarbonate solution and common salt solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. 23.8 g of pure 3-chloropropyl-4,4,5,5,5pentafluoropentanesulfone is obtained as crystals with a melting point of 74-76 0
C.
b) 3-Iodopropyl-4,4,5,5,5-pentafluoropentanesulfone A solution of 23.5 g of 3-chloropropyl-4,4,5,5,5pentafluoropentanesulfone in 500 ml of ethyl methyl ketone is stirred with 40 g of sodium iodide for 5 hours at a bath temperature of 100 0 C under nitrogen. Then, it is evaporated to the dry state in a vacuum, added to water, extracted three times with ethyl acetate, washed neutral, and dried on sodium sulfate and concentrated by evaporation in a vacuum. 30.6 g of 3iodopropyl-4,4,5,5,5-pentafluoropentanesulfone is obtained as crystals with a melting point of 88-89 0
C.
116 c) N-Methyl-[3-(4,4,5,,5-pentafluoropentanesulfonyl)-propyl]amine A solution of 23.5 g of 3-iodopropyl-4,4,5,5,5pentafluoropentanesulfone in 200 ml of absolute tetrahydrofuran is condensed at a bath temperature of -780C, 44 g of methylamine, and it is stirred for 1.5 hours at room temperature and for 4 hours at 600C in a pressurized reactor. To open the reactor, it is allowed to cool overnight to room temperature and then to -78°C. Then, it is allowed to come to room temperature, excess methylamine is evaporated, diluted with ethyl acetate, washed neutral, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with dichloromethane/methanol. 14.8 g of N-methyl-[3-(4,4,5,5,5pentafluoropentanesulfonyl)-propyl]-amine is obtained as crystals with a melting point of 55-57 0
C.
a) ml of concentrated sulfuric acid is added in drops to a solution of 50 g of 5-bromopentyl acetate in 1.6 1 of methanol, and the mixture is stirred for 30 hours at room temperature. The methanol is drawn off in a vacuum, the residue is taken up in diethyl ether, washed neutral with saturated common salt solution, dried on sodium sulfate and concentrated by evaporation. 28 g of 5-bromo-l-pentanol is obtained as a crude product.
117 b) A solution of 28 g of crude 5-bromo-l-pentanol in 144 ml of tetrahydrofuran is mixed with 24 g of imidazole. Then, a solution of 30.3 g of tert-butyldimethylchlorosilane in 46 ml of tetrahydrofuran is added in drops, and it is stirred for 4 hours at room temperature. The reaction mixture is poured into water, shaken out with diethyl ether, the organic phase is washed 4 times with water, dried on sodium sulfate and concentrated by evaporation. The crude product is chromatographed on silica gel with hexane/diethyl ether. 42 g of the title compound is obtained as a colorless liquid.
(2S)-2-(4,4,5,5,5-Pentafluoropentylthiomethyl)-pyrrolidine a) N-tert-Butyloxycarbonyl-L-prolinol-p-tosylate 24.2 g of p-toluenesulfonic acid anhydride is added in portions to a solution of 10 g of N-tert-butyloxycarbonyl-Lprolinol in 170 ml of pyridine at 0°C, and the mixture is stirred for 5 hours at 0 C. The reaction mixture is poured onto 2N hydrochloric acid, extracted with ethyl acetate, the organic phase is washed with saturated common salt solution, dried on sodium sulfate and concentrated by evaporation. 17.7 g of Ntert-butyloxycarbonyl-L-prolinol-p-tosylate is obtained as an oily crude product. 22 -28.00 (c 0.545 in chloroform).
118 b) N-tert-Butyloxycarbonyl-(2S)-2-(4,4,5,5,5pentafluoropentylthiomethyl)-pyrrolidine A solution of 3.93 g of 4,4,5,5,5pentafluoropentylthioacetate in 18 ml of methanol is mixed with 2.94 ml of a sodium methanolate solution (30% in methanol), and it is stirred for 30 minutes at room temperature. This reaction solution is added to a solution of 3.0 g of N-tertbutyloxycarbonyl-L-prolinol-p-tosylate, and the mixture is stirred for 3 hours at room temperature and for 3 hours at 50 0
C.
The reaction mixture is poured into water, extracted with ethyl acetate, washed with saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation. The residue is chromatographed on silica gel with hexane/ethyl acetate. 2.59 g of N-tert-butyloxycarbonyl-(2S)-2-(4,4,5,5,5pentafluoropentylthiomethyl)-pyrrolidine is obtained as an oil.
[]D
22 -41.30 (c 0.530 in chloroform).
c) (2S)-2-(4,4,5,5,5-Pentafluoropentylthiomethyl)-pyrrolidine 2.55 g of N-tert-butyloxycarbonyl-(2S)-2-(4,4,5,5,5pentafluoropentylthiomethyl)-pyrrolidine is added to 5.4 ml of trifluoroacetic acid, cooled to 0 C, and the mixture is stirred for 1.5 hours at 0 C and for 16 hours at room temperature. The reaction mixture is poured onto 10% sodium bicarbonate solution, extracted with ethyl acetate, washed with saturated common salt solution, dried on sodium sulfate and concentrated by evaporation. 1.8 g of the title compound is obtained as an oily crude product.
xI~,T cG 119 (2R)-2-(4,4,5,5,5-Pentafluoropentylthiomethyl)-pyrrolidine Exactly as described in the production of pentafluoropentylthiomethyl)-pyrrolidine, 9.69 g of the title compound is obtained as an oily crude product from 10 g of Ntert-butyloxy-carbonyl-D-prolinol.
(4,4,5,5,5-Pentafluoropentyl)-vinyl sulfone a) (4,4,5,5,5-Pentafluoropentyl)-vinyl sulfide A solution of 40 g of 4,4,5,5,5-pentafluoropentylthioacetate in 200 ml of methanol is stirred with 34 ml of a 30% sodium methylate for 1 hour at 25 0 C, mixed drop by drop with 21 ml of 1,2-dibromoethane, stirred for another 2 hours at room temperature, mixed drop by drop with another 70 ml of 30% sodium methylate and stirred for 3 hours at 25 0 C. Then, methanol is concentrated by evaporation in a vacuum, added to water, extracted three times with ethyl acetate, washed with water and common salt solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. 34 g of (4,4,5,5,5-pentafluoropentyl)vinyl sulfide is obtained.
b) (4,4,5,5,5-Pentafluoropentyl)-vinyl sulfone A solution of 34 g of (4,4,5,5,5-pentafluoropentyl)-vinyl sulfide in 74 ml of glacial acetic acid is mixed drop by drop with 59 ml of 30% hydrogen peroxide in such a way that the reaction temperature does not exceed 70 0 C. Then, it is stirred for one hour at a bath temperature of 70 0 C. Then, it is added to water, extracted three times with ethyl acetate, washed with 120 sodium thiosulfate, water and common salt solution, dried on sodium sulfate, concentrated by evaporation in a vacuum and chromatographed on silica gel with hexane/ethyl acetate. 12.3 g of (4,4,5,5,5-pentafluoropentyl)-vinyl sulfone is obtained as an oil.
2-(3-Chloro-propylthiomethyl)-furan 3.3 ml of a 30% sodium methylate solution in methanol is added in drops to 1.77 ml of furan-2-yl-methanethiol in 18 ml of anhydrous acetonitrile at 0°C. After 5 minutes, the drop-by-drop addition of 2.6 ml of l-bromo-3-chloropropane is carried out.
Then, the reaction solution is allowed to stir for 5 hours at room temperature. For working-up, the batch is diluted with ethyl acetate, washed with water and common salt solution, dried on magnesium sulfate and concentrated by evaporation in a vacuum.
Chromatography of the crude product on silica gel with a hexaneethyl acetate gradient yields 1.1 g of 2-(3chloropropylthiomethyl)-furan as an oil.
2-(3-Chloro-propylthiomethyl)-thiophene ml of a 30% sodium methylate solution in methanol is added in drops to 1.0 g of thiophen-2-yl-methanethiol in 8 ml of anhydrous acetonitrile at 0°C. After 5 minutes, the drop-by-drop addition of 1.1 ml of l-bromo-3-chloropropane is carried out.
Then, the reaction solution is allowed to stir for 5 hours at room temperature. For working-up, the batch is diluted with ethyl acetate, washed with water and common salt solution, dried on magnesium sulfate and concentrated by evaporation in a vacuum.
Chromatography of the crude product on silica gel with a hexaneethyl acetate gradient yields 1.3 g of 2-(3chloropropylthiomethyl)-thiophene as an oil.
(2S)-2-(4-Trifluoromethylphenylthiomethyl)-pyrrolidine a) N-tert-Butyloxycarbonyl-(2S)-2-(4trifluoromethylphenylthiomethyl)-pyrrolidine A solution of 1.65 g of 4-trifluoromethylthiophenol in 18 ml of dimethylformamide is mixed with 3 g of cesium carbonate and 3 g of N-tert-butyloxycarbonyl-L-prolinol-p-tosylate, and it is stirred for 8 hours at room temperature. The reaction mixture is poured into water, extracted with ethyl acetate, washed with saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation. The residue is chromatographed on silica gel with hexane/ethyl acetate. 2.59 g of N-tertbutyloxycarbonyl-(2S)-2-(4-trifluoromethylphenylthiomethyl)pyrrolidine is obtained as an oil.
b) (2S)-2-(4-Trifluoromethylphenylthiomethyl)-pyrrolidine A solution of 2.55 g of N-tert-butyloxycarbonyl-(2S)-2-(4trifluoromethylphenylthiomethyl)-pyrrolidine in 5.64 ml of trifluoroacetic acid is stirred for 1 hour at 0 C and then for hours at room temperature. The reaction mixture is poured onto 10% sodium bicarbonate solution, extracted with ethyl acetate, washed twice with 2 M hydrochloric acid, the water phase is extracted with ether, made basic with sodium bicarbonate, 122 extracted three times with ethyl acetate, washed with common salt solution, dried on sodium sulfate and concentrated by evaporation. 557 mg of (2S)-2-(4-trifluoromethylphenylthiomethyl)-pyrrolidine is obtained.
The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.
*S
C
**o **o

Claims (33)

1. Substituted 7c-(E-aminoalkyl) -estratrienes of general formula I 1 R 1 7' '4 16 e I IA R *1 I I I *1I *1 I I I 9 *1I*II I *1I*I* I *1*I in which side chain SK is a radical of partial formula -(CH 2 M-N-CH--CH- (CH 2 (CH 2 3 -E A B D whereby in is 4, 5 or 6, n isO of1or 2, x isO0, 1or 2, A is a hydrogen atom or a C 1 5 alkyl group, B and D each are a hydrogen atom, or A and.B together are an alkylene group (CH 2 with p p=2, 3, 4 or 5, and Dis ahydrogen atom or A and D together are an alkylene group (CH 2 with q 2, 3 or 4, and B is a hydrogen. atom, and E is an unsubstituted ethyl radical or an ethyl radical that is fluorinated in one to five places, or terminal substituent -(CH 2 3 -E in the side chain is replaced by an optionally substituted aryl or heteroaryl radical, which is bonded 124 directly or via a mono-, di- or trimethylene group to the sulfur atom, R 3 is a hydrogen atom, a hydrocarbon radical with up to 8 carbon atoms or a radical of partial formula R 3 in which R 3 is a hydrogen atom or a hydrocarbon radical with up to 8 carbon atoms or a phenyl radical, R 11 is a hydrogen atom, a halogen atom or a nitrooxy group -O-NO 2 R 14 R 15 a, R 1 5 B, R 16 a and R 16 8 each are a hydrogen atom or R 14 and R 15 a are an additional bond or a methylene bridge, or R 1 56 is a methyl group and R 15 a is a hydrogen atom, or R 15 and R 15 in each case are a methyl group, or R 158 and R 16 8 together are a methylene bridge, or R 16a or R 1 6 is a halogen atom or R 16 a and R 16s together are a methylidene group and the remaining substituents R 1 4 R 15 a, R 15 R 16 a and R 168 are each a hydrogen atom, R 17 in a- or B-position is a hydrogen atom, a C1- 5 alkyl, C 2 5 alkenyl or C2- 5 alkinyl group or a trifluoromethyl group and R 1 7 is a hydrogen atom or a radical of partial formula R 17 in which R 1711 is a hydrogen atom or a hydrocarbon radical with up to 8 carbon atoms, or, if R 17 is in a-position, R 17 together with R 14 means an ethano bridge, 125 provided that unless A and B together stand for -(CH2) p or D together stand for at least one of substituents R 14 R 15 1 R 15 R 16 and R 16 B is not a hydrogen atom, A and R 11 as well as their physiologically compatible addition salts with organic and inorganic acids.
2. Estratrienes
3. Estratrienes
4. Estratrienes Estratrienes
6. Estratrienes methyl group.
7. Estratrienes
8. Estratrienes
9. Estratrienes Estratrienes
11. Estratrienes according according according according according according according according according according claim claim claim claim claim claim claim claim claim claim which which which which which which which which which which is 0. is 1. is 2. is 1. and B together are -(CH2) 3
12. Estratrienes according
13. Estratrienes according
14. Estratrienes according perfluoroethyl radical. Estratrienes according hydrogen atom.
16. Estratrienes according methyl group.
17. Estratrienes according acetyl group. claim claim claim 11, in which n is 0. 12, in which x is 0. 1, in which E is a to claim 1, in which R 3 is a to claim 1, in which R 3 is a to claim 1, in which R 3 is an 126
18. Estratrienes according to claim in which R 11 is a hydrogen atom.
19. Estratrienes according to fluorine atom. Estratrienes according to nitrooxy group.
21. Estratrienes according to hydrogen atom.
22. Estratrienes according to with R 15 a forms an additional bond.
23. Estratrienes according to methyl group.
24. Estratrienes according to together form a methylene bridge. Estratrienes according to halogen atom Cl, Br, I).
26. Estratrienes according to fluorine atom.
27. Estratrienes according to together form a methylidene group.
28. Estratrienes according to position.
29. Estratrienes according to trifluoromethyl group. Estratrienes according to methyl group. claim 1, in which R 11 is a claim 1, claim 1, claim 1, claim 1, claim 1, claim 1, in which R 11 is a in which R 14 is a in which R 14 together in which R 158 is a in which R 158 and R 1 6 B in which R 16 is a claim 25, in which R 16 a is a claim 1, in which R 16 and R 166 claim 1, in which R 1 7 is in a- claim 28, in which R 17 is a claim 28, in which R 17 is a 127
31. Estratrienes according hydrogen atom.
32. Estratrienes according position.
33. Estratrienes according methyl group.
34. Estratrienes according hydrogen atom. Estratrienes according together form an ethano bridge.
36. Estratrienes according radical of partial formula to claim 28, in which R 17 is a to claim 1, in which R 17 is in B- to claim 32, in which R 17 is a to claim 32, in which R 17 is a to claim 28, in which R 14 and R 17 to claim 1, in which SK is a (CH2)--N(CH2)3-SOx--(CH2) 3- F5 with x 0, 1 or 2. CH 3
37. Estratrienes according to claim 13, in which m 5, E is a perfluoroethyl radical and the conformation of the 2-carbon atom of the heterocycle is R.
38. Estratrienes according to claim 13, in which m 5, E is a perfluoroethyl radical and the conformation of the 2-carbon atom of the heterocycle is S.
39. Estratrienes according to claim 37, in which R 17 is in a-position and is a hydrogen atom. Estratrienes according to claim 1, namely 14,17-Ethano-7a-{5-[N-methyl-N-3-(4,4,5,5,5- pentafluoropentylthio)-propylamino]-pentyl}-estra-l,3,5(10)- triene-3,17B-diol 128 14, 17-ethano-7h-{5- [N-methyl-N-3- (4,4,5,5,5- pentafluoropentanesulfinyl)-propylamino]-pentyl}-estra-1,3,5(10)- triene-3 ,1713-diol 3, 17B-diacetoxy-14a, 17a-ethano-7ca-{5-[N-methyl-N-3- (4,4,5,5,5-pentafluoropentylthio) -propylamino]-pentyl}-estra- 1,3,5(10) -triene 14, 17-ethano-7a-{5- [N-methyl-N-3- pentafluoropentanesulfonyl) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 17 B-dial 17a-trifluaromethyl-7h- (N-methyl-N-3- (4,4,5,5,5- pentafluarapentyithia) -propylarnina] -pentyl}-estra-1, 3,5(10) triene-3 ,17 B-dial 15B,16B-methano-17a-methyl-7ca-{5-fN-methy1-N-3-(4,4,5,5,5- pentafluoro-pentylthio) -prapylamina] -pentyl} -estra-1, 3,5(10) triene-3 ,1781-dial 15B3,16B-methano-17a-methy1-7r-{5- [N-rethyl-N-3- (4,4,5,5,5- pentafluoropentanesulfinyl) -prapylamino] -pentyl}-estra-1, 3,5(10) triene-3, 1713-dial 158,16B-methano-7cr-{5-[N-methyl-N-3-(4 ,4,5,5 pentyithia) -prapylamina] -pentyl }-estra-1, 3 ,5(10) -triene-3, 17B- dial 15B,16B-methano-7a-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro- pentanesulfinyl) -propylamino]-pentyl}-estra-1, 3,5(10) -triene- 3, 1713-dial 15B-methyl-7a- [N-methyl-N-3- pentyithio) -propylamino]-pentyl}-estra-1, 3,5(10) -triene-3, 17B- dial 129 15B,17c-dimethyl-7c-5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro- pentylthio) -propylaniino] -pentyl}-estra-1, 3,5(10) -triene-3, 17B- diol 11B-fluoro-7cr-{5-[N-methyl-N-3- (4,4,5,5,5- pentafluoropentylthio) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 11B-fluoro-7cz-{5-[N-methyl-N-3- (4,4,5,5,5- pentafluoropentanesulfinyl)-propylamino]-pentyl}-estra-1,3,5(1o)- triene-3, 17B-diol
118-fluoro-7cr-{5-[N-methyl-N-3-(4,4,5,5,5- pentafluoropentanesulfonyl) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 16r-f luoro-l7cr-nethyl-7cr-{5- N-rnethyl-N-3- (4,4,5,5,5- pentafluoropentylthio) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 16a-fluoro-17B-methyl-7cr-{5-[N--methyl-N-3-(4,4,5,5,5- pentafluoropentylthio) -propylamino]-pentyl-estra-1, 3,5(10) triene-3, l7c-diol 16a-fluoro-17a-methyl-7cr-{5-[N-rnethyl-N-3-(4,4,5,5,5- pentafluoropentanesulfinyl) -propylamino] -pentyl}-estra-1, 3,5(10) triene-3, 17B-diol l6c-fluoro-17c-methyl-7c-5-[N-methyl-N-3-(4,4,5,5,5- pentafluoropentanesulfonyl) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 16a-fluoro-7r-{5- [N-methyl-N-3- (4 ,4,5,5,5- pentafluoropentylthio) -propylamino] -pentyl }-estra-1, 3, 5(10) triene-3, 17B-diol 130 l6a-fluora-7a-{5-(N-methyl-N-3-(4,4,5,5,5- pentafluoropentyithia) -prapylamino) -pentyl }-estra-1, 3,5(10) triene-3, 17a-dial 16a-fluaro-7a-{5- [N-methyl-N-3- (4,4,5,5,5- pentaf luoropentanesulf inyl) -prapylamino] -pentyl}-estra-1, 3 ,5(10) triene-3, 17B-diol 16a-fluaro-7a-{5-[N-xuethyl-N-3-(4,4,5,5,5- pentaf luoropentanesulfaonyl) -prapylamina] -pentyl }-estra-1, 3,5 (10) triene-3, 17 B-dial 7a-{ 5- (N-iethyl-N-3- 5-pentaf luaropentyithia) propylamino] -perityl}-estra-1, 3, 5(10) ,14-tetraene-3, 178-dial 7a-{5-[N-methyl-N-3- 5,5, 5-pentaf luaraperitanesulf inyl)- propylamino]-pentyl}-estra-1, 3,5(10) ,14-tetraene-3, 178-dial 7a-{5-[N-methyl-N-3- (4,4,5,5',5-pentafluoropentanesulfanyl) prapylamina]-pentyl}-estra-1, 3,5(10), 14-tetraene-3, 178-dial (2S) 5-pentafluoropentyithiomethyl) pyrralidin-1-yl]-pentyl}-estra-1, 3,5 (l0)-triene-3, L7B-diol (2R)-2-(4,4,5,5,5-pentafluarapentylthialnethyl)- pyrralidin-l-yl).-pentyl}-estra-l, 3,5(10) -trierie-3, 178-dial 17 a7-methy 1 7 a-{5-[C2 4, 5, 5, 5- p ent af 1u oraop enty Ith iamethyl1) pyrroli d in- 1- y 1 p ent y I-es t ra 1,3, 5( 10) -tr ie ne 178- d io 1 I 18- f1ua r o 7 a-{5 -4,4 5, 5 -p ent af 1uoraop e ntyIthi omethy1) pyr r a1i d in- 1 -yl1) -p e nty 1} e st r a-I, 3, 5(10) tr ien e- 3, 17 8- d ial pertafluoropentyithiomethyl) -pyrrolidin-1-yl]-pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol 11B-fluoro-l7cr-methyl-7a-{5-[(2S)-2-(4,4,5,5,5- pentafluoropentanesulfinylmethyl) -pyrrolidin-1-yl]-pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol 11B-fluoro-17ca-methyl-7a-{5-[(2S)-2-(4,4,5,5,5- peritafluoropentanesulfonyliethyl) -pyrrolidin-1-y1] -pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol (2S)-2-(4,4,5,5,5-pentafluoropentanesulfinylmethyl)- pyrrolidin-1-yl)-pentyl-estra-1,3,5(10)-triene-3,17B-diol (2S)-2-(4,4,5,5,5-pentafluoropentanesulfonylmethyl)- pyrrolidin-1-yl] -pentyl-estra-1,3,5(10) -triene-3, 17B-diol 11B-fluoro-17a-methyl-7a-{5-(N--methyl-N-3-(4,4,5,5,5- pentafluoropentylthio) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 17B3-di'ol 11B-fluoro-17a-methyl-7a-{5-[N-methyl-N-3-(4,4,5,5,5- pentafluoropentanesulfinyl) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 11B-fluoro-17a-methy-7a-{5- [N-methyl-N-3- (4,4,5,5,5- pentafluoropentanesulfonyl) -propylamino]-pentyl}-estra-1, 3,5(10) triene-3, 17B-diol 11B-fluoro-7ca-{5-[N-methy1-N-2-(4,4,5,5,5- pentafluoropentanesulfonyl) -ethylamino]--pentyl}-estra-1,3,5(10)- triene-3, 17B-diol 132 118-fluoro-7a-{5-IIN-methyl-N-3-(4,4,5,5,5- pentafluoropeitylthio) -propylamino] -pentyl}-3-hydroxy-estra- 1,3,5(10) -trien-17-one 11B-fluoro-7a-{6-[N-methyl-N-3- (4,4,5,5,5- pentafluoropentylthio)-propylamino3-hexyl}-estra-1,3,5(10)- triene-3, 17B-diol 11B-fluoro-7a-{6- [N-methyl-N-3- (4,4,5,5,5- pentafluoropentanesulfinyl) -propylamino] -hexyl }-estra-1, 3,5(10) triene-3, 17B-diol 11B-fluoro-7ca-(5-{[N-3-(furan-2-ylmethylthio)-propyl]-N- methyl-amino}-pentyl) -estra-1,3,5(10) -triene-3, 17B-diol 11B-fluoro-7a- (5-{N-inethyl- (thiophen-2-ylmethylthio) propyl]-amino}-pentyl}-estra-1, 3,5(10) -triene-3, 178-diol 11B-fluoro-7a-{5-[ (2S)-2-(4-trifluoromethylphenyl- thiomethyl) -pyrrolidin-1-yl] -pentyl}-estra-1, 3,5(10) -triene- 3, 17B-diol pentafluoropentanesulfinylmethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol 11B-fluoro-17a-methyl-7a-{5-[ pentafluoropentyithiomethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5(10) -triene-3, 17B-diol 11B-fluoro-7a-{5-[(2S)-2-(4,4,5,5,5- pentafluoropentylthiomethyl) -pyrrolidin-1-yl] -pentyl}-estra- 1,3,5(10) -triene-3, 1713-diol 133 llB-fluoro-7a-{5-[(2S)-2-(4,4,5,5,5- pentaf luoropentanesulf inylmethyl) -pyrrolIidin-1--yl] -pentyl}I-estra- 1,3,5(10) -triene-3, 17B-diol 1lB-fluoro-7a-{5-((2S)-2-(4,4,5,5,5- pentaf luoropentanesulfonylmethyl) -pyrrolidin-l-yl] -pentyl}-,estra- 1,3,5(10) -triene-3, 17B-diol. 41. Pharmaceutical preparations that' contain at least one compound of general formula I according to claim 1 as well as a pharmaceutically compatible vehicle. 42. Use of the compounds of general formula I according to claim 1 for the production of pharmaceutical agents. 43. An estratriene intermediate compound of the formula: "R 16a in which 5 X is halogen, NHMe, OH or a protected hydroxy group, the Aring is xoo R 3 is a hydrogen atom or -OR 3 is a protected hydroxy group, R 14 R 15 R 15, R 1aand R 1 6 P each are a hydrogen atom 134 or R 1 4 and R 1 5 are an additional bond or a methylene bridge, or R 1 P is a methyl group and R 15 a is a hydrogen atom, or RI" and R 51 in each case are a methyl group, or R 15 P and R 6 1 together are a methylene bridge, or R 16 a or R 1 6 P is a halogen atom or R 1 6 a and RI 16 together are a methylidene group and the others of substituents R 14 R 15 R 1 5 p, R 16 a and R 1 6 0 are each a hydrogen atom, R 17 in a- or P-position is a hydrogen atom, R 17 is a hydrogen atom or a radical of partial formula S. R 1 7 in which R 1 7 is a hydrogen atom or a i hydrocarbon radical with up to 8 carbon atoms, or R7 and OR 17 together are 0, as well as their physiologically compatible addition salts with organic and inorganic acids. 44. A compound according to claim 43, in which the A ring S .is 'S and R' 7 and OR' 7 together are -0. A compound according to claim 43, in which X is OH or a protected hydroxy group. 46. A compound according to claim 44, in which X is OH or a protected hydroxy group. 47. A compound according to claim 43, wherein the protected S-ST hydroxy groups are ester or ether groups. 135 48. A compound according to claim 44, in which X is -OH Or -OC-CH 3 .7 49. A compound according to claim 48, in which R 14 RIa R' Ma and R'1 616 P are all -hydrogen. A compound according to claim 43, in which R 17 and OR1 7 together are the A ring is Soo* S.6 :0 .0 3S", R0 I hr sttayrprnladXi ounsloy prtctdh..x gop 51 opud codn ocli 3 nwhc 7 n R toehrae-0 h igi WS 136 where R 3 is hydrogen and X is halogen. 52. A compound according to claim 43, in which R7 and R" 7 together are the A ring is RO.0 where R 3 is hydrogen and X is -NHMe. 53. A compound according to claim 43, which is: 11 P-Fluoro-7a-(5-hydroxypentyl)-estr-4-ene-3,17-dione S 7 a-(5-Acetoxypentyl)- 11 1-fluoro-estr-4-ene-3,17-dione 11p-fluoro-3-hydroxy-estra-1,3,5 (10)-trien-1 7-one 0** 11-Fluoro-3 -hydroxy-7a-(5-iodopentyl)-estra- 1,3,5 (10)-trien-17- one. 0. 54. An estratriene according to claim 1, a pharmaceutical preparation involving/containing same and/or a use thereof substantially as hereinbefore described especially with reference to the Examples. An estratriene intermediate compound according to clam 43 and/or use thereof in the preparation of an estratriene according to claim 1 substantially as hereinbefore described especially with reference to the Examples. DATED this 2nd day of November 2000 Schering Aktiengesellschaft By its Patent Attorneys DAVIES COLLISON CAVE
AU45520/97A 1996-08-20 1997-08-20 7alpha-(epsilon-aminoalkyl)estratrienes, process for preparing the same, pharmaceutical preparations containing said 7alpha-(epsilo-aminoalkyl)estratrienes and their use for preparing medicaments Ceased AU728843B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19635525 1996-08-20
DE19635525A DE19635525A1 (en) 1996-08-20 1996-08-20 New 7-alpha-(xi-aminoalkyl)- oestratriene derivatives
PCT/EP1997/004517 WO1998007740A1 (en) 1996-08-20 1997-08-20 7α-(κ-AMINOALKYL)ESTRATRIENES, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 7α-(κ-AMINOALKYL)ESTRATRIENES AND THEIR USE FOR PREPARING MEDICAMENTS

Publications (2)

Publication Number Publication Date
AU4552097A AU4552097A (en) 1998-03-06
AU728843B2 true AU728843B2 (en) 2001-01-18

Family

ID=7804367

Family Applications (1)

Application Number Title Priority Date Filing Date
AU45520/97A Ceased AU728843B2 (en) 1996-08-20 1997-08-20 7alpha-(epsilon-aminoalkyl)estratrienes, process for preparing the same, pharmaceutical preparations containing said 7alpha-(epsilo-aminoalkyl)estratrienes and their use for preparing medicaments

Country Status (29)

Country Link
EP (1) EP0920441B1 (en)
JP (1) JP2001503024A (en)
KR (1) KR20000068261A (en)
CN (1) CN1231670A (en)
AR (1) AR009278A1 (en)
AT (1) ATE231882T1 (en)
AU (1) AU728843B2 (en)
BG (1) BG62972B1 (en)
BR (1) BR9711328A (en)
CA (1) CA2263708A1 (en)
CZ (1) CZ57999A3 (en)
DE (2) DE19635525A1 (en)
DK (1) DK0920441T3 (en)
EA (1) EA001577B1 (en)
EE (1) EE04021B1 (en)
ES (1) ES2191857T3 (en)
HU (1) HUP9903106A3 (en)
IL (1) IL128601A (en)
IS (1) IS4976A (en)
NO (1) NO315655B1 (en)
NZ (1) NZ334277A (en)
PL (1) PL186309B1 (en)
PT (1) PT920441E (en)
SK (1) SK18899A3 (en)
TR (1) TR199900432T2 (en)
TW (1) TW552267B (en)
UA (1) UA50792C2 (en)
WO (1) WO1998007740A1 (en)
ZA (1) ZA977482B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513162B2 (en) 2008-12-24 2013-08-20 Sumitomo Chemical Company, Limited Halogen-containing organosulfur compound and use thereof
US11279730B2 (en) 2016-07-07 2022-03-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11407782B2 (en) 2016-05-06 2022-08-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11613556B2 (en) 2016-10-18 2023-03-28 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11884697B2 (en) 2016-04-01 2024-01-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11905309B2 (en) 2013-03-13 2024-02-20 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
US11926646B2 (en) 2016-09-30 2024-03-12 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
US12129276B2 (en) 2014-06-18 2024-10-29 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US12129275B2 (en) 2011-09-08 2024-10-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US12617814B2 (en) 2024-01-05 2026-05-05 Sage Therapeutics, LLC Neuroactive steroids and methods of use thereof

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR015500A1 (en) * 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALOGEN-STRATRIENS REPLACED IN 7 ALPHA, PROCEDURE FOR PREPARING PHARMACEUTICAL PREPARATIONS THAT CONTAIN SUCH 11 BETA-HALOGEN-STRATRIENS REPLACED IN 7 ALPHA, AS WELL AS USED IN THE PREPARATION OF MEDICINES.
US6503896B1 (en) 1997-12-24 2003-01-07 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6548491B2 (en) 1997-12-24 2003-04-15 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
DE19807791A1 (en) * 1998-02-19 1999-08-26 Schering Ag Combination preparation of estrogen with 7-aminoalkyl-estratriene antiestrogen, useful in hormone replacement therapy, e.g. for treatment osteoporosis, Alzheimer's disease and hot flushes
DE19833786A1 (en) * 1998-07-18 2000-01-20 Schering Ag New diphenyl-benzocycloheptene derivatives, are tissue-selective estrogens and antiestrogens useful e.g. for treating osteoporosis or hormone-dependent tumors or in hormone replacement therapy
DE19842123C1 (en) * 1998-09-05 2000-07-13 Schering Ag 11beta-fluoro-7alpha- (14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl) estra-1,3,5 (10) - triene-3,17beta-diol as crystalline solvate
DE19906159A1 (en) * 1999-02-09 2000-08-10 Schering Ag 16-hydroxyestratrienes as selectively active estrogens
AU6913700A (en) * 1999-08-18 2001-03-13 Schering Aktiengesellschaft Piperidine and pyrrolidine derivatives displaying neuronal activity
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
DE10019171A1 (en) * 2000-04-07 2001-10-18 Schering Ag Compositions for use as penetration enhancers in transdermal formulations for highly lipophilic active ingredients
AU2006202187B2 (en) * 2001-11-27 2008-11-06 Bayer Schering Pharma Aktiengesellschaft 17alpah-alkyl-17beta-oxy-estratrienes and intermediate products for their production, uses thereof and pharmaceutical preparations
DE10159217A1 (en) 2001-11-27 2003-06-05 Schering Ag 17alpha-alkyl-17ß-oxy-estratrienes and intermediates for their preparation, use of 17alpha-alkyl-17ß-oxy-estratriene for the preparation of medicaments and pharmaceutical preparations
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
US7790910B2 (en) 2004-07-27 2010-09-07 Sicor Inc. Process for the preparation of 7α-alkylated 19-norsteroids
EP1951664A1 (en) 2005-11-22 2008-08-06 Sumitomo Chemical Company, Limited Organic sulfur compounds and use thereof as arthropodicides
DE102007023614A1 (en) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft New amide compounds used for treatment of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy, has general formula
DE102007049630A1 (en) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft New amide compounds used for therapy and/or prophylaxis of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy
TW200904329A (en) 2007-05-18 2009-02-01 Sumitomo Chemical Co Organic sulfur compound and its use for controlling harmful arthropod
JP2009001551A (en) 2007-05-18 2009-01-08 Sumitomo Chemical Co Ltd Organic sulfur compounds and their use for controlling harmful arthropods
JP5298631B2 (en) 2007-05-18 2013-09-25 住友化学株式会社 Organic sulfur compounds and their use for controlling harmful arthropods
DE102007032800A1 (en) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nonsteroidal progesterone receptor modulators
BRPI0818637A2 (en) 2007-10-16 2015-04-07 Repros Therapeutics Inc Methods of treating symptom of impaired fasting glucose, metabolic syndrome, metabolic syndrome, and impaired fasting glucose in subjects with secondary or idiopathic hypogonadotropic hypogonadism
DE102007058747A1 (en) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nonsteroidal progesterone receptor modulators
EP2070941A1 (en) 2007-12-14 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Stereoselective synthesis of selective estrogen receptor down-regulators
EP2070909A1 (en) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Non-steroidal progesterone receptor modulators
DE102008057230A1 (en) 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistic pharmaceutical combination with an estrogen receptor antagonist and a progestin
EP2258375A1 (en) 2009-06-04 2010-12-08 Bayer Schering Pharma Aktiengesellschaft 17B-alkyl-17alpha-oxy-estratrienes
DE102009034367A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-benzylidene derivatives, process for their preparation and their use for the treatment of diseases
DE102009034362A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034366A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-methyleneoxyalkylene aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034368A1 (en) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034525A1 (en) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases
DE102009034526A1 (en) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-ethynylphenyl derivatives, process for their preparation and their use for the treatment of diseases
WO2011092127A1 (en) 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
DE102010007719A1 (en) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesterone receptor antagonist
DE102010007722A1 (en) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesterone receptor antagonist
EA026675B1 (en) 2010-06-16 2017-05-31 Эндорешерш, Инк. Methods of treating or preventing estrogen-dependent diseases
DE102010030538A1 (en) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments
DE102011004899A1 (en) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft New 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl-derivatives are progesterone receptor antagonists useful to treat and prevent e.g. uterine fibroids, endometriosis, heavy menstrual bleeding and meningioma
DE102011087987A1 (en) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments
JP2015508825A (en) 2012-02-29 2015-03-23 レプロス セラピューティクス インコーポレイティド Combination therapy to treat androgen deficiency
US20160296534A1 (en) 2013-04-11 2016-10-13 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
US20160060288A1 (en) * 2013-04-18 2016-03-03 Xi'anlibang Pharmaceutical Technology Co., Ltd. Ester derivatives of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)-estra-1,3,5(10)-triene-3,17beta-diol having anticancer activity and preparation method thereof
EP3828194B1 (en) 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3373967B9 (en) 2015-11-10 2023-10-04 Paracrine Therapeutics AB Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
CN115505019B (en) * 2022-11-07 2024-01-26 南宁师范大学 7-amide substituted estrogen compounds and their preparation methods and applications
CN116041412A (en) * 2023-01-13 2023-05-02 香港中文大学（深圳） Fulvestrant derivative and its preparation method, application and medicine for treating breast cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
HU208150B (en) * 1988-10-31 1993-08-30 Endorecherche Inc Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives
DE3925507A1 (en) * 1989-07-28 1991-01-31 Schering Ag 14,17 (ALPHA) ETHENO AND ETHANOESTRATRIA, METHOD FOR PRODUCING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICINAL PRODUCTS
DE4218743C2 (en) * 1992-06-04 2001-10-25 Schering Ag Process for the preparation of C (7) -substituted Estra-1,3,5 (10) -trienes and new starting products for this process

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8513162B2 (en) 2008-12-24 2013-08-20 Sumitomo Chemical Company, Limited Halogen-containing organosulfur compound and use thereof
US12129275B2 (en) 2011-09-08 2024-10-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11905309B2 (en) 2013-03-13 2024-02-20 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
US12129276B2 (en) 2014-06-18 2024-10-29 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11884697B2 (en) 2016-04-01 2024-01-30 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11407782B2 (en) 2016-05-06 2022-08-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11279730B2 (en) 2016-07-07 2022-03-22 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US11926646B2 (en) 2016-09-30 2024-03-12 Sage Therapeutics, Inc. C7 substituted oxysterols and methods of use thereof
US11613556B2 (en) 2016-10-18 2023-03-28 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US12617814B2 (en) 2024-01-05 2026-05-05 Sage Therapeutics, LLC Neuroactive steroids and methods of use thereof

Also Published As

Publication number Publication date
IL128601A0 (en) 2000-01-31
PT920441E (en) 2003-06-30
IL128601A (en) 2003-07-31
HUP9903106A2 (en) 2000-03-28
NO315655B1 (en) 2003-10-06
JP2001503024A (en) 2001-03-06
ATE231882T1 (en) 2003-02-15
KR20000068261A (en) 2000-11-25
EP0920441A1 (en) 1999-06-09
BG62972B1 (en) 2000-12-29
BG103185A (en) 1999-11-30
SK18899A3 (en) 1999-08-06
DE59709239D1 (en) 2003-03-06
WO1998007740A1 (en) 1998-02-26
NO990793D0 (en) 1999-02-19
EA199900210A1 (en) 1999-08-26
EP0920441B1 (en) 2003-01-29
DE19635525A1 (en) 1998-02-26
HUP9903106A3 (en) 2000-05-29
DK0920441T3 (en) 2003-05-26
EE9900075A (en) 1999-10-15
PL186309B1 (en) 2003-12-31
BR9711328A (en) 1999-08-17
TR199900432T2 (en) 1999-04-21
IS4976A (en) 1999-02-11
EA001577B1 (en) 2001-06-25
CN1231670A (en) 1999-10-13
ZA977482B (en) 1998-02-23
AU4552097A (en) 1998-03-06
AR009278A1 (en) 2000-04-12
PL331863A1 (en) 1999-08-16
CA2263708A1 (en) 1998-02-26
NO990793L (en) 1999-04-20
CZ57999A3 (en) 1999-08-11
UA50792C2 (en) 2002-11-15
TW552267B (en) 2003-09-11
NZ334277A (en) 2000-10-27
ES2191857T3 (en) 2003-09-16
EE04021B1 (en) 2003-04-15

Similar Documents

Publication Publication Date Title
AU728843B2 (en) 7alpha-(epsilon-aminoalkyl)estratrienes, process for preparing the same, pharmaceutical preparations containing said 7alpha-(epsilo-aminoalkyl)estratrienes and their use for preparing medicaments
US5986115A (en) 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
US6780855B2 (en) 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES, PROCESS FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS THAT CONTAIN THESE 11β-HALOGEN-7α-SUBSTITUTED ESTRATRIENES AS WELL AS THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS
AU707723B2 (en) 7alpha-(5-methylaminopentyl)-estratrienes, process for their production, pharmaceutical preparations that contain these 7alpha-(5-methylaminopentyl)-estratrienes as well as their use for the production of pharmaceutical agents
RU2182153C2 (en) Steroid compound, methods of its synthesis, pharmaceutical composition
US6790842B1 (en) 11β LONG-CHAIN SUBSTITUTED ESTRATRIENES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β LONG-CHAIN SUBSTITUTED ESTATRIENES, AND THEIR USE FOR PRODUCING MEDICAMENTS
MXPA99001736A (en) 7&agr;-(&xgr;-AMINOALKYL)ESTRATRIENES, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 7&agr;-(&xgr;-AMINOALKYL)ESTRATRIENES AND THEIR USE FOR PREPARING MEDICAMENTS
CZ20002393A3 (en) 11›-halogen-7alpha-substituted estratrienes, their use and pharmaceutical preparation containing these substances
HK1016188B (en) Steroid compounds having contraceptive and anti-osteoporosis activity
MXPA00007351A (en) Combination preparation of estrogen and anti-estrogen

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)